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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 INTRODUCTION 
Today, protein drugs including cytokines and monoclonal antibodies still represent a growing 
and upcoming class of therapeutic molecules as they had been for the last 20 years even if 
the rate of approvals for new biopharmaceuticals has slowed down [1, 2]. Furthermore, the 
pipelines of pharmaceutical companies are loaded with new types and variants of therapeutic 
proteins such as antibody fragments or antibody-drug-conjugates [3]. Protein drugs are well 
established pharmaceuticals for the treatment of serious life-threatening and chronic 
diseases such as cancer, rheumatoid arthritis and hepatitis [1]. 
In contrast to low molecular weight drugs, proteins exhibit a fragile, three-dimensional 
macromolecular structure and are much more susceptible to different chemical and physical 
degradation. Short half-lives further complicate the application of therapeutic proteins [4]. 
Therefore, the development of suitable protein formulations as well as the development of 
new strategies for protein delivery is a major challenge for R&D in pharmaceutical industry in 
order to overcome the restriction to frequent parenteral administration of pharmaceutical 
proteins [5]. 
Sustained delivery of protein drugs can reduce application frequency and systemic burden 
for patients. Several delivery systems, e.g. colloidal formulations (liposomes, microparticles 
etc.) and implants have been investigated in order to achieve a controlled and sustained 
release of protein drugs [6, 7]. As poly-lactid acid (PLA) and poly-lactic-co-glycolic acid 
(PLGA) implants and microparticles had already been approved by regulatory authorities, 
these synthetic polymers were employed first for developing protein depot formulations [8]. 
Peptides such as Leuprolide and Octreotide were successfully embedded and released from 
such systems, but protein delivery appeared more difficult and complex. Nutropin Depot® 
(recombinant human growth hormone, PLGA microparticles) has been the only protein depot 
formulation approved by the US Food and Drug Administration (FDA), but was withdrawn 
from the market in 2004. It was explained by manufacturing and commercializing issues 
according to Alkmers Inc. and Genentech Inc (press release). No implant or colloidal 
formulation for sustained delivery of a therapeutic protein is on the market today. 
Another important reason for this situation is the lack of innovation in the area of 
pharmaceutical excipients. Global excipient research and development has faced challenges 
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in the regulatory and safety framework [9]. FDA does not allow for approval of a new 
excipient outside the dossier of a new drug approval (NDA) although the need for new 
excipients is obvious. For this reason, the International Pharmaceutical Excipient Council 
(IPEC) published guidelines on the development of novel excipients to support industry [10]. 
This effort led to the approval and monograph for Solutol® HS15 in 2010. 
In academia, various innovative synthetic polymers and biomaterials have been employed for 
in vitro and in vivo delivery of protein drugs during the last decade [8, 11]. Therein, silk as a 
well-known material with unique mechanical properties gained increasing attention also for 
biomedical applications. Silk proteins including silk fibroin from Bombyx mori and spider silk 
proteins showed excellent biocompatibility, customizable properties and easy processing into 
various morphologies like scaffolds, films and spheres [12-16]. Silk fibroin has already been 
employed for the delivery of different kind of active ingredients including e.g. growth factors 
[12, 17]. However, silk fibroin from Bombyx mori is an entirely natural product. The quality of 
the protein can vary between species and individuals of the same species, and an elaborate 
degumming process has to be applied to remove Sericin from the natural product. Finally, 
quality control of this material is difficult with regard to regulatory approval [12]. 
The engineered spider silk protein eADF4(C16) was developed by Scheibel et al. [18, 19]. 
The protein sequence was adopted from the natural occurring spider silk protein ADF4 which 
is produced by the European garden spider Araneus diadematus for the use as dragline silk 
fiber. This spider silk protein can be produced in large quantities as a recombinant protein in 
E. coli. The manufacturing process is by now performed by AMSilk GmbH (Martinsried, 
Germany), which has been founded as a spin-off company from the group of Prof. Scheibel. 
Previous studies on the assembly process of the recombinant protein showed that smooth 
protein spheres with high β-sheet content are formed by an easy salting-out process avoiding 
organic solvents [20, 21]. The particle preparation process was further evaluated and drug 
loading and release were performed using eADF4(C16) submicron particles and low 
molecular weight drugs [22-24]. These studies revealed promising results regarding a 
controlled and sustained drug release.  
Nevertheless, spider silk particles are especially of high interest for depot formulations of 
therapeutic proteins and for an application in the area of vaccination. Therefore, the focus of 
this thesis was on the evaluation of the recombinant spider silk protein eADF4(C16) as a new 
colloidal drug carrier for protein therapeutics. 
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1.2 DRUG DELIVERY SYSTEMS FOR THERAPEUTIC PROTEINS 
Protein drugs usually have to be administered by subcutaneous injection or intravenous 
infusion due to their inherent instability in the gastrointestinal tract [5, 6]. As frequent 
applications are necessary because of short circulating half-lives of most proteins, Langer 
and Folkman introduced non-degradable polymers as matrix material for parenteral protein 
depots [25]. Since that time, numerous polymers have been evaluated for their suitability as 
matrix for protein depots [26]. Besides this early work on non-degradable polymers, 
biodegradable polymers are preferred from a patient perspective as no second medical 
intervention for implant removal is necessary. Thus, synthetic and natural biodegradable 
polymers have been developed and investigated as matrix-forming polymers for protein 
delivery. Selected biodegradable polymers are listed in Table 1.1. 
Implants and microspheres made of polylactic acid (PLA) and polylactic-co-glycolic acid 
(PLGA) were approved by regulatory authorities for the delivery of small molecules and 
peptides. Due to their proven safety and biocompatibility record, polyesters are still the most 
frequent used class of polymers. Many therapeutic proteins were embedded into PLGA-
based drug delivery systems (DDS) such as interferon-α [27] and erythropoietin [28, 29]. 
However, inherent shortcomings of the PLA/PLGA-systems were also observed. Both 
chemical (e.g. solvent evaporation/extraction) and physical preparation processes (e.g. spray 
drying) require the loading of an organic polymer solution with the protein drug due to the low 
solubility of PLGA in water. This was shown to be detrimental for protein stability as proteins 
tend to unfold and aggregate in hydrophobic environments and at interfaces [30]. 
Additionally, destructive conditions for proteins are generated within the polyester matrix 
during the time period of sustained drug release. The degradation products lactic and glycolic 
acid are trapped within the polymer matrix and create altered environmental conditions for 
the incorporated proteins, including a significant drop in pH and an increase of osmotic 
pressure [7, 31-34]. Despite all partially successful attempts to overcome these 
shortcomings, no formulation using polyesters for therapeutic protein delivery is on the 
market today. 
Table 1.1. Selected biodegradable polymers used for delivery of protein drugs 
Synthetic polymers Natural polymers 
Biodegradable Polysaccharides Proteins 
Polyesters: PLA, PLGA Chitosan Albumin 
Polycarbonates Alginate Gelatin 
Lipids  Silk 
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Besides the strategy to invent varieties of synthetic polymeric constructs, natural polymers 
represent promising materials for the use as DDS as well. 
Among this group, polysaccharides like chitosan and alginate have been investigated in 
great depths. Chitosan, a biomaterial obtained by alkaline deacetylation of chitin, is regarded 
as non-toxic, biocompatible and biodegradable. It is water-soluble and positively charged at 
physiological conditions, which allows for interaction with negatively charged molecules and 
polyanions in an aqueous environment. However, the use of chitosan is so far limited by a 
rapid water absorption and a high swelling degree, leading to fast drug release from non-
modified chitosan delivery systems [35-37]. 
Alginate is a polysaccharide isolated from brown seaweed and its sodium or calcium salts 
are also regarded as non-toxic and biocompatible. Divalent or multivalent metal ions (e.g. 
calcium ions) easily form gels or colloidal precipitates with alginate in aqueous media. A 
large number of proteins have been encapsulated in mainly alginate hydrogels for 
applications in tissue engineering [38-40].  
However, there remains a need for biomaterials that fulfill the high requirements in terms of 
composition and sequence, structure, mechanical properties and function [12]. For the 
development and the optimization of such release systems, it is crucial to understand how 
drug release is controlled. 
Detailed mechanistic studies on the release from non-degradable matrices revealed that 
protein release occurs via diffusion through a complex porous pathway within the inert 
matrix [41]. At first, water penetrates into the matrix and dissolves the water-soluble drug. 
Likewise, hydrophilic excipients are dissolved and a porous microstructure is created. The 
subsequent leaching out of the drug and excipients further alters the matrix morphology. 
Randomly distributed pores and channels are formed, enabling the diffusion of the protein 
into the bulk fluid. However, this tortuosity of the porous structure cannot fully explain why 
proteins are released in such a sustained manner. Thus, Siegel and Langer suggested that, 
besides tortuosity, the connection of the pores through narrow channels contributes to the 
retardation of protein release [42]. The protein performs a random walk and will therefore 
need a certain time until it reaches the next pore. In addition, release kinetics depends on the 
drug loading and particle size of the incorporated drug. Higher drug loading enables a 
complete protein release due to a fully interconnected network, and large particle size results 
in a faster release of the protein. 
The release from degradable polymer matrices is a more complicated process governed by 
diffusion through a water-filled pore network, degradation of the polymer and possible 
swelling of the polymer matrix. In the majority of cases, a combination of all three processes 
was observed [8, 109]. Protein release from PLGA microspheres shows a pulsatile liberation 
profile. A burst release of surface located and poorly encapsulated protein is followed by a 
Chapter 1 
 
5 
phase of lower release rates controlled by diffusion. Finally, increased release occurs due to 
starting polymer degradation [43]. 
To address all these requirements of a suitable DDS, proteins were also broadly explored as 
matrix materials for controlled drug delivery. Therein, silk proteins have gained more and 
more interest over the last few years. 
  
General introduction 
 
6 
1.3 PROTEIN-BASED DRUG DELIVERY SYSTEMS 
Drug delivery systems composed of proteinaceous materials, e.g. albumin, gelatin and silk, 
benefit from their compatibility with biological systems and have served as alternative 
biomaterial to synthetic polyesters [44]. Especially solid protein particles have been in focus 
because particulate DDS offer the possibilities of systematic drug delivery via different 
administration routes and prevention of non-specific biodistribution. They can be applied for 
new imaging techniques and targeting of specific tissue dependent on their physico-chemical 
properties and particle size. However, safety concerns like folding pattern-derived or 
sequence derived immunogenicity as well as contamination with transmissible diseases are 
often associated with protein-based materials [45]. For this reason, careful choice of the 
source of the natural material is necessary and even better, recombinant material should be 
used wherever possible. Recombinant proteins are in the meantime available for the most 
important representatives such as albumin, gelatin and silk. 
1.3.1 PREPARATION TECHNIQUES FOR PROTEIN PARTICLES AS DRUG CARRIERS 
Several distinct methods have been developed for the preparation of solid particles in a 
particle size range from micrometers down to approx. 100 nm. It should be mentioned that 
each method needs to be optimized for entrapment of a drug of interest at high efficiency and 
retention of its pharmacologic activity [44]. With regard to protein therapeutics, the latter 
necessity is one of the major challenges. 
1.3.1.1 EMULSION / SOLVENT EXTRACTION 
The emulsion / solvent extraction technique, which is the most employed procedure for 
particles made of polyesters, requires a primary emulsion of the aqueous protein solution in 
an organic solution of the polymer and is therefore known to be critical for protein 
stability [46, 47]. However, further development of the process towards a W/O/W double-
emulsion method enabled the encapsulation of hydrophilic drugs and proteins [28, 29, 48]. 
Solvent extraction processes for the preparation of proteinaceous drug carriers are adapted 
from the emulsion technique applied for synthetic polymers. In brief, the protein is dissolved 
in an aqueous buffer and a W/O emulsion is created by the addition of a non-solvent. After 
removal of both solvents, solid protein particles are obtained. However, this methods lacks 
from comparatively large particle sizes as reported for BSA (100 to 800 nm) in dependence 
of protein concentration and relative W/O volume ratio [49]. 
With regard to protein-based materials, other preparation methods are more common which 
will be described in section 1.3.1.2 and 1.3.1.3. 
Chapter 1 
 
7 
1.3.1.2 COACERVATION – NON-SOLVENT 
The coacervation/desolvation process was the most frequently applied method in the last 
decade for the preparation of protein-based nanoparticles due to comparatively mild process 
conditions. In brief, the protein matrix is dissolved in a solvent (e.g. aqueous buffer) and 
subsequently extracted into a non-solvent phase (e.g. ethanol). By phase separation, a 
phase with a colloidal component / coacervate and a second phase with a solvent / non-
solvent mixture are formed [44, 50]. Consequently, solvent and non-solvent have to be 
miscible in order to be able to form the second phase (e.g. ethanol/water or acetone/water). 
A stable particle size is reached after an initial process period so that further desolvation 
(addition of non-solvent) solely leads to an increased particle yield. As the coacervation 
process is faster and more efficient at conditions of zero net charge (isoelectric point of the 
protein), the pH of the protein solution is of major importance and can be adjusted towards 
the desired conditions regarding particle size and process yield. 
The described process was performed with several proteins such as human serum albumin 
(HAS) [50-52], bovine serum albumin (BSA) [44], gelatin [53] and β-lactoglobulin [54]. 
However, all protein nanoparticles had to be stabilized by cross-linking of the prime NH2-
groups using chemical cross-linkers. Glutaraldehyde was widely employed without negative 
side effects [50], but as carcinogenic properties of free glutaraldehyde cause regulatory 
issues, new approaches have to be developed to overcome this critical process limitation. 
1.3.1.3 COACERVATION – SALT PRECIPITATION 
A simple approach for preparation of protein-based nanoparticles is the salting out of a 
protein solution to form protein coacervates. Since only aqueous solutions are necessary, 
this approach seems to be very interesting for DDS employing sensitive therapeutic proteins. 
Furthermore, certain therapeutic proteins may be directly transformed into particles without a 
loss of biological activity. This was described e.g. for insulin by exposing the protein solution 
to high sodium chloride concentrations (> 0.5 M) at low pH (< 2.0) in order to obtain insulin 
nanoparticles [55]. The simple technique is also of interest for protein particles acting as drug 
carriers only (e.g. HSA or silk), because large amount of particles can be easily and 
continuously produced. However, higher heterogeneity in particle sizes was reported as 
process parameters may be more difficult to control [44].   
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1.3.2 ALBUMIN 
The most prominent protein used as particulate drug carrier is the blood transporter protein 
albumin, namely human serum albumin (HSA) or in certain cases for research purposes 
bovine serum albumin (BSA). HSA had been intensively investigated as drug carrier for 
several active drug molecules and even successfully entered the market. Two albumin-based 
formulations were approved for use in humans: Albunex™ as ultrasound contrast agent and 
Abraxane™ as a carrier of anticancer drug paclitaxel for treating metastatic breast 
cancer [56, 57]. However, both formulations do not represent a particulate formulation where 
the colloidal system comprises solid discrete and uniformly shaped spheres. 
Albunex™ is an ultrasound contrast agent consisting of a slowly diffusing gas C3F6 which is 
encapsulated by an elastic HSA shell [58]. Thereby, this formulation can be classified as a 
microbubble formulation with an mean diameter of approx. 4 µm (95% < 10 µm) and an 
average shell thickness of 30 to 50 nm [59]. 
Abraxane™ is a self-assembling nanoagglomerate of HSA and paclitaxel which is produced 
by high pressure homogenization [60]. The particle size of the formulation was determined to 
be about 130 nm. This drug product was designed for therapy against metastatic breast 
cancer [61], but was meanwhile evaluated for other anti-cancer treatments such as non-small 
cell cancer, ovarian cancer and pancreas cancer [62, 63]. 
In research, albumin nanoparticles were applied for lots of in vitro and in vivo studies [64]. As 
albumin exhibits a high binding capacity due to multiple drug binding sites present in the 
albumin molecule, electrostatic adsorption of positively (e.g. Ganciclovir) and negatively 
charged (e.g. oligonucleotides) molecules is possible [63]. Furthermore, targeted delivery of 
anticancer drugs can be achieved because of the presence of albumin-binding proteins such 
as membrane associated gp60 (albonin) [57]. Albumin-ligand combinations on the 
nanoparticle’s surface can be used for modifying pharmacokinetic parameters 
(e.g. polysorbate 80 [65]), enhancing the colloidal stability by cationic polymers [66], 
prolonging the circulation half-life (e.g. coating with PEG [64]), slowing down drug release 
and specific targeting (e.g. monoclonal antibodies [67]). 
1.3.3 GELATIN 
Gelatin is a natural polymer derived from animal collagen by acidic (type A) or alkaline 
(type B) degradation. Collagen itself exhibits high stability due to the unique triple-helix 
structure consisting of three polypeptide α-chains. Only collagen types I-III are used for the 
production of gelatin [68]. Gelatin type A is obtained from porcine skin with acidic 
pretreatment before the extraction process, whereas gelatin type B is derived from ossein 
and cut hide split from bovine origin. Due to the different preparation processes, both gelatin 
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types exhibit different isoelectric points (9.0 for type A vs. 5.0 for type B) [69]. Gelatin is 
classified as ‘generally regarded as safe’ (GRAS) by the FDA and is known to be 
biocompatible and biodegradable without toxic degradation products [69, 70]. Moreover, 
intravenous application of gelatin derivatives as plasma expanders is approved for human 
use. 
The preparation of gelatin nanoparticles using a two-step desolvation method and 
subsequent chemical cross-linking by glutaraldehyde was introduced by Coester et al. [53]. 
These nanoparticles exhibited higher storage stability than liposomal liquid formulations and 
maintained their non-toxic properties throughout the preparation process. Furthermore, good 
in vivo stability upon administration was shown [71]. Even though no undesired effects were 
associated with chemically cross-linked gelatin particles, an alternative to glutaraldehyde was 
evaluated [72]. Efficient cross-linking by microbial transglutaminase was demonstrated and 
particle sizes, size distributions and storage stability were comparable to chemically cross-
linked particles so that glutaraldehyde could be substituted in order to ease future clinical 
trials in humans. Nevertheless, immunogenicity of animal-derived gelatin is still an issue. 
Therefore, animal-derived gelatin can be replaced by recombinant human gelatin [73]. 
Similar to albumin, drug delivery applications of gelatin particles covered a wide range 
throughout the last decade and are reviewed elsewhere [69, 74]. Typical applications like the 
delivery of anticancer drugs like paclitaxel [75] and further small molecular weight drugs such 
as chloroquine [76] were investigated. Matrix loading of gelatin particles was shown to 
improve drug load and delivery [77]. However, gelatin nanoparticles were in particular 
successfully evaluated as drug carrier for oligonucleotides [78-80]. In vivo, immunization with 
RNA-loaded gelatin nanoparticles led to an increased and efficient antitumoral immune 
response. Moreover, formulation development regarding freeze-drying of oligonucleotide-
loaded gelatin nanoparticles was performed to provide stable and high concentrated 
formulations [81]. Klier and Fuchs et al. optimized, transferred and successfully implemented 
this drug delivery platform as the first colloidal nanocarrier-mediated immunotherapy in food-
producing animals [82, 83]. Treatment with nebulized CpG-loaded gelatin nanoparticles 
resulted in partial remission of the allergic condition. 
1.3.4 SILK 
A rather new material of natural origin used for drug delivery applications are silk proteins. 
Silk is an ancient material since silk fibers from the mulberry silkworm Bombyx mori have 
been used to produce textiles for thousands of years. The material is known for its attractive 
luster along with light weight and tear resistance. These extraordinary material 
characteristics were also responsible for attracting the attention of biomedical research. Silks 
and especially spider silks combine impressive mechanical stability (see Table 1.2) with 
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biocompatibility and biodegradability and allow various side chain modifications for 
functionalization [84]. Silks are produced by about 34,000 known spider species (class 
Arachnida), most of the 113,000 species of the insect order Lepidoptera (including mites, 
moths and butterflies) and other members of several orders in phylum of arthropods [85]. 
Among all these different silks, the most intensively investigated and characterized ones are 
the cocoon silk from the domesticated silkworm Bombyx mori and spider silk proteins from 
two spider species, namely Nephila clavipes (golden orb-web spider) and Araneus 
diadematus (European garden cross spider) [86-88]. Silk is a very evolutionary specialized 
material with outstanding mechanical properties which can be indispensible to the life of 
animals due to the necessity of silk for prey capture and reproductive success [89]. 
Table 1.2. Mechanical properties of spider silk fibers and other materials [84] 
Material 
Stiffness 
Einit (GPa) 
Strength 
Gmax (GPa) 
Extensibility 
εmax 
Toughness 
(MJ*m
-3
) 
Araneus MA silk 10 1.1 0.27 160 
Araneus viscid silk 0.003 0.5 2.7 150 
Bombyx mori silk / 0.6 0.18 70 
Tendon collagen 1.5 0.15 0.12 7.5 
Bone 20 0.16 0.03 4 
Wool 0.5 0.2 0.5 60 
Elastin 0.001 0.002 1.5 2 
Synthetic rubber 0.001 0.05 8.5 100 
Nylon fiber 5 0.95 0.18 80 
Kevlar 49 fiber 130 3.6 0.027 50 
Carbon fiber 300 4 0.013 25 
High-tensile steel 200 1.5 0.008 6 
1.3.4.1 STRUCTURE AND PROPERTIES OF SILK PROTEINS 
Generally, silk fibers have a core shell type structure and are typically composite materials 
formed of silk protein(s) and other associated molecules such as glycoproteins and 
lipids [90]. Silk proteins from arthropods are extremely large proteins with molecular weights 
ranging from 70 to 700 kDa [91]. The proteins are usually produced in epithelial cells, 
followed by the secretion into the lumen of specialized glands where the silk proteins are 
stored prior to the spinning process [85]. 
Despite the variability in primary sequences, all silk proteins show a well-defined organization 
(see Figure 1.1). The central and by far the largest part of silk fibroin (Bombyx mori) is 
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composed of a repetitive hydrophobic motif (green) and more complex hydrophilic spacers 
(dark blue) of variable but smaller size. In contrast, the N- and C-terminal sequences (purple 
and red) are non-repetitive, more hydrophilic and have a more heterogeneous amino acid 
sequence [92]. Deduced from the characteristic primary structure, silk proteins exhibit a 
predominantly hydrophobic nature. On this account, silk fibers can resist swelling and 
dissolution and are insoluble in most solvents, including water, dilute acid and alkali. 
Investigations on the composition of silk fibroin from Bombyx mori revealed a complex of 
three proteinaceous components. The heavy-chain fibroin (392 kDa) and light-chain fibroin 
(26 kDa) are linked by a disulfide bond. The third component is a glycoprotein called P25 
which has a molecular weight of about 30 kDa [93, 94]. The core sequence of the heavy 
chain comprises hydrophobic core repeats with alanine, glycine and serine residues. These 
core repeats dominate the hydrophobic silk properties. 
B.mori silk fibroin heavy chain 
 
Major ampullate silk protein 
 
 
Figure 1.1. Model of primary structures of silk proteins 
Major ampullate (MA) silk fibers are composed of two silk proteins which differ in their 
hydrophobicity [95], e.g. ADF-3 (hydrophilic) and ADF-4 (hydrophobic) in the case of dragline 
silk produced by the spider Araneus diadematus [96]. A major ampullate silk protein is 
characterized by the repetition of a low complexity consensus motif (grey and blue) wherein 
the hydrophilic component is already included [18]. The presence of higher contents of 
charged amino acid residues such as glutamic acid and arginine is another significant 
difference to Bombyx mori silk. 
Regarding the different mechanical properties of different silks, structure-function 
relationships were determined as listed in Table 1.3. 
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In Bombyx mori cocoon silk, the repetitive core motif is GAGAX (where X = A, S, V or T) and 
is known to be the building block for β-sheet crystals. The non-repetitive, more hydrophilic 
regions act as spacers between the hydrophobic blocks and may adopt a loop structure, 
facilitating an anti-parallel β-sheet formation [92, 97-99]. 
In major ampullate spider silk proteins, polyalanine motifs (GA)n / (A)n adopt the crystalline 
β-sheet structures in assembled fibers. β-sheet stacks and their crystalline characteristics 
result in a high-tensile strength [100, 101]. Glycine-rich motifs GPGQQ or GGX form β-turn 
and 310-helices which connect the crystalline β-sheets. These structures introduce elasticity 
and flexibility in spider silk fibers [18, 102]. The remarkable combination of strength and 
extensibility results in toughness greater than that of any other known high performance 
fibrous material (see Table 1.2) [103]. The central repetitive region is terminated at both ends 
by non-repetitive (NR) domains, which were found to adopt a mainly helical conformation. 
Both NR-domains are not influencing mechanical properties, but the C-terminal domain is 
strongly involved in the protein assembly process [104] and the N-terminal domain is an 
important signal sequence [105]. 
Table 1.3. Typical amino acid motifs of Bombyx mori cocoon silk and major ampullate silk proteins 
correlated with their putative structure 
Origin Motif Putative structure Property 
Bombyx mori  
cocoon silk 
GAGAGS 
β-sheet crystalline 
GAGAGY 
spacer random coil amorphous 
GAAS β-turn elastic 
Major ampullate 
spider silk 
(GA)n / An β-sheet crystalline 
GPGQQ β-turn elastic 
GGX 310-helix amorphous 
NRN-domain 
α-helical assembly process 
NRC-domain 
1.3.4.2 NATURAL ASSEMBLY PROCESS 
In nature, spiders possess the ability to control, adjust, and rapidly fine-tune silk protein 
composition, fiber diameter and drawing rate, all leading to silks with highly `tuned` 
mechanical properties. Up to date, the highly complex natural spinning process cannot be 
entirely mimicked in vitro [106]. For this reason, several studies were performed in order to 
clarify the detailed mechanism of the silk fiber formation process [21, 98, 107]. A detailed 
review on the natural self-assembly process is given by Heim et al. [108]. 
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In brief, silk fibers are formed on demand in the spinning duct by a complex liquid-solid 
phase transition process which is accompanied by structural changes to form a stable fiber. 
The phase transition is triggered by several biochemical and physical factors involving slight 
acidification from pH 7.2 to 6.3, ion exchange of more chaotropic (e.g. Na+) to more 
kosmotropic (e.g. K+) ions and water removal. In combination with an elongational flow and 
shear forces, the unique structure of a spider silk fiber is formed. Once silk proteins have 
been spun into fibers, extreme conditions such as high salt concentrations or strong acids 
are required to facilitate resolving of the assembled silk proteins [109]. Interestingly, protein 
solutions having concentrations of up to 50% are stored in the glands without premature 
protein aggregation prior to the spinning process. The prevention of aggregation is most 
likely based on their almost completely random coiled structure [110, 111]. Furthermore, a 
high concentration of sodium chloride is assumed to stabilize the one-phase solution and to 
inhibit a premature phase-separation and oligomerisation of silk proteins [96, 112]. 
Two theories on the molecular mechanism of the silk fiber assembly have been 
proposed [98, 113]. The first one assumes a liquid crystalline state to be the basis for the 
formation of intermolecular interactions. This liquid crystalline behavior is a result of the 
alignment of protein molecules and the increased protein concentration [113]. The second 
theory describes an assembly into small micelles due to the amphiphilic character of silk 
proteins. A multitude of these micelles form larger globules and shear stress finally forces 
these globules into an elongated shape, leading to fiber formation [98]. 
1.3.4.3 IMMUNOGENICITY AND BIODEGRADATION OF SILK PROTEINS 
Silk fibers from Bombyx mori have been used as surgical sutures for decades. Besides this 
proven efficacy, some biological responses to silk proteins have raised questions about its 
biocompatibility. In contrast to spider silks, core fibers from Bombyx mori are encased in a 
sericin coat. Sericin proteins are a family of glue-like proteins which hold two fibroins together 
to form the composite fiber of the cocoon case [13]. On this account, silkworm silk is 
subjected to a degumming procedure and purification steps to almost entirely remove sericin 
[93]. The core fibroin without sericin appeared to be comparable to other biomaterials when 
used as suture material [13]. 
Santin et al. investigated the inflammatory potential of silk membranes [114]. In comparison 
to polystyrene and poly(2-hydroxyethyl)methacrylat, silk membranes elicited a lower 
macrophage activation. Panilaitis et al. analyzed native silk fibers and sericin-free silk in an in 
vitro macrophage assay [115]. Only the sericin comprising silk fibroin represented a potential 
stimulus, whereas sericin-free silk induced neither macrophage activation nor pro-
inflammatory cytokines transcription. Likewise, inflammatory responses in vitro and in vivo 
were determined to be more conspicuous around collagen and PLA films when compared to 
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silk fibroin films casted from hexafluoroisopropanol solutions seeded with bone-marrow 
derived mesenchymal stem cells [116]. 
It is self-evident that silk proteins are susceptible to proteolytic degradation. However, silk 
fibers as mechanically robust material showed only long-term degradation 
characteristics [13, 117]. The in vivo degradation of three-dimensional scaffolds made of 
Bombyx mori silk in rats strongly depended on the preparation method (aqueous or 
hexafluoroisopropanol) and structural characteristics. Therefore, biodegradation could be 
predicted and controlled to match different needs. All scaffolds investigated were well 
tolerated and immune responses to silk implants were mild [118]. Native spider silk was 
shown to combine biodegradability and immunotolerance that equals other commonly used 
implantable polymers [14]. Further in vivo studies also found no evidence for any 
immunological response to native spider silks [119]. In vivo biocompatibility and 
biodegradation behavior of non-wovens made of the recombinant spider silk protein 
eADF4(C16) were performed by AMSilk and did not reveal any immunologic responses to 
the biomaterial (oral communication). 
1.3.4.4 SILKWORM SILK FOR DRUG DELIVERY 
Due to the described mechanical and non-immunogenic properties, silk fibroin provides an 
interesting material for an application as surgical threads, biomaterial for tissue engineering 
and drug delivery system [120]. This section focuses on the latter and describes the 
published studies on silkworm silk in the field of drug delivery. Tissue engineering and other 
applications are reviewed elsewhere [121-126]. Silk protein scaffolds are able to support in 
vitro cell adhesion, proliferation and differentiation, and are mainly used in stem-cell based 
tissue engineering for bone and nerve regeneration. 
Drugs that have been employed in delivery systems made of silk fibroin are summarized in 
Table 1.4. Drug release was controlled by both the characteristics of the incorporated drug 
and the used polymer matrix. The silk protein matrix is in vitro considered as a non-
degradable material with regard to release mechanisms, whereby attention should be paid to 
the swelling of the system. In vivo, the matrix is degraded by proteases over a long time 
period (> 60 days). However, it is assumed that due to the very slow degradation process 
this will not have a pronounced influence on the release profile of incorporated drugs. 
Silk fibroin provides an interesting new coating material. It has been investigated as a 
potential aqueous film coating agent for solid pharmaceuticals. Theophylline tablets were 
coated with a silk fibroin solution mixed with polyethylene glycol as plasticizer [127]. A 
sustained drug release following zero-order kinetics was achieved. Silk coating was further 
applied to emodin-loaded liposomes [128]. The overall efficacy to breast cancer cells was 
enhanced due to increased retention of emodin in the cell and protection against fast release 
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and metabolism. This was achieved by a reduced swelling behavior of silk coated liposomes. 
Wang et al. coated PLGA and alginate microspheres with silk protein by layer-by-layer 
assembly technology and investigated the release of encapsulated protein model drugs 
horseradish peroxide (HRP) and BSA [129]. A significantly retarded protein release was 
obtained which could be further enforced by methanol treatment of the silk coating. 
Table 1.4. Applications of Bombyx mori silk in the field of drug delivery 
Silk fibroin coatings and silk films    
Topic Drug Reference  
Dip coating of theophylline tablets Theophylline Bayraktar et al. [127] 
Silk coated emodin-loaded liposomes Emodin Gobin et al. [128] 
PLGA and alginate microspheres coated with silk fibroin HRP 
TMR-BSA 
Wang et al. [129] 
Nanoscale layered coatings on quartz slides Rhodamine B 
Evans Blue 
Azoalbumin 
Wang et al. [130] 
Silk coatings on tissue culture plates and metallic stents to 
modulate vascular cell responses 
Paclitaxel 
Clopidogrel 
Heparin 
Wang et al. [131] 
Sustained adenosine release in rats Adenosine Szybala et al. [132] 
Silk coating of solid powder reservoirs for sustained release of 
adenosine 
Adenosine Pritchard et al. [133] 
Release of macromolecules in dependence of crystallinity of the 
silk films 
Dextrans 
HRP 
Lysozyme 
Hofmann et al. [134] 
Silk fibroin/gelatin multilayered films for controlled drug release Trypan blue 
FITC-inulin 
FITC-BSA 
Mandal et al. [135] 
Release of HRP from silk fibroin films HRP Lu et al. [136] 
NGF-loaded silk fibroin nerve conduits for peripheral nerve repair NGF Uebersax et al. [137] 
Silk films for enhanced thermostability of both antibiotics and 
vaccines 
Tetracycline 
MMR vaccine 
Zhang et al. [138] 
Silk fibroin particles    
Topic Drug Reference  
Microspheres using lipid vesicles as templates HRP Wang et al. [139] 
Growth factor delivery by silk microspheres incorporated into 
alginate scaffolds 
rhBMP-2 
rhIGF-I 
Wang et al. [140] 
Preparation method using silk/PVA blend films and in vitro release 
evaluation for silk nano- and microspheres 
TMR-BSA 
TMR-Dextran 
Rhodamine B 
Wang et al. [141] 
Preparation by vibrational splitting of laminar jet and in vitro drug 
release studies 
Salicylic acid 
Propranolol 
IGF-I 
Wenk et al. [17] 
Silk fibroin microparticles prepared by ethanol addition and drug 
release of rhBMPs 
rhBMPs Bessa et al. [142] 
Preparation by salting out and in vitro release of compounds 
dependent on the secondary structure 
Alcian blue 
Rhodamine B 
Crystal violet 
Lammel et al. [143] 
Silk fibroin-albumin blended nanoparticles Methotrexate Subia et al. [144] 
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The mechanically stable shells stabilized the microspheres and provided an effective 
diffusion barrier. A multi-layered structure was created by a stepwise deposition of silk fibroin 
and model drugs by dip-coating on quartz slides as substrate [130]. Higher crystallinity and a 
thicker silk capping layer suppressed the initial burst and prolonged the duration of release. 
This multi-layered matrix was shown to be an effective system for drug-eluting coatings, such 
as for metallic stents when heparin or clopidogrel were incorporated [131]. Several studies 
were performed in order to evaluate the use of silk fibroin for controlled release of adenosine 
[132, 133]. Szybala et al. used implants comprising silk microspheres and silk films to 
release 1000 ng adenosine per day in kindled rats. At least partial anti-epileptogenic effects 
were observed [132]. Solid adenosine powder reservoirs were coated with silk fibroin to 
achieve local, sustained and controlled adenosine release from degradable implants. Eight 
layers of 8% [w/V] silk resulted in a linear and sustained release over 14 days [133]. 
With regard to silk films and particles, the structure and crystallinity of the silk matrix was 
shown to be crucial for drug release. The polymer matrix was modified by increasing the 
employed silk protein concentration, resulting in lower burst and total release rates [17]. 
Another strong influence on the release profile was observed when the crystallinity of the silk 
matrix was altered [134, 139]. An increased β-sheet structure led to a strong and molecular 
weight dependent retardation of the release of FITC-dextran [134]. Silk microparticles were 
either treated with methanol or sodium chloride in order to induce β-sheet formation by Wang 
et al. [139]. Methanol was more efficient and caused lower release of HRP compared to 
sodium chloride treated microparticles. HRP was released in its native and bioactive form, 
whereas the same post-treatment had a detrimental effect on lysozyme and led to a total loss 
of activity [134]. Using also HRP as model protein, Lu et al. stated that the loaded protein 
drugs are present in silk films in at least two states, untrapped and trapped [136]. The ratio 
and stability of both states depended on the interactions between the enzyme and silk fibroin. 
Untrapped enzyme was responsible for the burst release, whereas trapped HRP could only 
be released following very slow dissolution or proteolytic degradation. The entrapment 
occurred due to physical entrapment as well as hydrophilic and/or hydrophobic interactions. 
Due to different film treatments, the content of untrapped HRP was decreased to 
almost 0% [136]. A multilayer system made of silk fibroin/gelatin blend was successfully 
employed for controlled drug release of different model compounds [135]. The release was 
shown to be dependent on multilayer film degradation rate rather than on the molar mass of 
the drug molecules. For this reason, modification of the release rate could be achieved by 
selective change of the formulation. Controlled release of nerve growth factor (NGF) over 
3 weeks was obtained from silk fibroin nerve conduits [137]. The matrices were easily 
prepared by drying (air-dried or freeze-drying) in suitable molds. The potency of released 
NGF was retained within all formulations. A different approach was evaluated by Zhang et 
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al. [138]. Silk film systems were used as an effective carrier material to enhance 
thermostability of both antibiotics and vaccines, aiming for eliminating the cold chain. 
Increased stability of the susceptible formulations during storage at higher temperature was 
achieved by reducing residual moisture. 
With regard to the active ingredient, the molecular weight was shown to significantly 
influence the release kinetics as presented for dextrans with different molar masses [134]. 
Furthermore, the interaction of the drug with the silk matrix is critical. Wenk et al. 
demonstrated that propranolol (pKa = 9.5) has a slower release rate compared to salicylic 
acid (pKa = 3.0), which can be attributed to the opposite interaction forces with the negatively 
charged silk matrix (pKa = 4.2) [17]. Additionally, dissimilar hydrophobic interactions 
contributed to the observed release kinetics in this study.  
Silk fibroin can also be processed into spheres as a platform for controlled drug delivery. 
Water-insoluble microspheres were prepared by using the synthetic phospholipid derivate 
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC). Silk protein and a model protein drug 
(HRP) were encapsulated in multilamellar phospholipid vesicles [139]. Smaller unilamellar 
vesicles were generated by freezing and thawing steps. After lyophilization, the addition of 
methanol or sodium chloride solutions removed the DOPC, induced β-sheet formation and 
simultaneously entrapped the protein drug in the silk protein matrix. Silk fibroin was further 
used as matrix for microsphere-mediated growth factor delivery in polymeric scaffolds for 
osteochondral tissue engineering [140]. Silk microspheres were more efficient in the delivery 
of recombinant human bone morphogenetic protein 2 (rhBMP-2) than recombinant human 
insulin-like growth factor I (rhIGF-I), which was attributed to the different properties of both 
growth factors. After a release period of 14 days, 70% of rhIGF-I was released whereas only 
15% released rhBMP-2 was determined. Wang et al. developed a three-step preparation 
method for silk nano- and microspheres from silk/PVA blend films [141]. Spherical as well as 
spindle-shaped particles were obtained. As a proof of concept, tetramethylrhodamine-BSA 
(TMR-BSA), TMR-Dextran and Rhodamine B were encapsulated. The loading efficiency was 
94.5% for RhB, 51.2% for TMR-BSA and 1.2% for TMR-Dextran. The determined high 
release rate for TMR-Dextran and lower release rates for TMR-BSA and Rhodamine B 
indicated that the interaction between silk and the encapsulated drug controlled the release 
rather than diffusion processes. Silk fibroin microparticles were further employed as carrier 
for the delivery of BMP-2, BMP-9 and BMP-14 [142]. Particles were prepared by addition of 
an anti-solvent (ethanol). A two-phasic release profile was observed which consisted of a 
burst release in the first two days followed by a slower release for a period of 14 days. Higher 
loading resulted in lower release rates. Silk fibroin particles prepared by a simple salting out 
process using potassium phosphate were presented by Lammel et al. [143]. Loading of small 
model drugs was achieved by simple absorption and diffusion into the particle matrix in an 
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incubation step after particle preparation based on electrostatic interactions. In vitro release 
of these compounds revealed a dependency on the drug-specific interaction with the silk 
matrix (positively charged molecules – more prolonged release) as well as on the crystallinity 
(secondary structure) of the particles. Silk fibroin-albumin nanoparticles were prepared by a 
desolvation method without surfactant [144]. Loaded with methotrexate, those particles 
showed promising results regarding drug release (85% of methotrexate was released within 
the first 12 days), internalization by cells, viability and biocompatibility. 
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1.4 SPIDER SILK PROTEINS 
Spider silks gained an increasing interest in the group of silk proteins because of their 
extraordinary mechanical properties by which they are able to outperform every other natural 
or synthetic material (see Table 1.2). Therefore, applications of spider silks are conceivable 
in a multitude of different ways ranging from body armor or cosmetics to pharmaceutical and 
biomedical applications. 
However, spider silk materials were not commercialized due to a number of challenges. The 
major issue was to overcome the limitations of a biomaterial being only available from natural 
origin at very low amounts compared to e.g. silkworm silk [13]. The group of Prof. Scheibel 
solved this problem by developing a recombinant production process that is able to produce 
spider silk-like proteins at high yields and sufficiently high amounts (at least at kilogram 
scale). This process enabled the broad use of spider silk proteins for the variety of the 
abovementioned applications. 
1.4.1 DEVELOPMENT OF RECOMBINANT SPIDER SILK PROTEINS 
1.4.1.1 TYPES OF SPIDER SILK PROTEINS 
Spiders evolved the ability to produce a variety of task-specific silks which exhibit surprisingly 
different mechanical properties. Spiders use their silks for many different purposes compared 
to insects. Figure 1.2 shows the seven different silks Araneus diadematus is able to produce. 
 
Figure 1.2. Different types of silk produced by the European garden cross spider Araneus diadematus. 
The yellow box highlights the dragline silk consisting of two proteins, namely ADF3 and ADF4. 
Araneus diadematus
(garden cross spider)
major ampullate silk gland
dragline silk
flagelliform silk gland
capture spiral thread
minor ampullate silk gland
auxiliary spiral thread
aggregate silk gland
sticky aqueous coating
piriform silk gland
attachment center
cylindrical silk gland
tough outer egg case
aciniform silk gland
soft inner egg and wrapping
two proteins 
ADF-3/ADF-4
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The dragline and flagelliform silk are the two most interesting silks. The major ampullate 
glands produce the dragline silk that is utilized for radial threads and spider safety lines. 
These silk fibers are between 1 and 20 µm in diameter and exhibit very high tensile strength 
combined with moderate elasticity [100]. Major ampullate silks are composed of two types of 
silk protein. In the case of Araneus diadematus, these proteins are abbreviated as ADF3 and 
ADF4. All pairs of dragline silk proteins even from different spider species share a common 
repetitive architecture [95, 97] and additionally display a distinct distribution in hydrophobicity 
and charge (see section 1.3.4.1) [145]. 
In contrast to structural silks, flagelliform silks are used for capturing prey where the silk fiber 
has to withstand the impact energy of flying insects. Consequently, mechanical properties 
have to be different from dragline silks. As depicted in Table 1.2, elasticity is nearly 9-fold 
higher. Flagelliform silks consist only of a single protein whose primary sequence is 
composed of large amounts of proline and valine and reduced alanine content [93]. 
1.4.1.2 ENGINEERED SPIDER SILK PROTEINS 
As mentioned previously, harvesting of spider silk from spiders would not allow for the 
intended applications of this biomaterial. Therefore, large amounts of spider silk proteins can 
only be obtained by recombinant production processes as established for other therapeutic 
proteins. However, spider silk gene sequences comprise some difficulties and limitations 
concerning recombinant protein production. The highly repetitive nature and length of the 
gene sequences (over 9,000 base pairs), the large molecular weight and specific codon 
usage of spiders inhibited a successful expression of full length spider silk clones up to 
now [18, 146, 147]. The well-known and comparatively cheap host system E. coli was not 
suitable to maintain such highly repetitive protein sequences due to genetic deletions and 
termination errors during protein synthesis. Thus, other host systems like insect cell lines 
were studied, but even though these approaches were not successful [120, 146]. 
Alongside the purpose to create native spider silk proteins, the group of Prof. Scheibel 
focused on the development of engineered synthetic spider DNA. Finally, they succeeded in 
producing high yields of spider silk-like proteins in a cheap host system (E. coli) [18]. In brief, 
Huemmerich et al. chose the dragline silk from Araneus diadematus as natural model [19]. 
Single conserved oligonucleotides were engineered and synthesized which encode for the 
consensus motifs of the original protein (see Figure 1.3). Furthermore, codons of the host 
system were adapted. Using a seamless cloning strategy, these oligonucleotides were 
replicated to generate longer silk-encoding gene sequences and finally, authentic non-
repetitive regions were linked to the synthetic gene sequence. 
ADF3 and ADF4 were used as templates [19]. Only one conserved module C was necessary 
for the construction of the engineered Araneus diadematus fibroin 4 (eADF4). This 
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engineered eADF4 protein consists of 16 identical modules C as shown in Figure 1.3 and is 
therefore also called C16. 
The recombinant spider silk proteins contain one third fewer polyalanine motifs compared to 
their natural models. But altogether, these proteins closely resemble the authentic silk 
proteins and can be produced at high yields and purities in an established bacterial 
expression system, thereby enabling cost-efficient large scale production [18]. Furthermore, 
spider silks produced by recombinant techniques offer the possibility to modify gene 
sequences and to create proteins with specialized characteristics. This was already shown 
for genetically engineered silkworm silk [148]. Genetic engineering can also lead to a novel 
family of fusion (= chimeric) proteins which then exhibit tailored properties. The new options 
for processing and control of material properties may result in important benefits for 
biomedical applications [149]. 
Natural spider silk protein ADF4 
 
Engineered spider silk protein eADF4(C16) 
 
Figure 1.3. Development and structure of the engineered spider silk protein eADF4(C16) 
1.4.2 SPIDER SILK PROTEIN eADF4(C16) 
1.4.2.1 CHARACTERISTICS OF eADF4(C16) 
A detailed characterization is essential to describe and compare the characteristics of 
eADF4(C16) to other silk proteins or polymers in general. Table 1.5 provides an overview of 
selected biochemical properties both of the natural protein ADF4 and the engineered protein 
eADF4(C16). Higher hydrophobicity, expressed by higher mean hydropathicity, and a lower 
net charge for ADF-4 compared to eADF4(C16) resulted in a high intrinsic insolubility of the 
native protein. eADF4(C16) was up to 8% [w/V] soluble in water and gel-like states occurred 
upon higher concentration [19]. 
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Table 1.5. Selected properties of native spider silk protein and engineered eADF4(C16) [19] 
 
eADF4(C16) ADF-4 
molecular weight [kDa] 47.7 34.9 
no. of charged amino 
acid residues [pos/neg] 
0 / 16 2 / 6 
mean hydropathicity - 0.464 - 0.075 
solubility [%, w/V] 8 < 1 
Subsequently, the influence of ions on the assembly behavior was studied according to the 
natural assembly process [19]. Concentrations of 300 mM sodium and potassium chloride 
did not result in any protein aggregation. However, potassium and sodium phosphate at the 
same concentration induced precipitation (12%) of eADF4(C16), but in a lower extent 
compared to the natural protein ADF-4. It was assumed that weaker precipitation tendency 
can be assigned to the relatively strong net charge of the recombinant protein and missing 
phosphorylated amino acid residues. Therefore, protonation of glutamate residues of 
eADF4(C16) is not as efficient as protonating the native ADF-4 protein regarding protein 
aggregation. Even acidification (pH 1) was not able to promote aggregation by establishing a 
strong hydrophobic core [150]. Liquid-liquid phase separation occurred at potassium 
phosphate concentrations higher than 400 mM. Spherical eADF4(C16) particles were 
spontaneously formed in contrast to nanofibrillar structures at lower concentrations [151]. 
1.4.2.2 PROCESSING OF eADF4(C16) 
The correlation of molecular sequence to mechanical properties and consequently the 
feasibility to control the properties of the biomaterial have attracted several research groups 
to produce multi-purpose materials of controlled strength, extensibility and stiffness [152]. 
The spider silk protein eADF4(C16) can be processed into a diverse set of morphologies 
including solid spheres, hydrogels, films and microcapsules. 
eADF4(C16) particles 
Slotta et al. investigated the concentration dependent formation process of solid protein 
spheres and its underlying mechanism [20]. It is shown in Figure 1.4 that low concentrations 
of potassium phosphate (< 300 mM) led to protein self-assembly into nanofibrils. These 
nanofibrils with a diameter between 2 and 10 nm were formed due to a neutralization of the 
columbic repulsion between the glutamate residues of eADF4(C16). Therefore, formation of 
nanofibrils was further influenced by pH and ionic strength of the aqueous buffer solution. 
Higher concentrations of potassium phosphate (> 400 mM) resulted in the formation of stable 
and solid protein spheres with a particle size of approx. 1 µm. The underlying mechanism 
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was described as a phase separation process induced by potassium and phosphate ions 
which are known to strengthen hydrophobic interactions and to decrease the solubility of 
nonpolar molecules according to the Hofmeister series [153-155]. A dense protein-rich phase 
was created which caused the formation of protein nuclei accompanied with structural 
transition of the protein’s secondary structure and further sphere growth [20]. Sphere 
formation happened fast and was completed after 120 s. The surface analysis revealed 
smooth protein particles and the secondary structure of the particles’ protein matrix showed a 
significant amount of β-sheet structure (64%). 
 
Figure 1.4. Self-assembly and phase separation process of eADF4(C16) in dependence of potassium 
phosphate concentration. 
Detailed insight in the importance of processing conditions for eADF4(C16) particle formation 
was given by Lammel et al. [22]. The size of eADF4(C16) particles was easily controlled by 
protein concentration (direct proportionality) and mixing intensity (indirect proportionality). 
Furthermore, the concentration of potassium phosphate was confirmed to be crucial for the 
particle formation process. A concentration of 500 mM resulted in large clusters of 
eADF4(C16) particles which disintegrated upon shear stress. At a concentration of 1 M, fully 
developed eADF4(C16) particles were formed at an eADF4(16) concentration of 0.5 mg/mL. 
These protein particles maintained their particle size of about 300 nm during shear stress. 
The time period for the salting out process at 1 M potassium phosphate was determined to 
be 30 s. 
eADF4(C16) films 
Spider silk protein films were easily prepared by casting eADF4(C16) solutions onto 
substrates and subsequent evaporation of the solvent (see Figure 1.5) [156]. The dried films 
needed to be peeled off from the support for further usage and could be structurally or 
chemically modified afterwards [157, 158]. Non-aqueous solvents such as 
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hexafluoroisopropanol (HFIP) [157, 159] and formic acid [160] were used first due to the high 
solubility of eADF4(C16) in these organic solvents. However, aqueous protein solutions were 
employed recently and the different impact of the used solvent on the thermal stability and 
mechanical properties of the resulting spider silk films was demonstrated [161, 162]. 
Junghans et al. compared the mechanical properties of films made of recombinant 
eADF4(C16) protein to other silk proteins such as sericin-free silkworm silk and another 
recombinant spider silk protein from plants [163]. Thin layers were prepared by spin-coating 
and casting from HFIP silk protein solutions. The outcome of this study was that only films 
made of eADF4(C16) combined superior hardness with a predominantly elastic behavior. 
As a separate research project on the development of eADF4(C16) films for drug delivery 
was started in our research group in 2010, further details about spider silk films will not be 
presented in this work. 
 
Figure 1.5. Preparation of eADF4(C16) films by casting/evaporation and subsequent post-treatment [156] 
eADF4(C16) microcapsules 
A second particulate morphology was derived from eADF4(C16) due to its amphiphilicity and 
controllable structure. Microcapsules were generated by an emulsion process as it is shown 
in Figure 1.6. The aqueous spider silk protein solution was emulsified in an oily component 
(e.g. toluene), so that the amphiphilic protein quickly adsorbed at the water-oil interface. A 
thin protein film was formed at the surface of the aqueous droplets encapsulating its content. 
During the film formation process, protein conformation changed to a β-sheet rich 
conformation. Therefore, the obtained microcapsules were stable and could be transferred 
into an aqueous phase by sedimentation or by the addition of ethanol. The capsule formation 
process was, similar to sphere formation, a very fast process due to the intrinsically unfolded 
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structure of eADF4(C16). Microcapsules with diameters from 1 to 30 µm were obtained. The 
protein shell was determined to be not more than 6 nm in thickness [164]. 
The microcapsules were further characterized by encapsulating fluorescein isothiocyanate 
(FITC) labeled dextran with a median molecular weight of 40 kDa. Partial permeation was 
observed and attributed to a fraction of FITC-dextran with lower molecular weight than the 
molecular weight cuff off of the spider silk capsule [164]. Hence, this cut off was calculated to 
be 27 kDa by determination of the permeability of FITC-dextran [165]. Permeability varied 
inside the capsule dispersion, but was always between 16 and 47 kDa. Further investigation 
of this morphology revealed resistance to osmotic stress, high elasticity and excellent 
chemical stability against denaturants. The protein capsules were digested by Proteinase K 
to release encapsulated molecules [164]. Chemical crosslinking of eADF4(C16) with 
ammonium persulfate (APS) prevented enzymatic digestion. 
 
Figure 1.6. Preparation of microcapsules made of eADF4(C16) protein [164] 
eADF4(C16) hydrogels 
The major disadvantage of hydrogels made of biopolymers for biomedical applications is the 
limited range of mechanical properties [166]. Therefore, hydrogels made of silk proteins may 
overcome this drawback. 
Rammensee et al. performed a rheological characterization of hydrogels made of 
eADF4(C16) [167]. The addition of 10% [w/V] methanol to eADF4(C16) solutions with 
concentrations between 5 and 30 mg/mL led to self-assembly of the spider silk protein into 
semi-flexible nanofibers which formed branch-like structures in a concentration dependent 
manner. The obtained hydrogels were transparent and sufficiently viscous. Although being 
easily disrupted by agitation or shearing, the hydrogels were stable over weeks and had a 
high elastic modulus due to the persistence length of the semi-flexible spider silk protein 
network. 
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1.4.2.3 eADF4(C16) FOR DRUG DELIVERY 
All presented morphologies of eADF4(C16) can in principle be applied for drug delivery of 
active pharmaceutical ingredients. However, the deep understanding of the phase transition 
behavior of the recombinant protein eADF4(C16) from initially unstructured protein molecules 
into solid protein spheres [22] and the ease of handling led to the prioritization of studies on 
eADF4(C16) particles. 
Liebmann et al. conducted a proof-of-concept study for the encapsulation of poorly water-
soluble substances into spider silk microbeads [168, 169]. eADF4(C16) microbeads were 
formed by mixing or dialyzing a solution containing eADF4(C16) at 10 mg/mL and β-carotene 
(30 to 300-fold excess of soluble eADF4) with or against 600 mM potassium phosphate 
(pH 8.0). β-carotene was chosen due to its strong affinity to hydrophobic surfaces. The study 
revealed that eADF4(C16) is able to colloidally stabilize β-carotene in an aqueous solution by 
encapsulation/co-precipitation of β-carotene (nano)particles into eADF4(C16) protein 
microbeads. Thereby, further agglomeration of β-carotene particles was prevented. The 
protein microbeads were qualitatively analyzed by electron microscopy. The microbeads 
exhibited diameters in the range from 1 to 5 µm. The surface of microbeads comprising β-
carotene particles appeared to be considerably rougher than the surface of empty 
eADF4(C16) particles. The encapsulated β-carotene was released by proteolytic degradation 
of the protein microbeads using proteinase K and intestinal fluid (pankreatin), whereas 
gastric fluid containing pepsin was not able to digest eADF4(C16) particles. Therefore, it was 
assumed that poorly water-soluble substances can be transported through the stomach and 
delivered in the intestine by encapsulation into eADF4(C16) microbeads. 
A different formulation strategy for drug delivery was carried out by Lammel et al. [23, 24]. 
eADF4(C16) particles were prepared first and loading with an active pharmaceutical 
ingredient was performed afterwards. It was shown that small molecules with a positive net 
charge can diffuse into the negatively charged protein matrix driven by electrostatic 
interactions. The efficiency of this loading strategy depended on the properties of the small 
molecules of weak alkaline nature: the distribution coefficient (logD) and the weigth (size) of 
the molecule (MW) (see Figure 1.7). During this study, constant release rates were obtained 
for ethacridine lactate and methyl violet at physiological conditions over a period of one 
month. For this reason, this formulation strategy was chosen for further proceeding 
employing protein molecules, aiming for efficient loading at gentle conditions and constant 
release over a sufficiently long time period. 
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Figure 1.7. Loading efficiencies for model drugs of weak alkaline nature [23]: Ephedrine (Eph), 
Procain (Prc), Biperiden (Bip), Propranolol (Prp), Papaverine (Pap) and Tetracaine (Tet) 
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1.5 OBJECTIVES OF THE THESIS 
The overall aim of this thesis was a broad investigation of the spider silk protein eADF4(C16) 
with regard to an application as new biomaterial for colloidal drug delivery systems. The 
obtained results using eADF4(C16) particles may further be transferred to other 
morphologies like spider silk protein films or hydrogels. 
This project was justified because there is to date still a clear need for biodegradable 
materials which have to be available in adequate amounts meeting the required quality and 
safety profile for pharmaceutical excipients. The derived delivery systems have to be easily 
prepared using an adaptable and upscalable technique. Stability of the encapsulated drugs 
with special attention to protein therapeutics is a further necessity. A broad field of 
application makes such a delivery system an exciting technology for investors and 
pharmaceutical companies. 
Thus, the first major objective of this thesis was the clarification of the phase separation 
process in order to set up a standardized particle preparation technique and manufacturing 
process (chapter 3). Two different techniques for the preparation of eADF4(C16) nano- and 
microparticles were evaluated and process limitations as well as critical process parameters 
were elaborated. The aqueous eADF4(C16) solution as intermediate of the manufacturing 
procedure was deeply characterized to elucidate its potential influence on the following 
phase separation process. A second goal of this particular project was the development of a 
stable colloidal formulation. For this reason, lyophilization of particulate formulations 
comprising different excipients was developed for empty and lysozyme-loaded eADF4(C16) 
nanoparticles. 
The use of eADF4(C16) particles for drug delivery was recently investigated for small 
molecular weight drugs [23]. Different types of drugs were loaded on submicron particles by 
so-called remote loading which means loading during an incubation step after particle 
preparation. This study was the basis for the second major aim of this thesis: the applicability 
of eADF4(C16) particles as drug carrier for high molecular weight drugs like protein 
pharmaceuticals (chapter 4). First, loading was performed according to the explained remote 
loading procedure and the in vitro release was examined. Lysozyme and nerve growth factor 
(NGF) were employed as protein drugs for this study. The loading mechanism was 
investigated using different fluorescein isothiocyanate (FITC) labeled macromolecules. 
Secondly, drug encapsulation was performed as comparison to the remote loading 
procedure. 
Besides an application as potential drug delivery system, another objective of this thesis was 
the evaluation whether the colloidal formulation consisting of NGF-loaded spider silk particles 
can be superior to a particle-free NGF formulation regarding the prevention of protein 
aggregation in forced degradation studies (chapter 5). Especially the determined matrix 
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loading of particles was supposed to be beneficial as the protein itself is less exposed to 
stress factors compared to the particle-free formulation. Binding of the protein to the particles 
driven by electrostatic interactions may also stabilize the native, folded state of the protein. In 
order to prove these assumptions, forced degradation studies comparing the suspension and 
the particle-free protein formulation were performed. Freeze-thawing, stirring, light exposure 
and incubation at elevated temperatures were conducted to obtain an insight into the 
different processes and mechanisms occurring without or in presence of spider silk particles. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 PROTEINS 
2.1.1.1 SPIDER SILK PROTEIN eADF4(C16) 
An introduction to the unique properties of spider silk proteins has already been given in 
section 1.4 of the first chapter. For this reason only the biochemical properties of 
eADF4(C16) will be explained in the following section. 
The amino acid sequence and recombinant production of eADF4(C16) was developed by 
Prof. Dr. Thomas Scheibel [1]. The protein consists of 16 repetitions of a protein sequence 
named module C. 
 
Figure 2.1. Amino acid sequence of the engineered module C of the spider silk protein eADF4(C16) 
Important features can be derived from the primary structure displayed in Figure 2.1. Firstly, 
the protein is dominated by hydrophobic amino acid residues such as alanine or tyrosine, but 
hydrophobic blocks are interrupted in each case by hydrophilic side chains such as serine 
residues resulting in a mean hydropathicity of -0.464 [2]. Secondly, this spider silk protein 
does not contain any tryptophan residues. This is a very important fact for the separation 
from other foreign protein species during downstream processing. Thirdly, on account of its 
amino acid sequence, which includes glutamic acid as the only one charged amino acid 
residue per module C, eADF4(C16) has a theoretical isoelectric point of 3.48. 
The entire protein eADF4(C16) has a molecular weight of 47.7 kDa and was provided by 
AMSilk GmbH (Martinsried, Germany) after downstream processing and subsequent drying 
of the final protein solution. Furthermore, at this point of development AMSilk provided the 
eADF4(C16) protein incorporating a T7-Tag (MASMTGGQQMG). This tag was initially 
coupled to the protein in order to detect the protein in first vivo experiments. eADF4(C16) 
exhibits a molar extinction coefficient of 46,400 M-1*cm-1 at 276 nm [2]. The extinction 
coefficient was used for the concentration determination by UV-spectroscopy which was 
carried out on an Agilent 8453 UV-VIS diode array spectrophotometer. 
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2.1.1.2 LYSOZYME 
Lysozyme from chicken egg white was purchased as lyophilized powder from Sigma Aldrich 
(St. Louis, MO, USA). It is a single chain polypeptide of 129 amino acids and exhibits a 
molecular mass of 14,307 Da. The isoelectric point of lysozyme is 11.35 according to 
literature [3]. An extinction coefficient of EmM (280 nm) = 36 was used for the calculation of 
lysozyme concentration by UV-spectroscopy (Agilent 8453 diode array spectrophotometer). 
The activity was declared to be ≥ 40,000 units/mg protein, and aqueous solutions should 
retain their activity for at least one month when stored at 2-8°C [4]. 
2.1.1.3 NERVE GROWTH FACTOR 
Recombinant human nerve growth factor (NGF) was a gift from Roche Diagnostics GmbH, 
Penzberg, Germany. Nerve growth factor plays an important physiological role in the 
development and maintenance of both sympathetic and sensory neurons and their neuronal 
extensions [5] as well as in the regeneration of lesioned peripheral nerves [6]. Therefore, it 
has been successfully applied in clinical trials (phase II) for the treatment of symptomatic 
diabetic polyneuropathy [7], but failed in clinical studies (phase III) to show significant 
beneficial effects [8]. For this reason Genentech stopped further development of NGF [9]. 
Interestingly, in recent years drug substances against NGF were developed. Tanezumab and 
other anti-NGF monoclonal antibodies show an analgesic effect and are under clinical 
investigation for the treatment of pain associated with osteoarthritis or other chronic pain 
conditions [10]. 
Nerve growth factor is the best characterized member of the neurotrophin family. Its crystal 
structure was described over 30 years ago and revealed that one end of the monomer 
carries a cysteine-knot motif consisting of three disulfide bonds [11]. This cysteine-knot 
stabilizes the fold and locks the molecules in their conformation. The biologically active form 
of NGF consists of two monomers which are arranged in a parallel manner to form a close-
packed homodimer as illustrated in Figure 2.2, B. The residuals from the β-sheets (AB and 
CD in Figure 2.2, A) are responsible for the majority of interactions that stabilize the non-
covalent dimer structure. 
  
Figure 2.2. Monomer (A) and non-covalent homodimer (B) of human β-nerve growth factor [12] 
A B 
Chapter 2 
 
43 
The bulk drug substance contained NGF at a concentration of 0.5 mg/mL. The protein was 
formulated in 100 mM acetate buffer at pH 6.0 and stored at -80°C prior to use. Thawing was 
performed by submersing formulation aliquots of 50 mL, 15 mL or 2 mL into a water batch at 
ambient temperature and the formulations were used as described in the appropriate 
sections in this chapter. The molecular weight of the rhNGF monomer and dimer is 
approximately 13.5 kDa and 27 kDa, respectively. For UV-spectroscopy using an Agilent 
8453 diode array photometer an extinction coefficient of E1mg/mL (280 nm)=1.5 was 
employed [13]. 
2.1.2 REAGENTS, CHEMICALS AND EXCIPIENTS 
The following table gives an overview of all reagents, chemicals and excipients used 
throughout this work. 
Table 2.1. Overview of used reagents, chemicals and excipients 
Excipient Description / Purity Source 
Di-potassium hydrogen 
phosphate 
p.a. 
AppliChem 
(Darmstadt, Germany) 
D-Mannitol p.a. 
Boehringer Ingelheim 
(Ingelheim, Germany) 
Ethacridine lactate 
monohydrate 
Ph. Eur.  
FAGRON GmbH & Co. KG 
(Barsbüttel, Germany) 
FITC-albumin From bovine albumin 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
FITC-Dextran 
Average molecular weight: 
21.2 kDa 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
Fluorescein isothiocyanate 
Isomer I 
≥ 90% 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
Guanidine thiocyanate For molecular biology 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
HYDRANAL-Coulomat AG - 
Honeywell Riedel de Haen 
(Seelze, Germany) 
Hydrochloric acid 1 mol/L 
VWR International GmbH 
(Darmstadt, Germany) 
Hydrochloric acid 32% 
Honeywell Riedel de Haen 
(Seelze, Germany) 
Methanol HPLC grade 
VWR International GmbH 
(Darmstadt, Germany) 
Methyl violet 
for microscopy, 
indicator (pH 0.1 – 2.0) 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
Micrococcus lysodeikticus 
ATCC No. 4698 
suitable for substrate for the 
assay of lysozyme 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
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Potassium dihydrogen 
phosphate 
p.a. 
Merck KGaA 
(Darmstadt, Germany) 
Potassium hydroxide solution 50% 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
Propranolol hydrochloride Ph. Eur. 
FAGRON GmbH & Co. KG 
(Barsbüttel, Germany) 
Rhodamine B p.a., ≥ 90% 
Merck KGaA 
(Darmstadt, Germany) 
Sodium dodecyl sulphate ≥ 99.0% 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
Sodium hydroxide 1 mol/L 
VWR International GmbH 
(Darmstadt, Germany) 
Sucrose p.a. 
Boehringer Ingelheim 
(Ingelheim, Germany) 
Trehalose dihydrate High purity, low endotoxin 
Ferro Pfanstiehl Lab., Inc 
(Waukegan, IL, USA) 
Trifluoroacetic acid p.a. 
Merck KGaA 
(Darmstadt, Germany) 
Trizma
®
 base ≥ 99.9% 
Sigma Aldrich GmbH 
(Steinheim, Germany) 
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2.2 METHODS APPLIED FOR SPIDER SILK PROTEIN AND SPIDER SILK 
PARTICLES 
2.2.1 PREPARATION OF LIQUID eADF4(C16) FORMULATIONS 
The spider silk protein eADF4(C16) was provided by AMSilk GmbH as a fairly free-flowing 
powder with a white to slightly brownish color. Drying of the purified protein solution was the 
final process at the laboratories of AMSilk and was changed from freeze-drying in the 
beginning to spray-drying due to improved dissolution of the obtained protein powder. 
Nevertheless, dissolving dried eADF4(C16) protein in aqueous buffer solutions at sufficiently 
high concentrations was almost impossible or at least too time-consuming for routinely 
performed processes. Therefore, 6 M Guanidine thiocyanate solutions were used to dissolve 
dried protein by employing gentle agitation or heating to 40°C. For further processing the 
denaturing agent had to be removed. Dialysis was performed at 4°C against 10 mM 
Tris(hydroxymethyl)aminomethane(=Tris)/HCl at pH 8.0 using Spectra/Por® 1 dialysis 
membranes with a molecular weight cut-off of 6,000-8,000 Da (Spectrum Laboratories Inc., 
Rancho Dominguez, USA). The buffer was exchanged three times and the overall dialysis 
time was 24 hours. The resulting protein solution usually contained small amounts of visible 
particles which were removed by centrifugation at 10,000-15,000 g for a minimum of 
15 minutes. The final step of the preparation process was filtration of the supernatant through 
a 0.45 µm or 0.22 µm cellulose acetate filter membrane (VWR International GmbH, 
Darmstadt, Germany). The concentration was determined according to section 2.1.1.1 by 
UV-spectroscopy. 
2.2.2 CHARACTERIZATION OF LIQUID eADF4(C16) FORMULATIONS 
2.2.2.1 ASYMMETRICAL FLOW FIELD-FLOW FRACTIONATION 
A suitable separation method for spider silk proteins such as AF4 was developed to 
investigate the state of dissolved eADF4(C16) prior to particle preparation. The separation 
principles of AF4 are reviewed elsewhere [14, 15]. The AF4 system consisted of the main 
device AF2000 Focus from Postnova Analytics GmbH (Landsberg am Lech, Germany) 
including focus and tip pump PN 1122, slot pump PN 1610, vacuum degasser PN 7505 and 
refractive index detector PN 3150. Further components were a SPD-10A UV-detector from 
Shimadzu (Duisburg, Germany) and a miniDAWN light scattering detector from Wyatt 
Technology (Dernbach, Germany). The AF4 channel was also produced by Postnova 
Analytics and had dimensions of 32.0 x 6.0 x 3.7 cm. 
For the separation of eADF4(C16) samples this AF4 channel was equipped with a 350 µm 
spacer and a fixed detection flow rate of 1.0 mL/min was used. The mobile phase was equal 
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to the formulation buffer using a 10 mM Tris-buffer at pH 8.0 in order to avoid any influence 
of the mobile phase during separation. During method development different membrane 
types and cut-offs were evaluated and the amount of injected spider silk protein was varied 
from 4 to 60 µg. New membranes were always saturated with BSA before sample analysis 
was performed. An important difference to HP-SEC analysis was that samples were not 
centrifuged prior to injection. For data analysis the ASTRA software (Wyatt Technology, 
Dernbach, Germany), an extinction coefficient of 972 mL*g-1*cm-1 at 280 nm, and a 
differential index of refraction (dn/dc) of 0.185 for eADF4(C16) were used. 
2.2.2.2 INCUBATION AT ELEVATED TEMPERATURE 
Based on the implementation of higher process temperatures during particle preparation (see 
section 2.2.3.1), the physical stability of eADF4(C16) at higher temperatures was 
investigated. For this reason, the most commonly used eADF4(C16) formulation consisting of 
1.0 mg/mL eADF4(C16) in 10 mM Tris / pH 8.0 was analyzed. 500 µL of the formulation were 
filled into 2.0 mL polypropylene tubes and incubated at 80°C for 4 hours. Afterwards, 200 µL 
of the samples were drawn and diluted with formulation buffer to a volume of 2.0 mL to 
perform turbidity and light obscuration measurements. The residual formulation was 
centrifuged and used for size exclusion chromatography. 
2.2.2.3 SIZE EXCLUSION CHROMATOGRAPHY 
After removing potential insoluble aggregates by centrifugation, the supernatants of the 
corresponding formulations were analyzed by size exclusion chromatography. The 
separation was carried out on a Shodex OHpak SB-803 column which was made of a 
polyhydroxymethacrylate matrix and can be used for alkaline running buffers up to pH 10 in 
contrast to silica-based columns. As mobile phase 100 mM Tris at pH 8.0 was used at a flow 
rate of 0.38 mL/min. The column was installed in the aforementioned AF4-system replacing 
the AF4 channel (see section 2.2.2.1). For elution mode during HP-SEC only the tip pump of 
the system was necessary. All three detectors were available for the calculation of protein 
content and molar mass of the eluted protein species. 
2.2.2.4 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS 
In order to obtain further information about potential spider silk protein aggregates 
SDS-PAGE was performed under non-reducing conditions. Samples were loaded on 
NuPAGE® 10% Bis-Tris precast gels (Life technologies GmbH, Darmstadt, Germany), which 
had been mounted in the XCell II Mini cell system (Novex, San Diego, CA, USA). The 
sample preparation included the dilution of the samples to an approximate protein 
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concentration of 0.025 mg/mL in a Tris-buffer at pH 6.8 and the denaturation of the samples 
at 95°C for 20 minutes. Finally, 10 µL of each sample were loaded into the different wells of 
the gel. Separation was carried out at a current of 40 mA per gel and the runtime was about 
90 minutes. Silver staining was carried out by using the SilverXPress® Staining Kit 
(Invitrogen, Carlsbad, CA, USA). A protein standard (Mark 12® Unstained Standard, 
Invitrogen, Carlsbad, CA, USA) was loaded onto the gel for the assessment of the molecular 
weight of protein species. 
2.2.2.5 NEPHELOMETRY 
The turbidity of spider silk protein formulations after incubation at 80°C was determined using 
a NEPHLA nephelometer (Dr. Lange, Düsseldorf, Germany). Turbidity was measured in 
formazine nephelometric units (FNU) by 90° light scattering at a wavelength of 860 nm. Each 
value represents the average of two measurements to exclude unspecific scattering effects 
by rotating the cuvette. As the required measurement volume is almost 2.0 mL, formulations 
were diluted 1:10 with formulation buffer before measurement. 
2.2.2.6 LIGHT OBSCURATION 
The size and amount of particles between 1 and 200 µm was measured by light obscuration 
on a SVSS C-40 apparatus equipped with a HCB-LD-25/25 sensor (PAMAS GmbH, 
Rutesheim, Germany). The light obscuration system was cleaned with highly purified water 
which had been filtered through a 0.22 µm filter membrane and was essentially free from 
particles. Cleaning was performed until the total particle count per mL was below 100 and 
less than 5 particles larger than 10 µm were detected. This cleaning step was performed and 
recorded before and in between the individual measurements after flushing the system with 
5 mL highly purified water. 
The light obscuration measurements were performed subsequent to the turbidity 
measurements. 0.5 mL of the sample was used for flushing the system. Afterwards, three 
aliquots of 0.3 mL sample volume were analyzed for subvisible particles. The average value 
of the three aliquots was calculated and related to the total particle number in 1.0 mL. 
Typically, the range of subvisible particles is divided into three classes of particle sizes: 
≥ 1 µm, ≥ 10 µm and ≥ 25 µm.  
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2.2.3 PREPARATION OF eADF4(C16) PARTICLES 
This section provides an overview of different techniques and devices applied for the 
preparation of spider silk particles resulting in liquid and dried formulations. As the 
optimization and results of the individual techniques will be explained in detail in chapter 3, 
the following descriptions are limited to brief explanations of the employed procedures and 
devices. 
2.2.3.1 MICROMIXING SYSTEM 
A syringe pump system consisting of two identical syringe pumps (model 100 DX, Teledyne 
Isco Inc., USA) and a digital control element (Series D, Teledyne Isco Inc., USA) were 
implemented for the preparation of particle dispersions with batch sizes of up to a total 
volume of 200 mL. The dead volume of each pump is approx. 2 mL and the required filling 
volume for an acceptable particle preparation especially at high flow rates is about 
15 - 20 mL. The digital regulation controlling the flow rate of each pump can be set 
separately. For our purpose an equal flow rate was used for both pumps in between a range 
of 1.0 to 50 mL/min. The syringe pump system included a heating jacket for both pumps 
which was tempered between 20 and 80°C using a bath circulator SC100-A10 (Thermo 
Scientific, Karlsruhe, Germany) as required. One syringe pump was filled with the 
eADF4(C16) solution (preheated if necessary) (10 mM Tris, pH 8.0). The concentration of the 
spider silk protein ranged from 0.5 to 2.0 mg/mL. The second pump was filled with a sterile-
filtered salt solution. Once the salt solution comes into contact with the spider silk solution, 
particles are formed due to a phase separation process (see chapter 3, section 3.1) [16]. In 
the case of the standard operation procedure (SOP), this salt solution was a 2 M potassium 
phosphate solution at pH 8.0. During process development also 2 M ammonium sulfate 
(pH 8) was used. Micromixing and precipitation of the particles was performed by connecting 
the syringe pumps via a T-shaped mixing element with a circular mixing zone. To investigate 
the impact of the mixing zone on the particle characteristics, an inner diameter of 0.50 mm 
(P-727 PEEK tee, Upchurch Scientific, Oak Harbor, USA) was compared to a diameter of 
1.25 mm (P-728 PEEK tee, Upchurch Scientific, Oak Harbor, USA). The P-727 PEEK tee 
with the smaller inner diameter (0.50 mm) was used in the SOP. 
The resulting spider silk particle suspensions were collected via the third outlet port of the 
mixing element, subsequently centrifuged (different speeds used for different particle sizes), 
and excessively washed with purified water.  
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2.2.3.2 DIALYSIS 
The eADF4(C16) solution at a concentration of 1.0 mg/mL was dialyzed against 
2 M potassium phosphate (pH 8.0) in a volumetric ratio of 1:50 at room temperature using 
Spectra/Por® 1 dialysis membrane with a molecular weight cut-off of 6,000-8,000 Da 
(Spectrum Laboratories Inc., Rancho Dominguez, USA). Afterwards, the spider silk particle 
suspension was excessively washed with purified water to remove the residual potassium 
phosphate. 
2.2.3.3 ULTRASONIC NOZZLE 
An ultrasonic nozzle was employed in order to establish an additional process for the 
preparation of spider silk particles. The ultrasonic nozzle operates at a specific resonance 
frequency of 120 kHz generated by a broadband ultrasonic generator (Sono-Tek 
Corporation, Milton, NY, USA). The nozzle is equipped with a dual liquid feed option bearing 
a maximum of 10.28 mL/min for the inner and 9.44 mL/min for the outer outlet. The 
characteristic fine mist spray is created at the atomizing surface of the nozzle tip as it is 
illustrated in Figure 2.3. In order to atomize the liquid, the vibrational amplitude of the 
atomizing surface must be carefully controlled. Below the so-called critical amplitude, the 
energy is insufficient to produce atomized drops. If the amplitude is excessively high, the 
liquid is ripped apart and large chunks of fluid are ejected. Only within a narrow band of input 
power is the amplitude ideal for producing the characteristic fine, low velocity mist. According 
to the manual and with respect to the maximum capacity of 5 W, the optimal input power for 
atomizing water was validated as 0.8 W. The input power was adjusted in the course of the 
preliminary tests to 1.6 W which ensured an appropriate spraying pattern for the potassium 
phosphate solution and low-concentrated protein solutions. High-concentrated protein 
solutions (> 5 mg/mL) required different settings of the input power up to 4.5 W. For liquid 
delivery both inlets of the nozzle were connected to an Ismatec® IPC peristaltic pump (IDEX 
Health & Science GmbH, Wertheim-Mondfeld, Germany). 
Different setups were tested regarding the feasibility to produce spider silk particles. In the 
first experiment the dual liquid feed option was applied and the eADF4(C16) solution was 
atomized via the inner and a potassium phosphate solution (pH 8.0) via the outer outlet. In a 
second experiment, phase separation was induced by spraying the aqueous eADF4(C16) 
solution into 2 M potassium phosphate (pH 8.0) or vice versa. Throughout the experiments 
different parameters and their impact on the resulting particle characteristics were 
investigated: eADF4(C16) concentration, potassium phosphate concentration, temperature of 
both solutions and amount of liquid atomized per unit time (= flow rate of the peristaltic pump) 
(listed in chapter 3, Table 3.2). 
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Figure 2.3. Atomization of water at the tip (flat shaped) of the employed ultrasonic nozzle operating at 
120 kHz and a spraying rate of 3 mL/min 
2.2.3.4 ULTRASONIC TREATMENT AND PURIFICATION 
Spider silk particles always showed severe agglomeration after the preparation and washing 
process as a result of the high salt concentration being present immediately after particle 
formation. Therefore, aqueous eADF4(C16) particle dispersions were subjected to an 
ultrasonic treatment. Throughout the work Sonopuls HD 2200 (Bandelin electronic, Berlin, 
Germany) in the laboratory of Prof. Vollmar, Pharmaceutical Biology, LMU Munich, and a 
Sonopuls HD 3200 (Bandelin electronic, Berlin, Germany) were used. The duration of the 
ultrasound treatment did not exceed 15 minutes. 
If the eADF4(C16) particles exhibited a particle size below 1 µm, the resulting particle 
suspension was filtered through 5 µm syringe filters with a surfactant-free cellulose acetate 
membrane (Minisart® NML, Sartorius Stedim Biotech GmbH, Goettingen, Germany) in order 
to remove any residual agglomerates. 
Particles obtained by dialysis and via spraying techniques were also subjected to the 
ultrasonic treatment, but were not filtered afterwards. 
2.2.3.5 GRAVIMETRICAL DETERMINATION OF PARTICLE CONCENTRATION 
The eADF4(C16) particle concentration of all suspensions in pure water was determined 
gravimetrically. For that purpose, aliquots in the range of 50-100 µL were transferred into 
small aluminum cups and dried at 80°C for a minimum of 3 hours. The concentration was 
calculated using a minimum of three cups per formulation and the following equation: 
conc. eADF4(C16) particles   
m(particles)
m (water)
   
m(cup, dried)   m(cup, blank)
(m(cup, susp)   m(cup, blank)   m(particles))   1
g
m 
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2.2.3.6 FREEZE-DRYING OF NANOSUSPENSIONS 
As suspensions of nanoparticles without further formulation additives usually lack long-term 
colloidal stability, freeze-drying of suspensions containing eADF4(C16) particles within the 
nanometer range was performed. 
Sucrose, trehalose and mannitol were investigated as excipients for freeze-drying of 
eADF4(C16) particles. The employed formulations (listed in chapter 3, Table 3.3) were 
prepared by mixing empty or lysozyme-loaded eADF4(C16) particles with aqueous solutions 
of the corresponding freeze-drying excipient. Loading of spider silk particles with 
15% [w/w] lysozyme was carried out as described in section 2.2.5. The particle concentration 
of all formulations was set to 1.0 mg/mL. The excipient-to-eADF4(C16) particles mass ratio 
was varied from 2.5:1 to 50:1. Consequently, the total solid content of the formulations 
ranged from 0.35 to 5.1% [w/V]. For experiments including lysozyme-loaded eADF4(C16) 
particles, the same excipient-to-eADF4(C16) particle mass ratio without accounting for the 
loaded lysozyme amount was used. Particle dispersions were immediately transferred to 
cleaned 2R glass vials (Schott AG, Mainz, Germany) using a multipette. All samples were 
freeze-dried in an EPSILON 2 6D pilot scale freeze-dryer (Martin Christ Freeze Dryers 
GmbH, Osterode, Germany). The formulations were dried as follows: After freezing samples 
at -50°C for 3 hours (-40°C for sucrose samples with 1.0 mL filling volume), the chamber 
pressure was reduced to 0.05 mbar. Primary drying included a temperature ramp increasing 
from -50°C to -20°C during 5 hours and drying at -20°C for another 10 hours. After the shelf 
temperature was constantly increased from -20°C to 20°C over three hours, secondary 
drying was conducted at 20°C for 10 hours. Upon completion of the freeze-drying cycle, the 
drying chamber was vented with nitrogen and vials were plugged under slight vacuum at 800 
mbar. Unless stated otherwise, the samples were stored at 2-8°C after drying before 
analysis. For reconstitution of lyophilized samples, purified water was used to end up with the 
the original filling volume. In addition, for formulations containing sucrose reconstitution at 
lower volumes was tested in order to concentrate the resulting particle suspension (see 
chapter 3, Table 3.3). 
2.2.4 CHARACTERIZATION OF eADF4(C16) PARTICLES 
2.2.4.1 DYNAMIC LIGHT SCATTERING 
The eADF4(C16) particle size represented by the Z-average value and the width of the 
particle size distribution expressed by the polydispersity index (PI) were determined by 
dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). All samples were diluted directly before the measurement to a 
concentration of 0.01 mg/mL in the corresponding buffer and filled into disposable PMMA 
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cuvettes. Each measurement consisted of three runs of at least 10 subruns and was started 
after an equilibration time of 90 seconds at 25°C. The measurement principles as well as 
limitations of this technique are summarized elsewhere [17]. 
The zeta-potential of eADF4(C16) particles was equally determined with the Zetasizer Nano 
ZS at the same particle concentration and temperature as used for particle size 
measurements, but measurements required the use of the disposable capillary cell 
(DTS1061, Malvern Instruments, Worcestershire, UK). 
The Zetasizer Nano ZS was equipped with the MPT-2 Autotitrator (Malvern Instruments, 
Worcestershire, UK) which allows the automatically determination of particle size and zeta-
potential as a function of pH, conductivity and other parameters. One important application of 
this setup is the determination of the isoelectric point of particles or protein molecules by DLS 
which was employed in this work for eADF4(C16) particles, lysozyme and nerve growth 
factor. As the zeta-potential is strongly dependent on the dispersion medium, a constant 
background of 10 mM sodium chloride was chosen for these measurements. The pH was 
adjusted by automatic titration of 0.25 M hydrochloric acid or sodium hydroxide to the sample 
solution. In order to avoid aggregation the starting point of each titration was set at the 
opposite pH range of the IEP, that means that e.g. the titration of eADF4(C16) particles with 
an estimated IEP around 4 started above the IEP (pH 9) and finished at pH 2. A 
concentration of 0.25 mg/mL was used for eADF4(C16) particles, whereas lysozyme was 
directly dissolved at 10 mg/mL in the dispersion medium. NGF was concentrated to 
4.4 mg/mL after dialysis using VIVASPIN 20 centrifugal concentrators with a PES membrane 
and a MWCO of 5,000 Da (Sartorius Stedim Biotech GmbH, Goettingen, Germany). Particle 
size and zeta-potential were determined in intervals of 0.5 pH-values at 25°C. The isoelectric 
point was calculated after the titration by the Zetasizer APS software (Malvern Instruments, 
Worcestershire, UK). 
2.2.4.2 LASER DIFFRACTION 
The size and size distribution of eADF4(C16) particles were determined by static light 
scattering or also called laser diffraction spectrometry (Horiba Practica LA-950, Horiba 
Scientific, Japan). Refractive indices of 1.33 for water and 1.60 for eADF4(C16) were used 
for the calculation of particle sizes and their distribution. The device is equipped with two 
different lasers (405 and 650 nm), one detector in forward direction, and 23 separate wide 
angle detectors (side and reverse direction) so that particle sizes from 0.01 – 3000 µm can 
be measured [18]. This technique was primarily used for spider silk particles in the range 
from 0.5 to 10 µm throughout this work. All results from laser diffraction were obtained from 
volume based distributions if not otherwise stated.  
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2.2.4.3 FOURIER TRANSFORMED INFRARED SPECTROSCOPY 
A small droplet of particle dispersion was vacuum-dried on a CaF2-crystal. Measurements 
were conducted in transmission mode using a Tensor 27 spectrometer with the Hyperion 
microscope (Bruker Optik GmbH, Ettlingen, Germany). Background measurements of the 
CaF2-crystal were carried out before measurement of each sample. Opus software 
Version 6.5 was used for data analysis. 
2.2.4.4 SCANNING ELECTRON MICROSCOPY 
eADF4(C16) particles were immobilized by vacuum drying on Thermanox™ coverslips 
(Thermo Scientifc/Nunc, Langenselbold, Germany), which were sticked on Leit-Tabs (Plano 
GmbH, Wetzlar, Germany) and connected with a conductive cupper tape (Plano GmbH, 
Wetzlar, Germany) to the sample holder. Samples were carbon sputtered under vacuum and 
analyzed by a Joel JSM-6500F field emission scanning electron microscope (Joel Inc., 
Peabody, USA). 
2.2.4.5 COLLOIDAL STABILITY OF eADF4(C16) PARTICLES 
The colloidal stability of eADF4(C16) particles was studied at three different pH (3, 5 and 7) 
at constant ionic strength of 30 mM and at different ionic strength (30 mM, 60 mM, 100 mM 
and 154 mM) at constant pH of 5 and 7, respectively. All buffers were prepared at 
concentrations of 10 mM and the ionic strength was adjusted with sodium chloride. The 
particle concentration was set to 0.25 mg/mL after centrifugation of the stock dispersion and 
samples with a total volume of 1.0 mL were allowed to stand at room temperature without 
agitation. Samples were analyzed directly after redispersion as well as after one hour and 
24 hours for particle size, size distribution and zeta-potential using the Zetasizer Nano ZS as 
described in sections 2.2.4.1. Storage stability of the eADF4(C16) stock dispersion in purified 
water was investigated at 2-8°C over a period of 6 months. 
2.2.4.6 DETERMINATION OF RESIDUAL MOISTURE 
Residual moisture of lyophilized samples was measured by using an Aqua 40.00 titrator 
comprising a headspace module (Analytik Jena AG, Halle, Germany). Samples were 
analyzed either directly using the original vial from freeze-drying or after sample preparation 
in a dry-nitrogen-purged glove box to avoid hydration resulting from atmosphere. The net 
weight of the analyzed samples ranged from 1 to 51 mg. In order to obtain reliable results 
blank values were obtained from empty vials which were identically treated to the verum 
samples. For the measurement the sample vials was placed in the headspace module and 
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heated up to 80°C. The evaporated water was evacuated by a needle system and 
transferred into the titration solution where the amount of water was automatically 
determined by Karl Fischer titration. 
The obtained results from the headspace module were cross-checked with results derived 
from methanol extraction and subsequent Karl Fischer titration. No significant difference was 
detected. 
2.2.4.7 DIFFERENTIAL SCANNING CALORIMETRY 
A Netzsch 204 Phoenix® DSC (Netzsch-Gerätebau GmbH, Selb, Germany) was used for 
determination of the glass transition temperature of the maximally freeze-concentrated 
solution (Tg’), the glass transition temperature of the amorphous matrix (Tg) and melting point 
(mp) of mannitol. 
Table 2.2. DSC temperature programs for sucrose, trehalose and mannitol 
sucrose + trehalose mannitol 
Tg’ Tg Tg + mp 
T [°C] 
time 
heating rate 
T [°C] 
time 
heating rate 
T [°C] 
time 
heating rate 
20 
20 → -70 
1 min 
5 K/min 
0 
0 → 80 
1 min 
10 K/min 
0 
0 → 80 
1 min 
10 K/min 
-70 
-70 → 20 
1 min 
10 K/min 
80 
80 → 20 
1 min 
10 K/min 
80 
80 → -10 
1 min 
10 K/min 
  
-20 
-20 → 180 
1 min 
10 K/min 
-10 
-10 → 180 
1 min 
10 K/min 
  
180 
180 → 20 
1 min 
10 K/min 
180 
180 → 20 
1 min 
10 K/min 
For the measurement of Tg’ 20 µ  of the formulation were analyzed in crimped aluminum 
crucibles. After lyophilization, hydration of the dried samples had to be avoided. Therefore, 
sample preparation was carried out in a dry-nitrogen-purged glove box. The relative humidity 
during sample preparation was kept below 10%. Sample amounts of 2 to 6 mg were used for 
the measurements and two samples of each formulation were analyzed regarding Tg or mp. 
Both values were calculated with the Netzsch Proteus® Software whereupon the point of 
inflection and the onset temperature were determined as Tg and mp, respectively. The 
different temperature programs are listed in Table 2.2.  
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2.5 REMOTE LOADING OF SPIDER SILK PARTICLES 
This section refers to the loading of eADF4(C16) particles after particle preparation which is 
further called remote loading of spider silk particles. 
2.2.5.1 LOADING PROCEDURE 
Loading of eADF4(C16) particles was performed with different kind of drugs such as low 
molecular weight drugs on the basis of previous studies [19] and proteins like lysozyme and 
nerve growth factor. If not otherwise stated, the so-called standard loading procedure was 
carried out in a loading buffer comprising 10 mM phosphate buffer at pH 7.0 and a total ionic 
strength of 30 mM adjusted with sodium chloride. In additional studies loading buffers 
exhibiting different total ionic strengths of 60 mM and 100 mM (adjusted with sodium 
chloride) were prepared in order to investigate the influence of ionic strength on the loading 
efficiency. 
The loading procedure was implemented as follows: A stock dispersion of spider silk 
particles in purified water was centrifuged (15,000 g, 30 min) and redispersed in the desired 
buffer media before loading. A second stock solution comprising the appropriate drug was 
prepared by dissolving the drug in the identical buffer solution or by dialysis (NGF). 
Appropriate volumes of spider silk particle suspension and drug stock solution were mixed to 
obtain a final spider silk particle concentration of 0.5 mg/mL and the desired w/w-ratio [%] of 
drug to spider silk particles. After 30 minutes of incubation at room temperature under gentle 
agitation (horizontal shaker with 40 rpm (GFL 3015, Burgwedel, Germany)), 20 µL of the 
particle suspension were used for dynamic light scattering measurements. Simultaneously, 
samples were centrifuged (15,000 g, 30 min) and the supernatant was analyzed for residual 
drug content (see section 2.2.5.2). 
2.2.5.2 DETERMINATION OF LOADING AND LOADING EFFICIENCY 
In order to determine the amount of drug loaded onto eADF4(C16) particles the supernatant 
obtained after centrifugation was analyzed for residual drug content. 
Low molecular weight drugs 
The sensitivity of UV-spectroscopy was sufficiently high to allow for the quantification of low 
molecular weight drugs via common UV-spectroscopy. The characteristics of the employed 
substances are listed in Table 2.3.  
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Table 2.3. Characteristics of employed low molecular weight drugs 
Drug molecule MW [Da] Amax [nm] pKa 
Methyl violet 2B 408.0 590 N.A. 
Ethacridine lactate * 1H2O 361.4 365 11.04 
Propranolol hydrochloride 295.8 290 9.46 
Lysozyme and nerve growth factor 
In case of lysozyme and nerve growth factor more sensitive methods had to be employed for 
protein quantification at low concentrations of several µg/mL. Therefore, the Micro BCA 
Protein Assay Kit (Thermo Scientific, Rockford, USA) was used. A standard calibration curve 
for both proteins in the corresponding buffer allowed the quantification of the protein 
concentration in the range from 0.5 - 40 µg/mL. Nevertheless, it had to be proven that no 
dissolved spider silk protein interferes the quantification for which reason control groups of 
empty eADF4(C16) particles were included. Furthermore, size exclusion chromatography of 
lysozyme and NGF containing supernatants was performed to quantify the residual protein 
and to prove in particular the absence of soluble spider silk protein. Both HP-SEC methods 
will be explained in section 2.2.7.3 and 2.3.2.1 of this chapter. 
Loading efficiencies [%, w/w] and loading [%, w/w] were determined using equation (1) 
and (2), respectively. 
Loading efficiency [%] =   
lysozyme loaded on eADF4(C16) particles  µg 
lysozyme initially added  µg 
   100  (1) 
Loading [%] =   
lysozyme loaded on eADF4(C16) particles  µg 
eADF4(C16) particles  µg 
   100   (2) 
2.2.5.3 CONFOCAL LASER SCANNING MICROSCOPY 
For the detailed analysis of the loading mechanism, eADF4(C16) particles were prepared by 
dialysis and loaded with FITC-labeled albumin, FITC-dextran and FITC-labeled lysozyme. 
The latter was prepared as described previously [20]. Briefly, 225 mg lysozyme and 9 mg 
fluorescein isothiocyanate (Isomer I) were dissolved in 45 mL of 100 mM borate buffer 
(pH 8.5). The fluorescein isothiocyanate solution was added dropwise to the stirred lysozyme 
solution and the complete mixture was stirred for another 16 hours at room temperature. The 
solution was afterwards extensively dialyzed against purified water to remove unbound 
fluorescein isothiocyanate. The resulting FITC-lysozyme solution was freeze-dried using a 
conservative freeze-drying protocol. 
eADF4(C16) particles obtained by dialysis were remote loaded (see section 2.2.5) with three 
different types of FITC-labeled macromolecules both at pH 2.0 (10 mM phosphate, 30 mM 
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ionic strength) and pH 7.0 (10 mM phosphate, 30 mM ionic strength). The FITC-labeled 
macromolecules were dissolved in the same buffer as employed for the loading procedure. In 
all cases the w/w-ratio of the FITC-labeled macromolecule to the spider silk particles was set 
to 15% [w/V] at a fixed eADF4(C16) particle concentration of 2.0 mg/mL. All samples were 
investigated in the liquid state with a confocal scanning laser microscope (Zeiss LSM 510 
Meta, Carl Zeiss Microscope Systems, Jena, Germany). 
2.2.6 ENCAPSULATION OF DRUGS INTO SPIDER SILK PARTICLES 
In contrast to remote loading of spider silk particles drugs can be also co-precipitated during 
particle preparation in order to encapsulate the drug in the spider silk matrix. Two different 
drugs were employed in this study, namely Rhodamine B as low molecular weight 
substance, and lysozyme as model protein. 
Spider silk particles were prepared by phase separation using an eADF4(C16) solution in 
10 mM Tris pH 8 and 2 M potassium phosphate pH 8 as described in section 2.2.3. By doing 
this it is in principle possible to add the drug both to the spider silk protein solution or the 
2 M potassium phosphate solution in order to co-precipitate the drug. However, the drugs 
were mixed solely with the spider silk protein prior to co-precipitation. 
2.2.6.1. CO-PRECIPITATION OF RHODAMINE B 
The main objective of this experiment was the clarification if uncharged molecules at the 
employed pH can be incorporated at significant amounts by co-precipitation. Thus, 
Rhodamine B was added to the aqueous eADF4(C16) solution with a protein concentration 
of 1.0 mg/mL at mass ratios of 0 / 1 / 2.5 / 5 / 7.5 / 10 / 15 and 30% [w/w] with regard to the 
mass of spider silk protein. 0.5 mL of this solution comprising eADF4(C16) and Rhodamine B 
was prepared immediately before phase separation was carried out by mixing it with 0.5 mL 
of a 2 M potassium phosphate at pH 8.0. The resulting particle suspension was centrifuged 
(15,000 g, 30 min), washed three times with purified water and subjected to ultrasonic 
treatment before DLS measurements were performed. The supernatants were collected and 
analyzed by UV-spectroscopy for Rhodamine B content. This easy determination by UV-
spectroscopy was possible due to sufficiently different absorption maxima of Rhodamine B 
and eADF4(C16). Loading and loading efficiencies were calculated according to equation (1) 
and (2) explained in section 2.2.5.2. 
2.2.6.2 CO-PRECIPITATION OF LYSOZYME 
It was not possible to dissolve lysozyme at the required concentrations in a 2 M potassium 
phosphate solution so that co-precipitation was only performed by adding lysozyme to the 
Materials and methods 
 
58 
aqueous eADF4(C16) solution. In order to evaluate the impact of particle size on the 
resulting drug release lysozyme was co-precipitated at conditions where nanoparticles and 
microparticles were formed. 
Preparation of lysozyme-loaded nanoparticles 
Lysozyme was added to an eADF4(C16) solution at a concentration of 1.0 mg/mL at mass 
ratios of 0 / 5 / 10 / 30 / 50 / 100 and 200% [w/w] with regard to the mass of spider silk 
protein. 2.0 mL of the spider silk solution containing lysozyme were prepared by dissolving 
lysozyme directly in 10 mM Tris-buffer at pH 8.0 and mixing the required amounts of 
lysozyme with the spider silk solution directly before precipitation was performed. Due to the 
small volumes and large sample number precipitation was conducted not via the syringe 
pumps but using a 10 mL pipette. 2.0 mL of 2 M potassium phosphate solution were 
provided in 8 mL polypropylene tubes (VWR International GmbH, Darmstadt, Germany) and 
the same volume of eADF4(C16)/lysozyme solution was added by intense mixing. Spider silk 
particles were formed immediately and subsequently centrifuged (15,000 g, 30 min). The 
obtained supernatant was analyzed for lysozyme and eADF4(C16) content, whereas the 
pellet was washed 3 times with purified water to remove salt and protein residuals. Each 
particle suspension was subjected to an ultrasonic treatment (2 minutes, 20% amplitude, 
pulsation 5 sec / 1 sec) prior to DLS measurements. 
Preparation of lysozyme-loaded microparticles 
Lysozyme was added to an eADF4(C16) solution at a concentration of 10 mg/mL at mass 
ratios of 0 / 5 / 10 / 30 and 50% [w/w] with regard to the mass of spider silk protein. 3.0 mL of 
the spider silk solution containing lysozyme were prepared by dissolving lysozyme directly in 
10 mM Tris-buffer at pH 8.0 and mixing the required amounts of lysozyme with the spider silk 
solution directly before particle preparation was performed. In order to obtain microparticles, 
the setup using an ultrasonic nozzle as described in section 2.2.3.3 was employed. The 
eADF4(C16)/lysozyme solution was provided in one well of a 6 well-plate. 3.0 mL of 
2 M potassium phosphate solution were atomized into this solution via the ultrasonic nozzle 
at an atomization rate of 3 mL/min. The formed particles were subsequently centrifuged 
(10,000 g, 30 min). The obtained supernatant was analyzed for lysozyme and eADF4(C16) 
content, whereas the pellet was washed 3 times with purified water to remove salt and 
protein residuals. Each particle suspension was subjected to an ultrasonic treatment 
(2 minutes, 20% amplitude, pulsation 5 sec / 1 sec) prior to SLS measurements. 
Quantification of lysozyme and eADF4(C16) content in the supernatants 
So far the particle preparation yield had always been at least 99%. Thus, the amount of 
eADF4(C16) in the supernatant would be negligible, but the impact of other proteins on the 
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phase separation process was unknown. The quantification of lysozyme in a potential 
presence of eADF4(C16) was performed by UV-spectroscopy at 280 nm, but as a 
prerequisite the absence of eADF4(C16) in the supernatant had to be demonstrated. For this 
reason, SDS-PAGE was carried out. Lysozyme and eADF4(C16) standards were included 
and the supernatants obtained after the first centrifugation step were diluted to a lysozyme 
concentration of 50 µg/mL. All supernatants including those from washing steps were 
analyzed and loading and loading efficiencies were calculated according to equation (1) 
and (2) explained in section 2.2.5.2. 
2.2.7  IN VITRO RELEASE FROM SPIDER SILK PARTICLES 
2.2.7.1 EXPERIMENTAL SETUP 
All in vitro release experiments were conducted at 37°C and at an eADF4(C16) particle 
concentration of 1.0 mg/mL. The pellet with loaded particles was resuspended in 
polypropylene tubes (1.5 or 2.0 mL total volume, VWR International GmbH, Darmstadt, 
Germany) with 37°C preheated release medium. At predetermined time points the medium 
was almost completely removed after centrifugation (15,000 g, 30 min) and replaced with 
980 µL of fresh release medium. The supernatant was analyzed for drug content using 
different methods as described in the following sections. The percentage of cumulative drug 
release was examined as a function of incubation time. Each release experiment was 
performed at least in triplicate. 
Low molecular weight drugs 
Spider silk particles were loaded with three different low molecular weight drugs, namely 
methyl violet, ethacridine lactate and propranolol-hydrochloride, at a payload of 10% [w/w]. 
The in vitro release for all three substances was investigated in the release medium 
consisting of 10 mM phosphate and 160 mM ionic strength at pH 7.4 (see Table 2.4). In the 
case of methyl violet the release medium at pH 7.4 was varied regarding its ionic strength to 
almost 0 (purified water), 50 mM and 100 mM. The samples were drawn every hour over a 
total period of 4 hours. 
Lysozyme 
The release of lysozyme was investigated as a function of pH and ionic strength of the 
release medium. All release experiments were conducted with a total theoretical payload of 
15% [w/w] lysozyme. In order to examine the release mechanism non-physiological 
conditions such as pH 2 and pH 4 were included in the in vitro release studies. Lysozyme 
loaded eADF4(C16) particles were centrifuged after the loading procedure and redispersed 
in the corresponding type and volume of the release medium as listed in Table 2.4. 
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In order to evaluate the influence of total payload on the resulting release profile eADF4(C16) 
particles loaded with 5, 10 and 15% [w/w] lysozyme were prepared as described in 
section 2.2.5.1. After loading, the physiological release medium consisting of 10 mM 
phosphate and 160 mM ionic strength at pH 7.4 was used for investigation of lysozyme 
release. 
In addition to the release setup using polypropylene tubes and centrifugation, the release of 
lysozyme was investigated using well-inserts. Wells of a 12 well-plate were filled with 1 mL of 
preheated release medium before placing a 12 well millicell hanging cell culture insert 
(0.4 µm, PET, Millipore, Germany). A pellet of loaded particles was resuspended with 500 µL 
of preheated release medium in a polypropylene tube. This volume was transferred and filled 
into the insert. The well plate was incubated at 37°C. After each hour inserts were taken out 
and release medium in the well was completely refreshed. 
The in vitro release of co-precipitated lysozyme was investigated for nano- and 
microparticles prepared at a lysozyme to eADF4(C16) mass ratio of 10, 30 and 50%. A 
release medium comprising 10 mM phosphate and 160 mM ionic strength at pH 7.4 was 
used. The calculated payloads were set as 100% and the percentage of released lysozyme 
was determined using the activity assay for lysozyme as described in section 2.2.7.4.  
Table 2.4. Experimental setup for the in vitro release studies of lysozyme from eADF4(C16) particles 
eADF4(C16) 
particles [µg] 
Lysozyme 
payload [µg] 
Release medium 
1000 150 pH 2.0 / 10 mM phosphate / ionic strength 50 mM 
1000 150 pH 4.0 / 10 mM formate / ionic strength 50 mM 
1000 150 pH 6.0 / 10 mM MES / ionic strength 50 mM 
1000 150 pH 7.4 / 10 mM phosphate / ionic strength 50 mM 
1000 150 pH ~ 7.4 / highly purified water (HPW) 
1000 150 pH 7.4 / 10 mM phosphate / ionic strength 100 mM 
1000 150 pH 7.4 / 10 mM phosphate / ionic strength 160 mM 
Nerve growth factor 
Based on the knowledge from results obtained for lysozyme, the in vitro release of NGF was 
investigated at pH 7.4 and the same variations in ionic strength namely 50 mM, 100 mM and 
160 mM. NGF was loaded onto eADF4(C16) particles with a total payload of 2.5, 5 and 
10% [w/w]. All other parameters were equal to those described for lysozyme. The amount of 
released NGF was determined by the Micro BCA Protein Assay Kit as described in 
section 2.2.7.2 and size exclusion chromatography (see section 2.3.2.1).  
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Release at physiological conditions including serum albumin 
In order to further mimic physiological conditions albumin was integrated in the release 
medium at a concentration of 40 mg/mL. Human serum albumin as well as bovine serum 
albumin was employed and the release of methyl violet and lysozyme was investigated as 
described in this section. The concentration of methyl violet was determined by UV-
spectroscopy, whereas the amount of released lysozyme was calculated using the activity 
assay (section 2.2.7.4) as the large excess of albumin interfered with the determination of 
lysozyme by size exclusion chromatography significantly. 
2.2.7.2 MICRO BCA PROTEIN ASSAY 
To determine the amount of lysozyme and nerve growth factor a Micro BCA protein assay 
(Thermo Scientific, Rockford, USA) was performed. 150 µL of protein standard or sample 
material and 150 µL of BCA reagent were filled into wells of a 96 well-plate. After 2 hours of 
incubation at 37°C the absorption of each well was measured photometrically by a microplate 
reader (BMG Labtech Fluostar Omega, Ortenberg, Germany). The amount of protein in the 
range of 0.5 – 40 µg/mL was calculated using standard curves of both proteins in the 
corresponding release media. 
2.2.7.3 SIZE EXCLUSION CHROMATOGRAPHY – LYSOZYME 
The stability of released lysozyme was analyzed by size exclusion chromatography on a 
Dionex HPLC system (P680, ASI-100, UVD170, RF2000, Dionex Softron GmbH, Germering, 
Germany). Separation was performed using a Superose 12 10/300 GL column (GE 
Healthcare Europe GmbH, Freiburg, Germany) at a flow rate of 0.6 mL/min using 
200 mM sodium phosphate at pH 6.8 as mobile phase. UV-detection was carried out at 
215 nm and 280 nm. 100 µL of the supernatant were injected and the protein was quantified 
by calibration curves of lysozyme standards dissolved in the corresponding release medium. 
2.2.7.4 ACTIVITY ASSAY – LYSOZYME 
The activity of lysozyme was determined by measuring the change of absorption of a 
Micrococcus lysodeikticus ATCC No. 4698 suspension at 450 nm. Due to the large number 
of samples the assay procedure was transferred from cuvettes with 1 cm path length to 
96 well-plates using a microplate reader. For that purpose lyophilized cells were suspended 
in 66 mM phosphate buffer, pH 6.2, at a concentration of 0.5 mg/mL. The cell suspension 
was prepared freshly each day. 200 µL of this suspension were provided in one well and 
100 µL sample volume was added. The measurement was started directly after sample 
addition and the absorption at 450 nm was determined over a period of 3 minutes in intervals 
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of 5 seconds. Nevertheless, for calculation of lysozyme activity only the slope of the first 
60 seconds was determined by linear regression as this part of the assay shows an almost 
linear decrease in the range of 1 – 20 µg/mL. Based on this procedure, it was possible to 
measure eight samples simultaneously. 
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2.3 METHODS APPLIED FOR STUDIES WITH NERVE GROWTH FACTOR 
2.3.1 FORCED DEGRADATION OF NERVE GROWTH FACTOR 
In this study, spider silk particles were tested as a stabilizing excipient during forced 
degradation studies of nerve growth factor which has been shown to be an excellent protein 
molecule for loading onto eADF4(C16) particles. In order to evaluate the potential of spider 
silk particles to stabilize bound NGF molecules, different stress studies using a particle-free 
NGF formulation and eADF4(C16) suspensions loaded with different payloads of NGF were 
performed. A standard procedure had to be developed that allows for reproducible and 
gentle desorption of NGF from eADF4(C16) particles after the stress testing was performed. 
2.3.1.1 EXPERIMENTAL SETUP 
Four different NGF containing formulations with or without eADF4(C16) particles were 
prepared as shown in Table 2.5. 
Table 2.5. Formulations used for the forced degradation of nerve growth factor 
Sample 
conc. NGF 
[mg/mL] 
conc. eADF4(C16) 
particles [mg/mL] 
NGF payload 
[%, m/m] 
Particle-free NGF 0.5 0 0 
0.5% eADF4(C16) 0.5 5 10 
1% eADF4(C16) 0.5 10 5 
2% eADF4(C16) 0.5 20 2.5 
Preparation of particle-free NGF formulations 
Appropriate aliquots of the NGF bulk solution were dialyzed against a buffer comprising 
10 mM phosphate and adjusted with sodium chloride to a total ionic strength of 30 mM at 
pH 7.0. This buffer had been routinely used for the remote loading procedure (see 
section 2.2.5.1) and was used as formulation buffer in this study. The dialysis was performed 
over 24 hours at 4°C using a Cellu Sep T1 dialysis membrane with a nominal molecular 
weight cut off of 3,500 Da (Membrane Filtration Products Inc, Seguin, TX, USA). The buffer 
was exchanged three times. Afterwards, the solution was filtered through a 0.22 µm 
Acrodisc® syringe filter with PVDF membrane (Pall GmbH, Dreieich, Germany) and the 
protein concentration was determined by UV-spectroscopy. This formulation was used 
without further dilution or concentration steps. The concentrations of the resulting NGF 
solutions were in the range of 0.48 - 0.50 mg/mL. In order to obtain equal concentrations as 
in the spider silk particle containing formulations, 15 µL of water were placed in 
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polypropylene centrifugal tubes (2.0 mL, VWR International GmbH, Darmstadt, Germany) 
and 300 µL of the NGF formulation were added. 
Preparation of remote loaded NGF formulations 
The appropriate volumes of the spider silk particle stock suspension (suspension medium: 
purified water) were transferred into polypropylene centrifugal tubes (2.0 mL, VWR 
International GmbH, Germany) and centrifuged at 15,000 g for at least 30 minutes. The clear 
supernatant was discarded with only a small residue of water remaining in the tubes (15 µL). 
The particle pellet was resuspended using 300 µL of the prepared NGF formulation and 
incubated for at least 30 minutes. This straightforward procedure was possible because it 
had been shown throughout the remote loading studies with NGF that at these given protein 
to eADF4(C16) ratios no residual protein could be detected in the supernatant. Therefore, all 
NGF molecules were loaded onto the spider silk particles before applying different stress 
methods. 
2.3.1.2 DESORPTION PROCEDURE 
Different procedures were evaluated in order to achieve a sufficient high desorption of NGF 
from the spider silk particles after the stress testing, whereas 80% desorption of the originally 
loaded NGF content was defined as target value. Due to the NGF concentration of 
0.5 mg/mL, a dilution factor of 1:2 should not be exceeded. During this initial evaluation, the 
eADF4(C16) particle concentration was set to 5 mg/mL with a payload of 10% [w/w] NGF 
and the suspensions were mixed with equal volumes of the desorption solutions. 
Finally, the desorption procedure was determined as follows: 300 µL of a buffer solution 
(pH 8.0, 200 mM sodium phosphate, 800 mM sodium chloride) were added to all 
formulations (300 µL) and the resulting mixtures were incubated for 30 minutes at 50°C and 
600 rpm using a Thermomixer compact (Eppendorf, Hamburg, Germany). Subsequently, 
formulations containing spider silk particles were centrifuged at 15,000 g for 30 minutes. 
Thus, the final concentration was approx. 0.25 mg/mL. Samples which were treated 
according to this procedure are further referred as ‘ iquid NGF WP’. 
Particle-free formulations were mixed with 300 µL loading buffer as a control. These samples 
are further referred as ‘ iquid NGF FB’. The control samples were equally incubated at 50°C 
for 30 minutes in order to clarify the impact of the high salt concentration and higher pH of 
the solution required for desorption. 
All samples were analyzed by size exclusion chromatography (see section 2.3.2.1), reversed 
phase chromatography (see section 2.3.2.2) and SDS-PAGE (see section 2.3.2.5). As the 
formulations comprising spider silk particles had to be centrifuged in order to obtain clear 
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supernatants, nephelometry (see section 2.3.2.3) and light obscuration (see section 2.3.2.4) 
measurements could be performed only for particle-free NGF samples. 
2.3.1.3 FREEZE-THAW STRESS 
Samples were prepared by filling the total volume (approx. 315 µL) of the respective 
formulation into 2.0 mL polypropylenes tubes. The tubes were immersed into liquid nitrogen 
for 5 min to ensure complete freezing of the samples. To thaw the samples tubes were kept 
in a Thermomixer compact (Eppendorf, Hamburg, Germany) for 15 min at 25°C without 
agitation. The freeze-thaw cycles were repeated 5, 10 and 15 times. Afterwards, samples 
were drawn from the tubes and the desorption procedure as described in section 2.3.1.2 was 
carried out. 
2.3.1.4 STIRRING 
Stirring stress onto the NGF formulations was performed at a constant stirring speed of 
400 rpm by placing glass vials with screw caps (max. filling volume: 1.5 mL; VWR 
International GmbH, Darmstadt, Germany) vertically onto a multi-position magnetic stirring 
device (VariomagTM Magnetic stirrer, Thermo Electron GmbH, Langenselbold, Germany). 
Washed 3 mm × 3 mm Teflon coated stirring bars (VWR International GmbH, Darmstadt, 
Germany) were placed into the vials and the corresponding formulations were added. Stirring 
was stopped after 24, 48 and 92 hours, whereby at each time point the complete sample 
volume was drawn before the desorption step as described in section 2.3.1.2 was applied. 
Samples were tested in triplicates and control samples without stirring bars were analyzed to 
proof that protein degradation was only induced by mechanical stress. 
2.3.1.5 LIGHT EXPOSURE 
For the evaluation of NGF stability during light exposure, formulations were filled into glass 
vials with screw caps (max. filling volume: 1.5 mL; VWR International GmbH, Darmstadt, 
Germany) and placed into the Suntest® CPS device (Hereaus, Hanau, Germany). The 
radiation energy of the xenon arc lamp instrument was set to 60 watt hours per square meter 
what represented medium illumination intensity. Samples were removed completely after 8, 
16 and 24 hours and subsequently analyzed after desorption of NGF had been conducted 
(see section 2.3.1.2). In order to exclude contribution from thermally induced change to the 
total observed change, dark control samples wrapped in aluminum foil were additionally 
analyzed. 
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2.3.1.6 INCUBATION AT ELEVATED TEMPERATURE 
In order to investigate NGF stability at elevated temperature formulations were filled into 
glass vials with screw caps (max. filling volume: 1.5 mL; VWR International GmbH, 
Darmstadt, Germany) and incubated at 60°C for a maximum of 7 days. Samples were drawn 
after 1 and 3 days of incubation. For each sampling point separate vials were prepared. In 
accordance to the other stress tests, the standard desorption procedure was applied after the 
removal of the samples from the hot-air cabinet (see section 2.3.1.2). 
In a second study, the same formulations were incubated at 40°C and 60°C, respectively. 
Samples were only analyzed after 1 and 3 days. 
2.3.2 ANALYTICAL METHODS 
2.3.2.1 SIZE EXCLUSION CHROMATOGRAPHY 
After removal of insoluble aggregates by centrifugation the supernatants were analyzed by 
size exclusion high performance liquid chromatography (HP-SEC) on a Dionex HPLC system 
(P680, ASI-100, UVD170, RF2000, Dionex Softron GmbH, Germering, Germany) or an 
Ultimate® 3000-system (Dionex Softron GmbH, Germering, Germany). 50 µL sample volume 
were injected onto an YMC-Pack Diol-120 – column (YMC Europe GmbH, Dinslaken, 
Germany) and a flow rate of 0.5 mL/min was used. The mobile phase consisted of 200 mM 
potassium phosphate and 450 mM potassium chloride at pH 7.0. The detection was carried 
out using a UV-VIS variable detector at 215 nm and 280 nm as well as a fluorescence 
detector using an excitation wavelength of 288 nm and an emission wavelength of 344 nm. 
The area of dimer, tetramer und high molecular weight aggregates was integrated and 
monitored throughout the different forced degradation experiments. The percentage of total 
protein recovery as well as of the respective soluble protein species was calculated by 
dividing the area obtained from incubated samples by the area of untreated control samples. 
Control samples at t0 were treated as described in section 2.3.1.2. 
Due to the centrifugation step before injection, the amount of insoluble aggregates was 
indirectly calculated by the difference between the total protein recovery at t0 and the 
different sampling points. Data analysis was performed with Chromeleon® software (Dionex 
GmbH, Germering, Germany). 
2.3.2.2 REVERSED PHASE CHROMATOGRAPHY 
In accordance to sample preparation for size exclusion chromatography insoluble aggregates 
were removed by centrifugation prior to injection. Likewise, 50 µL of the corresponding 
sample were injected onto a reversed phase C4 Eurosil® Bioselect column (Knauer, Berlin, 
Germany) and the separation was carried out on an Ultimate® 3000-system (Dionex Softron 
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GmbH, Germering, Germany) or on a Dionex HPLC system (P680, ASI-100, UVD170, 
RF2000, Dionex Softron GmbH, Germering, Germany). The applied gradient consisted of 
two mobile phases, namely solvent (A) water + 0.1% [m/m] TFA and solvent (B) 
100% acetonitrile + 0.1% [m/m] TFA. Each run started with 5 minutes of 100% solvent (A) 
and was followed by an increase of solvent (B) from 25% to 28% over 35 minutes. Residual 
protein was washed from the column by 100% solvent (B) and the run stopped with 
equilibration of the column at 100% solvent (A). The detection was carried out on a UV-VIS 
variable detector at 215 nm and 280 nm as well as on a fluorescence detector using an 
excitation wavelength of 288 nm and an emission wavelength of 344 nm. The calculations 
regarding protein recovery were performed according to the procedure described in 
section 2.3.2.1. 
2.3.2.3 NEPHELOMETRY 
The turbidity of particle-free NGF formulations was determined using a NEPHLA 
nephelometer (Dr. Lange, Düsseldorf, Germany). Nephelometry was measured in formazine 
nephelometric units (FNU) by 90° light scattering at a wavelength of 860 nm. This procedure 
is described in the European Pharmacopoeia (method 2.2.1). Each value represents the 
average of two measurements to exclude unspecific scattering effects. 
As the required measurement volume is 1.8 mL, all NGF formulations were diluted 1:10 with 
loading buffer before measurement. Therefore, the total dilution for turbidity and light 
obscuration measurements was 1:20 including the dilution step during the desorption 
procedure. 
2.3.2.4 LIGHT OBSCURATION 
The size and amount of particles between 1 and 200 µm was measured for particle-free NGF 
formulations by light obscuration using a SVSS C-40 apparatus equipped with a 
HCB-LD-25/25 sensor (PAMAS GmbH, Rutesheim, Germany). 
The detailed measurement procedure was already described for the measurement of spider 
silk protein formulations and it is therefore referred to section 2.2.2.6. 
2.3.2.5 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS 
In order to obtain further information about NGF aggregates SDS-PAGE was performed 
under non-reducing conditions. Samples were loaded on NuPAGE® 10% Bis-Tris precast 
gels (Life technologies GmbH, Darmstadt, Germany), which had been mounted in the XCell 
II Mini cell system (Novex, San Diego, CA, USA). The sample preparation included the 
dilution of the samples to an approximate protein concentration of 0.10 mg/mL in a tris-buffer 
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at pH 6.8 and the denaturation of the samples at 95°C for 20 minutes. Finally, 10 µL or 5 µL 
of each sample were loaded into the different wells of the gel for coomassie staining or for 
silver staining, respectively. Separation was carried out at a current of 40 mA per gel and the 
runtime was about 90 minutes. 
Coomassie staining of the gels was performed using the Imperial® protein stain solution 
(Thermo Fisher, Rockford, IL, USA). The gels were incubated in the staining solution for 
about 3 hours and washed excessively with purified water over night. 
Silver staining was carried out by using the SilverXPress® Staining Kit (Invitrogen, Carlsbad, 
CA, USA). 
Regardless of the staining procedure, the same protein standard (Mark 12® Unstained 
Standard, Invitrogen, Carlsbad, CA, USA) was loaded onto each gel for the assessment of 
the molecular weight of protein species. 
2.3.2.6 MICROCALORIMETRY 
Thermal stability of NGF in the formulation buffer was investigated using high sensitivity 
differential scanning calorimetry (µDSC) on a MicroCal differential scanning calorimeter 
(MicroCal Inc., MA, USA). After degassing, the NGF formulations were filled into the 
measurement cells of the calorimeter using a hamilton syringe. The samples were heated up 
from 20 to 90°C with a heating rate of 1°C/min. The reversibility of the unfolding process was 
controlled by a second consecutive heating scan.  
The thermogram of water samples was subtracted from the thermogram of the NGF 
formulations and the melting temperature (midpoint of unfolding, Tm) of the transition was 
determined using Origin 7.0 software. 
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CHAPTER 3 
PREPARATION TECHNIQUES, CHARACTERIZATION AND 
FORMULATION DEVELOPMENT OF SPIDER SILK PARTICLES 
3.1 INTRODUCTION 
As described in the introduction of this thesis particles made from biodegradable polymers 
represent a promising platform for drug delivery with a broad variety of potential 
applications [1-3]. For particle preparation several different strategies and techniques have 
been developed which are summarized elsewhere [4, 5]. Therein, the most employed 
techniques are emulsion-based preparation methods which are primarily used for particles 
made of polyesters such as poly(lactic-co-glycolic acid). The emulsion-based techniques can 
be used for microparticle as well as for nanoparticle preparation, but protein denaturation or 
aggregation is a severe issue during encapsulation due to the presence of water/organic 
solvent interfaces [6]. In the field of protein-based carriers most notably albumin, gelatin and 
silk particles have been developed throughout the last decade [7-10]. However, none of the 
investigated carriers is able to meet all requirements which are necessary for successful 
delivery of protein drugs. Gelatin nanoparticles have been successfully applied in vivo as 
nebulized drug carriers for immunostimulating agents like cytosine-phosphate-guanine-
oligodeoxynucleotides (CpG-ODN) in immunotherapy of allergic horses [11]. Nevertheless, 
particle preparation of gelatin nanoparticles by one or two-step desolvation exhibits important 
drawbacks such as the necessary use of glutaraldehyde and acetone as well as limited 
ability to upscale the process. This is quite critical regarding a potential commercialization of 
this drug delivery platform. Using silk fibroin from Bombyx mori, microspheres and 
nanoparticles were prepared by different and predominantly quite sophisticated preparation 
techniques: using lipid-based templates [12-14], film casting and subsequent sonication [15], 
vibrational splitting of laminar jet [16], usage of water-miscible organic solvents [17] and 
salting-out with lyotropic salts [18]. 
In summary, these examples show that there is still a need for new biodegradable materials 
which have to be available in adequate amounts meeting the required quality and safety for 
pharmaceutical excipients. These materials should be easily prepared using an adaptable 
and upscalable technique. 
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After development of the recombinant production of eADF4(C16), first studies on the specific 
assembly process of this protein were carried out [19, 20]. The group of Prof. Scheibel 
showed that smooth protein spheres with high β-sheet content were formed by a salting-out 
process with potassium phosphate as lyotropic salt. The underlying mechanism was 
described as liquid-liquid phase separation into a protein-poor and a protein-rich phase in 
which particulate protein aggregates were formed. Spherical growth of the protein 
aggregates stopped when the protein concentration was below the equilibrium of solubility 
[19]. The spider silk particles were shown to be chemically stable even at harsh conditions 
such as 6 M urea and could only be dissolved in the very strong denaturant 6 M guanidine 
thiocyanate [21]. Based on these results, the preparation conditions and the resulting 
eADF4(C16) particle sizes and size distributions were evaluated [22]. Lammel et al. 
observed that the size of eADF4(C16) particles can be easily controlled by the mixing 
intensity and the concentrations of potassium phosphate and eADF4(C16). Figure 3.1 
summarizes all impact factors on the phase separation process which lead to the formation 
of β-sheet dominated particles made of the originally unfolded eADF4(C16) protein. As a 
major advantage over the aforementioned preparation processes of other biodegradable 
particles it has to be highlighted that the entire particle preparation process using spider silk 
protein is performed in an aqueous environment avoiding any organic solvent and harsh 
preparation conditions. 
 
Figure 3.1. Liquid-liquid phase separation and structure formation of eADF4(C16) particles 
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However, results so far only covered the evaluation of the particle preparation process to 
some extent which was owed in particular to the limited availability of recombinant 
eADF4(C16) protein at the time. As protein production at AMSilk improved and protein 
amounts of up to 1 g were available, each single part of the phase separation process was 
investigated in more detail in this chapter. 
At first, different techniques for particle preparation were compared. In the course of this 
work, the need emerged for both small nanoparticles for approaches in the field of 
vaccination and for larger microparticles for application in other areas of drug delivery. Our 
work on optimizing the preparation techniques, identifying process limitations and defining 
critical process parameters will be described in section 3.2 of this chapter. 
Secondly, the improvement of the recombinant production process at AMSilk and results 
from particle preparation employing different protein qualities raised the demand for a 
detailed investigation of the liquid eADF4(C16) intermediate. So far it is known that the spider 
silk protein is intrinsically unfolded [19], but no data is available about its physical stability or 
its potential influence on the phase separation process. Therefore, section 3.3 deals with the 
characterization of liquid eADF4(C16) formulations using different analytical techniques and 
the investigation of eADF4(C16) stability during incubation at elevated temperatures. 
Thirdly, the obtained eADF4(C16) particles suspensions were analyzed regarding their 
colloidal stability at different conditions in section 3.4. So far no information was available 
from literature about the performance of spider silk particles after preparation which is 
obviously of great importance regarding their future application. Lyophilization of 
nanosuspensions is often applied in order to optimize the long-term stability of suspensions 
[23-25]. A feasibility study employing sucrose as lyoprotectant as well as the comparison of 
different formulations were carried out and are described in section 3.5. 
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3.2 PREPARATION OF eADF4(C16) PARTICLES 
Slotta et al. [19] and Lammel et al. [22] performed first studies in order to evaluate the 
mechanism of phase separation, different particle preparation techniques and the resulting 
particle size distributions. They found that above a potassium phosphate concentration of 
500 mM (pH 8) spider silk spheres were formed in aqueous solution [19]. The effect of 
different mixing conditions was investigated by simple mixing with a pipette, dialysis and 
micromixing within a t-shaped mixing element. At 500 mM potassium phosphate clusters of 
spider silk spheres were formed with all examined preparation methods, whereas the 
observed particles at 1 M potassium phosphate were separated and well-shaped. 
eADF4(C16) concentrations of 0.5 and 1.0 mg/mL were employed throughout the study and 
particles in the range of 250 - 510 nm were obtained by micromixing and mixing with a 
pipette. A particle size around 1.6 µm was measured for spider silk particles prepared by 
dialysis. After all, it was concluded that sphere size increases with increasing protein 
concentration and decreases with the mixing intensity [22]. 
Based on these findings, two different strategies were developed to fulfill the emerging need 
for significantly different particle sizes. 
3.2.1 SPIDER SILK NANOPARTICLES 
The required particle size of drug delivery systems depends on the desired application. In the 
case of spider silk particles an application in the field of vaccination is very promising as 
polymeric particles were already successfully evaluated as vaccine delivery systems [26]. 
For that purpose a perfect particle size cannot be defined, but in our case a particle size of 
500 nm is the invariable maximum. Much better would be a particle size below 300 nm so 
that the optimization of the particle preparation aimed to decrease the particle size as much 
as possible. 
Figure 3.2 gives an overview of the established preparation process of eADF4(C16) particles 
based on the micromixing method via a syringe pump system. The individual process steps 
are described in detail in chapter 2, section 2.2. The implementation of the syringe pump 
system has several advantages compared to the preparation by other mixing techniques 
such as using a pipette or dialysis: high reproducibility of the employed flow-rates due to 
digital controlling, temperature control due to the connection of the heating jackets to a batch 
circulator and broad tunable spectrum of both process parameters. Besides, upscaling of this 
technique is possible and the syringe pumps can be cleaned with almost each kind of 
solvent, acid or base so that an endotoxin-free preparation is feasible as well. 
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Figure 3.2. Overview of the preparation process of eADF4(C16) particles using the micromixing device 
As it is shown in Figure 3.2 an ultrasonic treatment and filtration step were implemented in 
addition to the washing procedure. The reason therefore is illustrated in Figure 3.3, where 
the obtained particle size distributions are compared. Due to the high ionic strength 
necessary for phase separation, the already formed particles immediately agglomerated into 
large clusters which were responsible for a distorted size distribution of the bulk suspension 
after the washing procedure. Neither the first peak around 300 nm nor the second one in the 
micrometer range indicated the actual particle size. Simple filtration through a 1.2 µm 
membrane removed the agglomeration peak, but the size distribution still demonstrated too 
large particle sizes compared to microscopic images from SEM (data not shown). Therefore, 
an ultrasonic treatment was established which enabled the disintegration of agglomerated 
eADF4(C16) particles without altering the particles’ secondary structure (data not shown). 
The significant decrease in particle size was also detected by dynamic light scattering (see 
Figure 3.3). It has to be mentioned that this method is much more sensitive towards small 
amounts of larger particles/agglomerates, because the resulting particle size/size distribution 
is based on the scattering intensity which depends on the particle diameter to the power of 
six in the Rayleigh approximation I ≈ d6 [27]. For this reason, the mean hydrodynamic 
diameter – usually reported as Z-average diameter – was significantly higher in the bulk 
suspension and in the 1.2 µm filtrate. Both SLS- and DLS-measurements reflected only 
minor differences between an ultrasonic treatment of 5 and 15 minutes for which reason 
shorter time periods were preferred. Additional filtration of the suspensions showed a positive 
effect on the Z-average diameter and is therefore recommended for the standard particle 
preparation procedure. Both sizing techniques revealed furthermore almost the identical 
particle size which argues for a correct analytical determination of the observed particle size. 
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DLS 
Sample 
Z-average 
[nm] 
bulk 1233 
filtrate 827 
5 min US 576 
5 min US 
+ filtration 
552 
15 min US 574 
15 min US 
+ filtration 
518 
 
Figure 3.3. Particle size distributions determined by static light scattering during the preparation process. 
The results from DLS-measurements of the corresponding samples are tabulated alongside the diagram 
However, ultrasonic treatment may not be a suitable process when drugs and especially 
proteins are encapsulated during the particle preparation process. Several studies have 
shown that ultrasound can be detrimental for protein stability, e.g. for lysozyme [28]. 
Nevertheless, the effect on the drug will be case-specific and strongly dependent on the 
applied process [29, 30]. Maybe the incorporation and interaction with the silk matrix can also 
stabilize the employed drug molecules. 
After the establishment of the preparation procedure, different settings and parameters were 
varied and the micromixing system was again compared to other preparation techniques. 
eADF4(C16) concentration was set to 1.0 mg/mL and a 2 M potassium phosphate solution at 
pH 8.0 was used for the salting out of the spider silk protein. The resulting Z-average 
diameters and polydispersity indices are listed in table 3.1. Raising the flow rate from 
1 mL/min to 50 mL/min slightly reduced the resulting particle size and PI, but a clear trend 
towards larger particles and especially broader size distributions were observed when an 
inner diameter of the circular mixing zone of 1.25 mm was employed. Mixing both solutions 
with a pipette resulted in a mean diameter of 531 nm. This particle size was quite 
comparable to the micromixing technique, but the PI value revealed a broader size 
distribution than micromixing in the small circular mixing zone. As already reported by 
Lammel et al. [22], eADF4(C16) particles formed by dialysis exhibited the largest diameter of 
all preparation techniques with an Z-average of 1.4 µm. However, due to the slow and more 
or less uncontrolled mixing process the particle suspension was very polydisperse. 
To sum it up, phase separation can be very well controlled by the use of the micromixing 
system leading to monodisperse particle distributions, whereas dialysis and mixing with a 
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pipette result in more polydisperse suspensions. With regard to the aim of preparing 
eADF4(C16) nanoparticles as small as possible, the highest available flow rate of 50 mL/min 
and the T-shaped mixing element with an inner diameter of 0.50 mm were used for further 
particle preparation processes if not otherwise stated. 
Table 3.1. Particle size and polydispersity indices (PI) of differently prepared eADF4(C16) particles as 
determined by dynamic light scattering. Each preparation technique was performed once. The standard 
deviation was calculated from three subruns performed for each particle batch 
Preparation technique 
Settings Z-average 
[nm] 
PI 
Flow rate ID 
Micromixing system 1 mL/min 0.50 mm 518.1 ± 8.0 0.188 ± 0.033 
Micromixing system 50 mL/min 0.50 mm 490.6 ± 7.8 0.187 ± 0.018 
Micromixing system 1 mL/min 1.25 mm 560.4 ± 15.1 0.280 ± 0.018 
Micromixing system 50 mL/min 1.25 mm 510.1 ± 8.2 0.245 ± 0.029 
Pipette N.A. N.A. 531.0 ± 8.7 0.232 ± 0.022 
Dialysis N.A. N.A. 1369.4 ± 56.2 0.757 ± 0.156 
Nevertheless, the obtained particle sizes of around 500 nm were still quite large related to 
their potential application in vaccination studies. Therefore, further optimization of the 
process had to be established which means that the phase separation process had to be 
further accelerated. For this purpose, three different strategies were followed: variation of the 
lyotropic salt, decrease of the protein concentration and implementation of higher process 
temperatures. The results from these process modifications are depicted in Figure 3.4. The 
use of a 2 M ammonium sulphate solution in exchange for the 2 M potassium phosphate 
solution did not significantly alter the resulting particle distributions even though ammonium 
and sulphate ions are described to be more lyotropic [31]. But, process temperature and 
protein concentration had a strong impact on the kinetics of the phase separation process. 
On this account it was possible to reduce the particle size to diameters slightly below 300 nm 
if a protein concentration of 0.5 mg/mL and a process temperature of 80°C were used. The 
corresponding polydispersity index below 0.15 completed the convincing outcome obtained 
by this modification of the preparation procedure. 
The suspensions were vacuum-dried on Thermanox™ cover slips (Thermo Scientifc / Nunc, 
Langenselbold, Germany) and analyzed by scanning electron microscopy in order to confirm 
the determined particle sizes. It is clearly visible that smooth and round particles with a quite 
dense surface were formed (see Figure 3.5). The size of the particles appears to be slightly 
smaller compared to DLS/SLS measurements, but the shrinkage can be likely attributed to 
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the drying step necessary prior to SEM investigation. The obtained micrographs 
(magnification: 9,500x) shown in Figure 3.5 are indicative of all particle batches produced 
throughout the work regarding shape and surface characteristics. 
 
eADF4(C16) concentration 
eADF4 
[mg/mL] 
T 
[°C] 
Z-average 
[nm] 
PI 
2.0 20 2087 0.57 
1.0 20 637 0.18 
0.5 20 474 0.20 
 
Figure 3.4. Particle size and polydispersity indices after preparation of eADF4(C16) particles at different 
temperatures (diagram) as well as after employing different eADF4(C16) concentrations (inserted table) 
Altogether, the development of a standardized preparation procedure was achieved and 
written down in a standard operation procedure. The particle size of eADF4(C16) 
nanoparticles can be tailored by variation of process parameters such as protein 
concentration or process temperature. The micromixing technique is moreover upscalable 
and should allow for adequate cleaning in place in order to produce endotoxin-free particles 
for vaccination studies. 
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Figure 3.5. Scanning electron micrographs (magnification: 9,500x) of eADF4(C16) particles prepared at 
conditions specified in the upper left corner of each micrograph 
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3.2.2 SPIDER SILK MICROPARTICLES 
Microparticles made of biodegradable polymers are commonly used drug delivery systems 
for different kind of applications. For example, PLA and PLGA-based microspheres were 
approved for parenteral depot formulations of leuprolide acetate for endometriosis or prostate 
cancer (Lupron® depot) and octreotide for acromegaly (Somatostatin® LAR), respectively. In 
order to develop depot formulations made of spider silk protein, larger eADF4(C16) spheres 
are needed compared to the prepared nanoparticles in section 3.2.1. The use of the 
straightforward preparation process based on phase separation should be continued, but in 
contrast to the nanoparticles’ preparation the thermodynamic kinetics of the process has to 
be slowed down. For this reason, an ultrasonic nozzle was employed for particle preparation 
using different setups to form eADF4(C16) particles (further details see chapter 2, 
section  2.2.3.3). The different settings are listed in table 3.2. 
Table 3.2. Ultrasonic nozzle – Different settings for the preparation of eADF4(C16) particles 
conc. (eADF4) 
[mg/mL] 
c (PO4
3-
) / Volume 
Temperature 
[°C] 
Atomization rate 
[mL/min] 
Simultaneous atomization 
A 
0.5 / 1.0 / 2.0 2 M / 100 mL RT 3 
2.0 / 5.0 4 M / 100 mL 55 3 
Atomization of eADF4(C16) into potassium phosphate solutions 
B 
0.5 / 1.0 / 2.0 / 5 / 10 / 15 2 M / 3 mL RT 3 
0.5 / 1.0 / 2.0 
0.5 / 1.0 / 2.0 
2 M / 30 mL / 60 mL 
2 M / 3 mL 
RT 
60 / 80 
3 
3 
Atomization of potassium phosphate into eADF4(C16) solutions 
C 
0.5 / 1.0 / 2.0 / 5 / 10 / 15 2 M / 3 mL RT 3 
0.5 / 2.0 / 10 
0.5 / 2.0 / 10 
5 
2 M / 3 mL 
1 M / 3 mL 
2 M / 3 mL 
4 
RT 
RT 
3 
3 
1.5 / 0.5 
3.2.2.1 SIMULTANEOUS ATOMIZATION OF eADF4(C16) SOLUTION AND POTASSIUM PHOSPHATE 
SOLUTION 
As the ultrasonic nozzle is equipped with a dual liquid feed option, both the protein and the 
potassium phosphate solution can be atomized at the tip of the nozzle simultaneously. At 
best, solid particles are created during the spraying period and prior to the collection of the 
spraying mist. In this study, 2 M potassium phosphate solutions and eADF4(C16) solutions 
with concentrations of 0.5 to 2.0 mg/mL were atomized into 100 mL purified water (see 
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Table 3.2, A). All prepared samples contained unfortunately significant amount of threads 
and fibrils and remained comparatively transparent (see Figure 3.6, A). For this reason it was 
concluded that almost no particle formation took place during the spraying period. This fact 
was controlled by spraying simultaneously into a 2 M potassium phosphate solution instead 
of purified water (see Figure 3.6, B). The resulting solutions exhibited higher turbidity as a 
result of phase separation / particle formation occurring after the spraying phase. 
Taken together, it can be stated that simultaneous atomization creates a situation where the 
phosphate to eADF4(C16) ratio is too low to form solid spider silk spheres, leading to fibrils 
and threads. Residual eADF4(C16) protein self-assembles into particulate aggregates 
primarily after spraying and not during the spraying period. In order to reduce aggregation 
into filaments and to promote particle formation during spraying, the process was 
thermodynamically accelerated by raising the potassium phosphate concentration to 4 M and 
the process temperature to 55°C, respectively. Nevertheless, fibril formation could not be 
prevented even if more smooth and round particles in the size between 300 – 500 nm were 
formed at a protein concentration of 2 mg/mL (SEM data not shown). The orifice congested 
due to severe creation of threads at the atomizing surface at higher protein concentration of 
5 mg/mL and prohibited further evaluation of the simultaneous atomization setup. 
Finally, simultaneous atomization of both solutions did not result in satisfying particle 
dispersions so far. The major issue was the formation of fibrils or other macroscopic 
agglomerates which occurred at every investigated experimental condition. This uncontrolled 
aggregation appeared due to the slow phase separation process and a too low potassium 
phosphate to eADF4(C16) ratio present in the created mist after atomization. Moreover, even 
if macroscopic agglomerates did not appear, the obtained eADF4(C16) particles exhibited 
particle sizes below 1 µm. For this reason, the approach described here seems not to be 
suitable for eADF4(C16) microparticle preparation. 
 
Figure 3.6. Suspensions obtained by simultaneous atomization of eADF4(C16) and 2 M potassium 
phosphate. eADF4(C16) concentrations of 0.5 mg/mL (1A, 1B), 1.0 mg/mL (2A, 2B) and 2.0 mg/mL (3A, 3B) 
were sprayed into 100 mL of purified water (A) or 2 M potassium phosphate solutions (B). 
1A 1B 2A 2B 3A 3B 
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3.2.2.2. ATOMIZATION OF eADF4(C16) INTO POTASSIUM PHOSPHATE SOLUTIONS 
This approach (see Table 3.2, B) was assumed to lead doubtlessly to the formation of spider 
silk particles. Six different protein concentrations from 0.5 to 15 mg/mL were evaluated by 
spraying 3 mL protein solution into an equal volume of a stirred 2 M potassium phosphate 
solution. The obtained particle suspensions were subjected to the standard purification 
procedure including washing and ultrasonic treatment of the suspensions. SEM micrographs 
(magnification: 9,500x) of the resulting particle batches are displayed in Figure 3.7. In 
contrast to nanoparticles prepared by the micromixing system (see section 3.2.1), striking 
difficulties to separate the occurring aggregates appeared and resulted in high PI and span 
values (data not shown). SEM micrographs further indicate that particle formation was rather 
incomplete as particles were not really defined in shape and still stuck together closely in 
large particle clusters. Interestingly, the obtained spider silk particles exhibited smaller 
diameters compared to approaches A and C so that spraying this way was further optimized 
towards smaller nanoparticles by accelerating the phase separation process. 
   
   
Figure 3.7. SEM micrographs (magnification: 9,500x) of eADF4(C16) particles prepared by the atomization 
of an eADF4(C16) solution with (A) 0.5 mg/mL, (B) 1.0 mg/mL, (C) 2.0 mg/mL, (D) 5.0 mg/mL, (E) 10 mg/mL 
and (F) 15 mg/mL into a potassium phosphate solution (2 M, pH 8) 
This acceleration was achieved by increasing the process temperature or the volume of the 
phosphate solution and the corresponding results are illustrated in Figure 3.8, A and B. Only 
low concentrated spider silk solutions (0.5 – 2.0 mg/mL) were used in this study. An increase 
of the volume of the potassium phosphate solution means an increase in the phosphate to 
eADF4(C16)-ratio. It was thereby possible to accelerate the particle preparation process 
significantly as well-defined particles with sizes between 300 and 500 nm were formed 
A B C 
D E F 
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(see SEM micrograph in Figure 3.8, A). Nevertheless, particle dispersions were still quite 
polydisperse with polydispersity indices above 0.2. Smaller particles and more narrow size 
distributions were obtained when both solutions were preheated to 60°C and 80°C, 
respectively. Well-shaped particles between 250 and 350 nm could be prepared with 
sufficiently low polydispersity indices below 0.15. This implied that an elevated temperature 
had stronger accelerating effects on the phase separation process than a higher phosphate 
to eADF4(C16) ratio. Furthermore, increasing the phosphate to protein ratio goes along with 
10- or 20-fold higher suspension volumes which have to be purified afterwards. Compared to 
other preparation techniques these eADF4(C16) particles were the smallest ever obtained, 
especially at protein concentrations of 1.0 or 2.0 mg/mL which allow for acceptable process 
yields. Therefore, this approach seems to be very suitable for the preparation of quite small 
nanoparticles with reasonable yields. 
 
 
 
 
Figure 3.8. Particle size and polydispersity indices of eADF4(C16) particles prepared by using different 
volumes of potassium phosphate solutions (A) or different process temperatures (B). The corresponding 
SEM pictures (magnification: 25,000x) are shown on the right hand side. 
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3.2.2.3 ATOMIZATION OF POTASSIUM PHOSPHATE INTO eADF4(C16) SOLUTIONS 
In a third approach (see Table 3.2, C), the potassium phosphate solution was atomized by 
the ultrasonic nozzle and the spraying mist was collected in an equal volume of stirred 
eADF4(C16) solutions. The same protein concentrations as employed for atomizing 
eADF4(C16) solutions were used throughout this study. Turbidity emerged suddenly after 
several seconds of the spraying process, but definitely not right at the beginning. 
Furthermore, the time point when visible turbidity occurred was solely dependent on the 
phosphate concentration gradient being created in the stirred solution and independent of the 
employed protein concentration. These facts indicate that the initiation of the phase 
separation for both approaches is different, leading to different particle size distributions. 
Interestingly, using this approach a sonication time of 2 minutes was sufficient to disintegrate 
agglomerates, even for suspensions prepared at higher protein concentrations. The resulting 
particle sizes and span values (D90-D10/D50) as determined by static light scattering are 
shown in Figure 3.9. 
For the first time, eADF4(C16) particles with diameters above 2 µm were obtained, 
whereupon the maximum particle size of approx. 5 µm was reached at an eADF4(C16) 
concentration of 10 and 15 mg/mL, respectively. As it can be deduced from SEM 
micrographs (see Figure 3.9, A-F), the produced particles possessed a smooth surface and 
round shaped morphology. Regarding the polydispersity it could be shown that especially at 
high protein concentration tight and monodisperse size distributions were achieved. 
However, SEM micrographs also illustrate a remarkable amount of smaller spider silk 
particles being present next to large microspheres and may suggest that further purification 
of the obtained particle dispersions would be necessary. 
Next, a deceleration of the self-assembly process was intended to further increase the 
particle size. Therefore, three process parameters were altered towards a slower kinetic 
process: temperature, phosphate concentration and atomization rate. The effect of a 
decreased process temperature and potassium phosphate concentration was studied at 
eADF4(C16) concentrations of 0.5, 2.0 and 10 mg/mL. A protein concentration of 5.0 mg/mL 
was used for the evaluation of slower atomization rates. 
At first, both employed solutions were precooled to 4°C prior to atomization. However, after 
purification and sonication the obtained eADF4(C16) particles exhibited nearly the same 
particle size as after preparation at room temperature (see Figure 3.10, A). Furthermore, with 
respect to their shape and surface characteristics it seems that particle formation was at 
least partially incomplete and rather rough particle surfaces were developed. Figure 3.10 B 
indicates that larger microspheres were formed if a 1 M potassium phosphate solutions were 
used. Microspheres with a mean diameter of 6.6 µm and a particle size distribution with a 
span value of 0.97 were obtained at a concentration of 10 mg/mL. Their macroscopic 
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appearance was satisfying as no clusters or shape-altered particles were observed. In a final 
step, the flow rate of the peristaltic pump was reduced from 3 mL/min to 1.5 mL/min and 
0.5 mL/min, respectively. As the drop size in an ultrasonically produced spray is governed by 
the vibration frequency, surface tension and density of the liquid being atomized, the created 
droplet size should not be affected significantly by a change of the atomization rate. 
Nevertheless, the decelerated addition of the salt resulted in larger microspheres compared 
to the standard flow rate of 3 mL/min as shown in Figure 3.10, C. The particle size could be 
increased by 60%, which is the highest percentage increase of all modified preparation 
procedures without affecting the particles’ morphology. 
 
   
   
Figure 3.9. Median and span of eADF4(C16) particles prepared by atomization of potassium phosphate 
into eADF4(C16) solutions. Images A to F show the corresponding SEM micrographs 
(magnification: 9,500x) starting from (A) 0.5 mg/mL to (F) 15 mg/mL. Each setup was performed in 
triplicate. 
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The corresponding span values around 1 indicated that the obtained particle size 
distributions exhibit a homogenous, almost Gaussian-like distribution curve. 
In summary, preparation of microspheres using an ultrasonic nozzle was successful. 
However, the initial idea to form spider silk particles within the spraying mist by simultaneous 
atomization of 2 M potassium phosphate and eADF4(C16) solutions was not possible so far. 
This is likely due to an inadequate phosphate to eADF4(C16)-ratio present at the atomizing 
surface and in the atomized droplet mixture as the situation could be improved by kinetically 
accelerating the phase separation process. Nevertheless, fibril formation was observed in all 
experiments using the simultaneous atomization so that this approach was put aside. 
Interestingly, rather small nanoparticles were obtained by the atomization of a spider silk 
solution into 2 M potassium phosphate. Indeed, this was not initially intended, but it could be 
shown that particle sizes around 300 nm were achieved at the time when both solutions were 
preheated to 60 or 80°C. 
Spraying vice versa enabled the formation of microspheres in the single-digit micrometer 
range. Especially atomization at lower flow rates and employing 1 M potassium phosphate 
solutions significantly increased the obtained particle sizes. The remarkable amount of 
smaller spider silk particles as shown by SEM can be reduced in the future by centrifugation 
at very low centrifugal forces or by separation using centrifugal filters with pore sizes around 
1 µm (e.g. Vivaclear Mini, 0.8 µm PES membrane, Sartorius Sedim Biotech GmbH, 
Goettingen) to retain large particles upon the filter membrane.  
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Figure 3.10. Particle size and span values of eADF4(C16) particles prepared at 4°C (A), by using 
1 M potassium phosphate (B) or at different flow rates (C). The corresponding SEM micrographs 
(magnification: 9,500x) are displayed on the right hand side. 
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3.3 CHARACTERIZATION OF LIQUID eADF4(C16) FORMULATIONS 
As described in the previous section, spider silk particle preparation is based on mixing an 
aqueous eADF4(C16) formulation with a high concentrated salt solution to induce phase 
separation. However, only little information is available in the literature on the characteristics 
of the aqueous spider silk protein solution. It is well established that recombinant 
eADF4(C16) protein behaves different to globular proteins as it is initially unfolded in an 
aqueous environment as determined by far-UV circular dichroism [32]. This statement was 
confirmed by FTIR-spectroscopy of an eADF4(C16) solution formulated at 10 mM Tris-buffer 
at pH 8.0 (see Figure 3.1). The minimum of the second derivation at approx. 1650 cm-1 is 
assigned to a primarily random coiled structure of the protein molecule according to Hu et 
al. [33]. Nevertheless, besides the determination of the protein’s conformation no data was 
published so far concerning the investigation of the physical or chemical stability of 
eADF4(C16) or other spider silk proteins. This characterization is obviously necessary for the 
establishment of reproducible and robust preparation processes of all kind of morphologies 
made of eADF4(C16). For this reason, analytical methods, which are commonly used for the 
characterization of protein formulations, have to be established. But, it has to be considered 
that eADF4(C16) is by nature a hydrophobic and very aggregation-prone protein molecule 
and therefore significantly different to therapeutic proteins like monoclonal antibodies. This 
aspect was taken into account by developing a suitable method for asymmetrical flow field-
flow fractionation (AF4) as described in section 3.3.1. Furthermore, the eADF4(C16) 
formulation was analyzed after incubation at 80°C due to the need of high process 
temperatures for the previously explained preparation process of spider silk nanoparticles. 
Altogether, the information obtained on the stability of eADF4(C16) will be very useful for 
further optimization of the protein formulation and subsequent preparation processes. 
3.3.1 CHARACTERIZATION OF eADF4(C16) BY AF4 
In order to gain insight into the physical state of solubilized eADF4(C16), the analytical 
technique called asymmetrical flow field-flow fractionation was employed. This method is a 
suitable tool for separating both soluble and insoluble protein aggregates even though size 
exclusion chromatography (HP-SEC) is still the default method for characterizing soluble 
protein aggregates in pharmaceutical industry. In the case of analyzing eADF4(C16) the 
following drawbacks of HP-SEC are of particular interest: (1) adsorption of protein and/or 
protein aggregates to the column matrix, (2) dissociation and/or formation of protein 
aggregates during the course of a sample run, (3) incapability of HP-SEC to resolve larger 
soluble protein aggregates (void volume) and (4) inability to separate soluble and insoluble 
protein aggregates simultaneously [34]. Adsorption to the column matrix can be avoided by 
increasing the ionic strength of the mobile phase, but regarding eADF4(C16) high ionic 
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strength causes severe protein aggregation. Furthermore, the pH of mobile phases is 
recommended to be slightly acidic (pH 4-7) for commonly used silica- or agarose-based 
matrices, but acidic conditions were shown to be detrimental for eADF4(C16) solubility [35]. It 
was also reported for eADF4(C16) that formation of nanofibrils having a length of several 
hundred nanometer can occur [36] so that standard HP-SEC conditions would not be able to 
resolve those morphologies or rather the column frit would be rapidly clogged. Altogether, it 
seemed to be worth to develop an alternative method to HP-SEC so that AF4 was employed 
to characterize amount, size and molecular weight of protein species in eADF4(C16) 
formulations. 
The detailed principles and mechanisms of separation in AF4 are described elsewhere [37, 
38]. Briefly, differences in hydrodynamic diameter and corresponding diffusion coefficients 
lead to a different diffusion into the center of the parabolic flow so that species exhibiting a 
smaller hydrodynamic diameter are eluted first. After separation, protein species are 
detected by UV-Vis, refractive index and multiple angle light scattering detectors. A suitable 
AF4 method should exhibit an adequate separation of protein species with a consistent 
recovery and a solid reproducibility. 
During preliminary method development different membrane materials and molecular weight 
cut-offs were tested. The most accurate and reproducible results were obtained using a 
10 kDa cut-off and a membrane made of regenerated cellulose. The formulation buffer was 
chosen (10 mM Tris-buffer, pH 8.0) as mobile phase in order to avoid any artificial effect or 
result created by the running buffer during separation. As described in chapter 2, section 
2.2.2.1, the detector flow was kept constant at 1.0 mL/min and a channel height of 350 µm 
was used. Method development included primarily the optimization of the cross flow profile 
which can be divided in general into four sections: (I) injection and focusing cross flow, (II) 
elution cross flow, (III) rinsing step and (IV) washing step (see Figure 3.11). The cross flow of 
each section was varied and optimized to obtain the most suitable elution profile. 
 
 
Figure 3.11. Separation of eADF4(C16) by AF4 using the developed cross flow profile. Red: Light 
scattering at 90°C; blue: Refractive index; green: UV-detection at 280 nm 
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Finally, an optimal resolution and determination of eADF4(C16) was achieved using the 
cross flow profile displayed in Figure 3.11. The corresponding chromatogram of the three 
employed detectors is also shown in this figure. First, a cross flow of 4.0 mL/min was applied 
for 5 minutes in order to focus the sample on the membrane which is necessary for high 
separation capacity. The monomeric form of eADF4(C16) eluted after approx. 10 minutes 
during a constant cross flow of 2.0 mL/min. Cross flow was stopped after 20 min. The shape 
of the detected protein peak shows a slight but unavoidable fronting. The corresponding UV-
signal at 280 nm was used for the calculation of recovery and molar mass of eADF4(C16) as 
shown in Figure 3.12. 
 
Figure 3.12. Recovery and molar mass of eADF4(C16) determined by AF4 using UV-detection at 280 nm 
and the developed cross flow profile 
Different protein masses were injected in order to evaluate the range for precise 
determination of molar mass and acceptable protein recovery. It was found that above an 
injection mass of 40 µg protein recovery is still acceptable (above 80%), but the calculated 
molar mass is completely out of any tolerable limit. The reason for this result is already 
observable in the chromatograms of the respective samples (see Figure 3.13, A). Whereas 
the UV-signals of the monomer peak were proportionally increasing with increasing injection 
mass (see small graph in Figure 3.13, A), the corresponding light scattering signals at 
approx. 10 minutes run time were multiple-fold stronger than expected just from higher 
protein masses. On the contrary, in the range from 15 to 25 µg injected protein mass the 
calculated molar mass perfectly matched the theoretical value of 47.7 kDa. Therefore, the 
eluted conformation of eADF4(C16) had to undergo a certain conformational change during 
the elution in the AF4 channel if higher protein masses are injected. It is known that during 
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and concentrated towards the membrane. Interestingly, the protein specimens can be 
concentrated up to 100-fold or more potentially leading to in situ protein 
association/aggregation (oral contribution from Wyatt technologies). As the aggregation 
mechanism of eADF4(C16) protein is very sensitive towards higher protein concentration, it 
is likely that protein association or conformational change takes place resulting in unmodified 
retention times and UV-signals, but extremely high light scattering. Therefore, the mass of 
injected eADF4(C16) has to be considered prior to analysis and should be in the range of 
10 to 30 µg. 
As it can be seen in Figure 3.11, a second weak UV-signal with a strong light scattering 
signal is detected after stopping the cross flow at 20 minutes run time. From that moment on 
every species or particle that has not been eluted so far is washed from the membrane. 
Based on the light scattering signal, the root mean square (rms) radius, meaning the radius 
of gyration, was calculated. Figure 3.13 displays the light scattering signals and rms radii vs. 
time obtained with different injection masses and after different sample preparation. 
   
  
 
Figure 3.13. Light scattering signals and calculated rms radii of eADF4(C16) samples vs. time as analyzed 
by AF4. (A) Injection of different masses of eADF4(C16), (B) AF4 analysis without or after centrifugation of 
the formulation. 
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The calculated rms radii revealed that besides monomeric eADF4(C16) small amounts of 
insoluble protein species with sizes between 50 and 200 nm were present in the protein 
formulations. The determined rms radii were independent of the injected eADF4(C16) mass, 
but the light scattering signal was significantly reduced by centrifugation of the formulation 
(15,000 g, 30 min). This indicates that an in situ formation as described for the monomer 
peak at high injection masses can be excluded. However, the corresponding UV-signal did 
not change upon centrifugation and remained at approx. 7% of the total eluted protein mass. 
For this reason, it is assumed that this UV-signal at the start of the rinsing step is mainly 
generated by soluble eADF4(C16) molecules which have not been eluted during the elution 
cross flow due to strong interaction with the AF4 membrane. The described insoluble species 
then overlay with these protein molecules. 
Therefore, appropriate sample preparation is recommended for future reproducible 
production of eADF4(C16) nano- and microparticles as these detected impurities may slightly 
alter phase separation processes. 
 
Figure 3.14. UV-absorbance at 280 nm and calculated molar mass of eADF4(C16) formulations during 
long-term storage at 2-8°C 
Throughout the work eADF4(C16) formulations were prepared and processed within a few 
days so that longer storage periods prior to particle preparation did not occur. Furthermore, 
differences between formulations from multiple preparation processes, that means different 
dissolving and dialysis processes (protein concentration, duration of dialysis), could not be 
detected by AF4 analysis (data not shown). All formulations showed only the same peak 
representing the eADF4(C16) monomer and small amounts of the described aggregates in 
the nanometer range. Soluble aggregates of eADF4(C16) were not observed at all. This was 
true except two formulations which residuals after particle preparation were stored in the 
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fridge at 2-8°C for a maximum storage time of 8 months. The corresponding chromatograms 
are displayed in Figure 3.14 and show that fronting of the monomer peak was clearly 
increased after storage. Lower retention time results in lower molar mass of the eluting 
species according to the separation principle of AF4. However, the obtained information is so 
far too insufficient to reasonably claim protein degradation of eADF4(C16) over time. 
3.3.2 STABILITY OF eADF4(C16) AT ELEVATED TEMPERATURE 
As described earlier, preparation of eADF4(C16) nanoparticles requires preheating of the 
protein solution to 60°C and 80°C, respectively. Therefore, stability of the spider silk protein 
formulation was investigated at 80°C over a period of 4 hours. The concentration was set to 
1.0 mg/mL and the commonly used formulation comprising a 10 mM Tris-buffer at pH 8.0 
was employed. 
 
Figure 3.15. Separation of eADF4(C16) on a Shodex OHpak SB-803 SEC-column. Red: Light scattering at 
90°C; blue: refractive index; green: UV-detection at 280 nm 
The samples were analyzed using a HP-SEC method developed by AMSilk. The resulting 
chromatogram of an unstressed eADF4(C16) formulation is shown in Figure 3.15. The order 
of the eluting peaks was vice versa as obtained by AF4 so that first high molecular weight 
(HMW) species with a huge light scattering signal were detected. This peak was followed by 
the monomer peak of eADF4(C16) and a slight tailing of the peak as it was also detected by 
AF4 (fronting). Throughout the incubation at 80°C the height and AUC of the monomer peak 
decreased continuously, whereas the amount of HMW-species and the tailing were not 
altered (data not shown). The total protein recovery decreased to 88% after 1 hour and 63% 
after 4 hours of incubation, respectively (see Figure 3.16, A). The result from HP-SEC was 
confirmed by SDS-PAGE under non-reducing conditions (see Figure 3.16, B). A decrease of 
the coloration of the monomer band was clearly detectable (line 4 vs. 7). More importantly 
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and in agreement with HP-SEC results, no further protein species occurred during incubation 
indicating that no soluble protein aggregates were formed. For this reason, the loss in protein 
content has to be accompanied by the formation of insoluble aggregates, but light 
obscuration measurements did not reveal a significant increase of subvisible particles (see 
Figure 3.16, C) as total particle counts around 2000 particles per mL (1:10 dilution) could not 
explain a protein loss of approx. 400 µg eADF4(C16). However, in all formulations large 
visible aggregates were formed, but these aggregates were not of particulate nature as it is 
usually found for aggregated protein drugs. Figure 3.16, D shows that spider silk fiber 
formation took place during incubation at 80°C in the 10 mM Tris-buffer at pH 8.0. 
  
 
 
4h / 80°C 
Figure 3.16. Stability of an aqueous eADF4(C16) solution at 80°C. (A) Total protein recovery determined 
by size exclusion chromatography. (B) SDS-PAGE (non-reducing conditions) and (C) light obscuration 
(1:10 dilution) results of the corresponding formulations. (D) Photographic image of the formulation after 
4 hours at 80°C (1:10 dilution) 
Summing up, section 3.3 of this chapter describes the implementation of analytical 
techniques for characterizing the physical stability of eADF4(C16) formulations. An AF4 
method was developed and established as an orthogonal method to size exclusion 
chromatography. The results from both analytics agreed concerning detected protein species 
and revealed that eADF4(C16) formulations contained low amounts of high molecular weight 
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aggregates, but no soluble protein oligomers. SDS-PAGE showed only the protein band 
representing the monomeric eADF4(C16), but due to the large size of the HMW-aggregates 
it is likely that they were not able to enter the gel and therefore not detected by silver 
staining. The amount of these HMW-aggregates could only be reduced by long centrifugation 
times which are not commonly used for HP-SEC sample preparation. 
The degradation process of eADF4(C16) induced by incubation at 80°C solely led to the 
formation of large visible protein fibers. The aggregation pathway is therefore different to 
globular therapeutic proteins like monoclonal antibodies or cytokines where soluble 
aggregates and subvisible particles play a major role in protein degradation [39]. The 
assembly of the spider silk protein eADF4(C16) starts with intrinsically random coiled protein 
molecules in the aqueous environment. Therefore, it is very likely that aggregates are formed 
directly by self-association of unfolded protein molecules which act as aggregation nucleus 
on their own. As a result and dependent on the environmental conditions like ionic strength, 
eADF4(C16) aggregates are easily formed and were determined in literature as fibrils at low 
and solid spheres at high potassium phosphate concentrations [19, 36, 40, 41]. In the case of 
heat-induced aggregation at low ionic strength (10 mM Tris buffer), it is assumed that those 
fibrils only occur as intermediates which are instantly transformed to larger protein fibers due 
to the increased kinetics of the aggregation process. 
As a consequence for the particle preparation procedure, two different preventive actions can 
be derived. At first, if a preheating of the formulation is intended, the salting-out process 
should be performed as quickly as possible. The technical requirements allow a filling of the 
pump with 100 mL in 5 minutes and the mixing takes 2 minutes at a flow rate of 50 mL/min. 
Therefore, the time period at which the formulation is processed at elevated temperature can 
be kept below a total of 10 minutes. Compared to the loss in protein recovery this short time 
period does not raise a problem for the preparation process. Secondly, in order to achieve a 
spider silk formulation without or at least with very low amounts of aggregates it is not only 
sufficient to filtrate the solution, but also long centrifugation times or ultracentrifugation 
should be applied shortly before particle preparation is carried out. 
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3.4 COLLOIDAL STABILITY OF SPIDER SILK NANOPARTICLES 
Stability issues regarding nanosuspensions have been widely investigated and can be 
categorized into physical and chemical stability. The latter is certainly specific for each drug 
delivery system and depends on the corresponding polymer and delivered drug. Physical 
stability is a common issue for nanosuspensions and includes primarily sedimentation and 
agglomeration effects. Sedimentation can be minimized by decreasing particle size and 
increasing medium viscosity to overcome the occurrence of deflocculated suspensions [42]. 
In the case of eADF4(C16) particles slow sedimentation effects were visually observed 
during storage, but redispersion was achieved quite easily. In general, the large surface area 
of nanoparticles creates high total surface energy which is thermodynamically unfavorable 
and leads to problems in terms of agglomeration [43]. As far as no steric stabilizers are 
added, the potential energy of interactions between particles can be explained by the 
Derjaguin-Landau-Verwey-Overbeek (D.L.V.O.) theory. Therein, the potential energy is the 
sum of repulsive forces due to the overlay of electrical double layers and attractive forces 
due to van der Waal’s forces [44]. The repulsive forces depend on several factors including 
the zeta-potential of the system, the particle radius, the interparticular distance and the 
dielectric constant of the medium, whereas van der Waal’s forces are affected by 
interparticular distance and particle radius. For this reason, one of the key parameters to 
predict the physical stability of a suspension is the zeta-potential, which is defined as the 
electrical potential at the shear plane around particles in the dispersion medium [43]. The 
higher the absolute value of the zeta-potential, the more stable is the suspension. On this 
account, the colloidal stability of spider silk particles was investigated at different pH and 
ionic strength in terms of particle size, polydispersity and zeta-potential. 
In order to evaluate the maximal range of the zeta-potential and to determine the isoelectric 
point of eADF4(C16) particles, a pH-titration was performed using a 10 mM sodium chloride 
solution as dispersion medium. The corresponding zeta-potentials and particle sizes are 
plotted vs. pH in Figure 3.17, A. An isoelectric point of 3.97 was determined and the zeta-
potential of eADF4(C16) particles at neutral pH (pH 6-8) is around -28 mV in 10 mM sodium 
chloride. The derived value for the isoelectric point of eADF4(C16) particles corresponds well 
to the calculated isoelectric point of 3.5 for the eADF4(C16) molecule including the T7-tag. 
Furthermore, the zeta-potential of eADF4(C16) particles was determined at different pH and 
ionic strengths as shown in Figure 3.17,B. The absolute value of the zeta-potential 
decreased from (-)27 mV at pH 7.0 and 30 mM ionic strength to (-)10 mV at pH 5 and 
100 mM ionic strength. The zeta-potential adopted positive values when the pH of the 
formulation was below the isoelectric point (pH 3, 30 mM ionic strength). 
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Figure 3.17. (A) Determination of the isoelectric point of eADF4(C16) particles by dynamic light scattering 
(dispersion medium: 10 mM sodium chloride). (B) Zeta-potential of eADF4(C16) particles at pH 3 / 5 / 7 and 
an ionic strength of 30 / 60 / 100 / 154 mM 
Next, the impact of the decreased zeta-potential concerning the colloidal stability was 
investigated. Spider silk nanosuspensions were analyzed at pH 3, pH 5 and pH 7 and an 
overall ionic strength of 30 mM. It was found that eADF4(C16) particles were colloidally 
stable at pH 7 over a period of 24 hours, whereas a decrease in pH towards (pH 5) or below 
(pH 3) the isoelectric point of eADF4(C16) resulted in significant particle agglomeration (see 
Figure 3.18, A). As ionic strength strongly influences the zeta-potential, its impact on the 
physical stability at pH 5 and pH 7 was investigated as shown in Figure 3.18, B. Spider silk 
particles were not colloidally stable at any ionic strength at pH 5. This was expected because 
eADF4(C16) particles showed already agglomeration at an ionic strength of 30 mM. In 
contrast, particle size and PI remained almost constant over 24 hours at pH 7 and an ionic 
strength of 30 mM. A further increase of the ionic strength to 100 mM or even 154 mM 
resulted in only minor changes in particle size and PI after 24 hours of incubation compared 
to the stock dispersion in purified water. To evaluate the long-term stability of eADF4(C16) 
particles in highly purified water, the particle size and size distribution was monitored over a 
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storage period of 6 months at 2-8°C (see Figure 3.18, C). Interestingly, colloidal stability was 
maintained during storage as the increase in particle size was only 5.7% and the PI 
remained below 0.20. 
In conclusion, these results indicate that eADF4(C16) nanosuspensions are colloidally stable 
only in liquid formulations with low ionic strength and a formulation pH higher than pH 5. 
 
 
 
Figure 3.18. (A) Particle size and PI of eADF4(C16) particles after 1 and 24 hours storage at pH 7.0 (10 mM 
phosphate), pH 5.0 (10 mM acetate) and pH 3.0 (10 mM phosphate). The overall ionic strength of all 
buffers was adjusted to 30 mM with sodium chloride. (B) Particle size and PI of eADF4(C16) particles 
incubated for 24 hours at pH 5.0 and pH 7.0 at different ionic strengths. (C) Storage stability of 
eADF4(C16) particles in stock dispersions (purified water). The standard deviation was calculated from 
three analytical subruns performed for each corresponding particle batch. 
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3.5 FREEZE-DRYING OF eADF4(C16) NANOSUSPENSIONS 
Two different strategies can be applied in order to overcome the limited physical and 
chemical stability of suspensions during storage. On the one hand, stabilizers are used to 
avoid a loss in physical stability due to steric stabilization and increased electrostatic 
repulsion [42]. On the other hand, pharmaceutical drying techniques are employed to 
withdraw the water from aqueous suspensions. For that purpose, freeze-drying is the most 
commonly used drying technique [23]. As one advantage of freeze-drying is the excellent 
stabilization of sensitive drugs like therapeutic proteins [45], freeze-drying was applied to the 
development of stable protein loaded eADF4(C16) particle formulations. Previous knowledge 
of other groups, which already reported on freeze-drying of nanosuspensions, gives 
indications concerning the choice of possible excipients (lyo- and cryoprotectants) and 
formulation parameters [23, 24, 46, 47]. An overview of all investigated formulations and 
parameters in this work is given in Table 3.3. 
Table 3.3. Freeze-drying of empty and lysozyme-loaded eADF4(C16) particles using different types of 
excipients, excipient-to-eADF4(C16) particles ratios [w/w] and reconstitution volumes after lyophilization 
Excipient 
Filling volume 
[mL] 
Excipient-to-eADF4(C16) 
particles weight ratio 
Reconstitution volume 
[mL] 
empty eADF4(C16) particles 
sucrose 1.0 0 / 5 / 10 / 30 / 50 0.1 / 0.2 / 1.0 
sucrose 
trehalose 
mannitol 
0.5 
0.5 
0.5 
2.5 / 5 / 20 / 50 
2.5 / 5 / 20 / 50 
2.5 / 5 / 20 / 50 
0.5 
0.5 
0.5 
lysozyme-loaded eADF4(C16) particles 
sucrose 
trehalose 
mannitol 
0.5 
0.5 
0.5 
30 
30 
30 
0.5 
0.5 
0.5 
3.5.1 FEASIBILITY STUDY 
The focus was to test the feasibility of freeze-drying eADF4(C16) nanosupensions. 
Therefore, a conventional lyophilization cycle could be employed because spider silk 
particles had shown no influence on Tg’ compared to placebo formulations (data not shown). 
Results from this freeze-drying cycle with empty eADF4(C16) particles and different 
concentrations of sucrose as freeze-drying excipient are displayed in Figure 3.19. Compared 
to particle sizes and polydispersity indices of the suspensions before lyophilization, none of 
the freeze-dried formulations containing 10:1 [w/w] or more sucrose showed increased 
values after reconstitution with the original filling volume of 1.0 mL (dashed bars). In contrast, 
freeze-drying of formulations lacking sucrose or comprising sucrose at a w/w-ratio of 5:1 
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resulted in agglomerated particles represented by the increase in particle size and PI. 
Therefore, a minimum excipient-to-eADF4(C16) particle ratio of 10:1 [w/w] is considered to 
be required for a sufficient stabilization of spiders silk particles during freeze-drying. 
Moreover, the effect of reduced reconstitution volumes was investigated according to Zillies 
et al. [25] as an opportunity to concentrate the formulations after freeze-drying. For instance, 
this technique may be necessary to obtain a required nanoparticle concentration and the 
corresponding drug load for a potential in vitro or in vivo study. An impact of reduced 
reconstitution volumes was only observed at an excipient-to-eADF4(C16) particles ratio of 
5:1 [w/w]. Herein, reduced volumes led to an increase in particle size and polydispersity 
index, indicating that reconstitution with low volumes creates agglomerated spider silk 
particles. At excipient-to-eADF4(C16) particles ratios of 10:1 [w/w] or above, the lower 
reconstitution volumes of 1/5th and 1/10th of the original volume led to only minor changes in 
particle size and PI. Therefore, the impact of the reconstitution volume can be neglected 
above the determined threshold and an increase of the nanoparticle concentration after 
lyophilization is possible without modification of the spider silk particles’ colloidal properties. 
 
Figure 3.19. Particle size of reconstituted empty eADF4(C16) particles right after freeze-drying using 
sucrose as freeze-drying excipient at different sucrose-to-eADF4(C16) particles ratios [w/w] and using 
different reconstitution volumes from 1.0 to 0.1 mL 
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3.5.2 FORMULATION DEVELOPMENT 
In a second set of freeze-drying experiments, two commonly used disaccharides, namely 
sucrose and trehalose as amorphous lyo- and cryoprotectants, and mannitol as bulking 
agent were compared regarding their ability to stabilize the physical properties of 
eADF4(C16) suspensions during freeze-drying (see Figure 3.20). As it can be concluded 
from the increased particle size after reconstitution, none of the three excipients was able to 
sufficiently prevent eADF4(C16) particles from agglomeration at an excipient-to-eADF4(C16) 
particles ratio of 5:1 [w/w] or less. The results above the determined threshold of a w/w-ratio 
of 10:1 were different. All formulations comprising either sucrose or trehalose showed no 
significant changes in eADF4(C16) particle size and no difference between the employed 
excipients. It is commonly known that freeze-dried formulations containing mannitol exhibit a 
different nature compared to sucrose or trehalose as mannitol readily crystallizes during 
freeze-drying. Hence, decreased protein drug recovery was detected after freeze-drying of 
different proteins with mannitol due to the prevention of requisite hydrogen bonding [48]. 
Nevertheless, it was described that in the case of freeze-drying particulate formulations 
mannitol was able to maintain nanoparticles’ integrity [25]. The authors explained their 
results by the so-called particle isolation theory which describes that almost any excipient 
disregarded of its behavior during freeze-drying is able to separate particles in the unfrozen 
fraction if sufficient amounts of the excipients are used. Our results confirm this hypothesis 
as an excipient-to-eADF4(C16) particle ratio of 10:1 is the threshold for sufficient stabilization 
of eADF4(C16) particles independent from the excipient used in the different formulations. 
 
Figure 3.20. Particle size of empty eADF4(C16) particles after freeze-drying with sucrose, trehalose or 
mannitol at different excipient-to-eADF4(C16) particles ratios 
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Nevertheless, the three employed excipients exhibit different properties regarding their 
stabilizing mechanism during freeze-drying and further storage of dried formulations. 
Sucrose and trehalose act as amorphous and glassy matrix formers which can be 
distinguished by their glass transition temperature. As shown in Figure 3.21, freeze-dried 
trehalose formulations possess a significantly higher Tg than sucrose formulations at almost 
equal residual moisture contents of around 1%. A higher Tg is known to be superior during 
storage stability of dried protein formulations so that trehalose containing formulations are 
recommended in the case of freeze-drying eADF4(C16) nanosuspensions. Mannitol 
containing formulations exhibited a typical crystalline structure represented by the melting 
point detected at 170°C. Therefore, mannitol does not possess any lyoprotectant activity 
regarding the stabilization of protein molecules [49]. The macroscopic appearance of sucrose 
containing formulations of the second freeze-drying experiment is exemplarily shown in 
Figure 3.21. The porosity of the resulting cake increased with decreasing solid content, but 
all investigated formulations exhibited an acceptable appearance after freeze-drying. 
50:1 [w/w] formulation 
excipient 
residual 
moisture [%] 
Tg 
[°C] 
mp 
[°C] 
sucrose 1.11 46.1 - 
trehalose 0.86 120.6 - 
mannitol 0.32 - 170.1 
  
Figure 3.21. Residual moisture and glass transition or melting temperature of freeze-dried formulations 
comprising a 50:1 [w/w]-ratio of excipient to eADF4(C16) particles. On the right hand side the 
macroscopic appearance of sucrose containing formulations is illustrated. 
In addition to empty eADF4(C16) particles, 15% [w/w] lysozyme-loaded eADF4(C16) 
particles (via remote loading) were freeze-dried either with sucrose, trehalose or mannitol at 
an excipient-to-particles weight ratio of 30:1 using the same freeze-drying cycle as before. All 
investigated formulations exhibited the same particle size and PI after lyophilization and 
reconstitution (see Figure 3.22). 
Therefore, two conclusions can be drawn from the set of freeze-drying studies. At first, 
freeze-drying of empty as well as lysozyme-loaded eADF4(C16) particles with an excipient-
to-eADF4(C16) particles weight ratio of at least 10:1 is possible without losing the physical 
properties of the original eADF4(C16) particle nanosuspensions. Secondly, trehalose at a 
mass ratio of 30:1 or 50:1 is the recommended excipient concerning the storage stability of 
lyophilized eADF4(C16) formulations as the highest Tg was obtained and the colloidal 
properties of the initial suspensions were maintained throughout lyophilization. 
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Figure 3.22. Particle size and polydispersity indices of reconstituted lysozyme-loaded eADF4(C16) 
particles using sucrose, mannitol or trehalose as freeze-drying excipients at a w/w-ratio of 30:1 
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3.6 SUMMARY AND CONCLUSIONS 
The preparation, characterization and formulation development of eADF4(C16) particles was 
described in this chapter. Furthermore, liquid eADF4(C16) formulations were characterized 
by multiple analytical techniques and subjected to incubation at elevated temperature. 
First of all, the phase separation process leading to solid eADF4(C16) spheres was analyzed 
in detail in order to obtain nanoparticles not significantly larger than 300 nm and 
microparticles with diameters of at least 5 µm. Both targeted particle sizes were achieved 
using the same phase separation mechanism, but different preparation techniques. In terms 
of nanosized spider silk particles a micromixing system consisting of two digitally controlled 
syringe pumps and a T-shaped mixing element with an inner diameter of 500 µm was 
established as standard preparation procedure due to its upscalability and excellent 
reproducibility. It was shown previously that the phase separation process of eADF4(C16) 
into solid spheres can be influenced by the mixing intensity and protein concentration [22], 
but further parameters altering the kinetics of the process were not evaluated so far. 
Especially an elevated process temperature of 60°C or 80°C dramatically reduced the 
resulting particle size and polydispersity of eADF4(C16) particles so that finally batches with 
homogenous particle size distributions and particle sizes slightly below 300 nm were 
obtained. eADF4(C16) microparticles were prepared by using an ultrasonic spray nozzle 
equipped with a dual liquid feed system. However, the simultaneous atomization of 
potassium phosphate and aqueous spider silk formulations resulted only in non-spherical 
protein aggregates like threads and fibrils at all investigated conditions. In contrast, 
microparticles were easily obtained by the atomization of potassium phosphate into 
eADF4(C16) solutions. This approach was further optimized by applying slower atomization 
rates and/or lower potassium phosphate concentrations so that it was able to prepare 
microparticles between 5 and 7 µm. 
As the aqueous eADF4(C16) protein solution is one important component of the phase 
separation process, different analytical techniques were developed and employed for the 
characterization of eADF4(C16) formulations after incubation at 80°C. The analysis by AF4 
and other techniques such as size exclusion chromatography and subvisible particle 
counting revealed that the spider silk protein formulation exhibits only limited protein stability 
over a period of 4 hours at 80°C. The protein loss accounted for around 40% at a protein 
concentration of 1.0 mg/mL and was mainly attributed to the formation of large and visible 
protein aggregates which formed thin spider silk fibers at the investigated conditions. 
Significant amounts of soluble eADF4(C16) aggregates could not be detected throughout 
heat-induced degradation. Consequently, the particle preparation procedure as described 
beforehand is not significantly affected as long as the liquid protein formulation is heated up 
and directly processed in the micromixing device. 
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eADF4(C16) particles in the submicron range were analyzed regarding their colloidal stability 
at different pH and ionic strength. The nanoparticles exhibit a zeta-potential around -30 mV 
at neutral pH and low ionic strength (10 mM sodium chloride) and a determined isoelectric 
point of 3.97. It was shown that nanosuspensions without further stabilizers are physically 
stable at low ionic strength (30 mM) and a pH above 5. The stock suspension in purified 
water can be stored for 6 months at 2-8°C without an altering the particle size distribution. 
Another step in formulation development was done by the implementation of freeze-drying to 
spider silk nanosuspensions. Sucrose, trehalose and mannitol were employed and analyzed 
regarding their ability to maintain the particle characteristics throughout the drying process. A 
threshold of an excipient-to-particles ratio [w/w] of 10:1 was determined as all excipients 
were able to stabilize eADF4(C16) particles at or above this ratio. The results therefore 
confirm the particle isolation theory described in literature for drying of nanosuspensions. 
Furthermore, lysozyme-loaded eADF4(C16) particles (remote loading) were successfully 
freeze-dried. For this reason, freeze-drying enables the preparation of stable drug-loaded 
nanosuspensions. 
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CHAPTER 4 
SPIDER SILK PARTICLES FOR DRUG DELIVERY 
4.1 INTRODUCTION 
Particulate drug delivery systems made of different types of biodegradable polymers have 
been in the focus of research for decades due to their excellent controllability [1]. 
Nanoparticles as well as microspheres have been employed for controlled delivery of various 
therapeutic agents including anticancer and antifungal drugs as well as peptides and 
proteins [2]. The latter class of pharmaceutical compounds requires special formulation due 
to their susceptibility to proteolysis, chemical modification and denaturation/aggregation 
during storage [3]. The polymer used as drug carrier system has to fulfill a number of 
requirements: protection of the protein drug from denaturation or degradation, control of drug 
release, biodegradability, no toxicity, low cost and easy processability [4]. Commonly used 
polymeric carriers for this purpose are of synthetic origin. Polyesters like polylactic-co-
glycolic acid (PLGA) are the most extensively studied among them [5, 6]. However, 
polyester-based matrices were often not suitable for protein drugs due to the required usage 
of organic solvents during preparation. In addition, an acidic microenvironment can occur by 
polymer degradation [6-9]. Therefore, research on hydrophilic polymers of natural origin, 
which can be easily processed in an aqueous environment, has received growing attention. 
Herein, especially chitosan was applied as a particulate drug carrier for protein delivery [10-
13]. Nevertheless, non-modified chitosan particles and also gelatin nanoparticles often 
require the utilization of toxic cross-linking agents so that their application for parenteral 
protein delivery is limited [14, 15]. 
In order to overcome the aforementioned limitations, new biomaterials are required as 
polymers for drug delivery applications. Silk proteins including silk fibroin from Bombyx mori 
and recombinant spider silk proteins represent very promising candidates regarding their 
non-cytotoxic and customizable properties as well as their easy processability into various 
morphologies like scaffolds, films and spheres [16-21]. Different kind of therapeutic agents 
have been incorporated into those systems and acceptable in vitro release profiles have 
been reported. However, the preparation techniques applied were quite sophisticated. 
Moreover, the used silk fibroin from Bombyx mori is a natural product and the quality of the 
protein may vary between individuals of the same species and depends on the required 
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degumming process [4]. For these reasons, quality control of such a biomaterial will be an 
issue as it may become difficult to obtain regulatory approval for such a material. 
The engineered spider silk protein eADF4(C16) represents a more favorable biomaterial due 
to its recombinant production process in E. coli [22]. As described in chapter 3, smooth 
protein spheres with high β-sheet content can be formed by a salting-out process with 
potassium phosphate as lyotropic salt, thereby avoiding the usage of any organic solvent. In 
order to evaluate these particles as a drug carrier system, small molecular weight drugs were 
recently loaded on eADF4(C16) particles using an incubation step after particle 
preparation [23]. Briefly, high loading efficiencies of almost 100% was achieved with 
positively charged and sufficiently hydrophobic drug molecules and constant in vitro release 
rates were obtained. The supposed mechanism for drug loading and release is displayed in 
Figure 4.1. Drug molecules are attracted through electrostatic forces in media with low ionic 
strength (1) and adsorb first to the particle’s surface. After saturation of the surface, drug 
molecules diffuse into the particle matrix (2) and are bound by a combination of hydrophobic 
and electrostatic forces (3). Redispersion of drug-loaded spider silk particles in release 
medium leads to a migration of drug molecules to the surface due to the present 
concentration gradient (4) and results in constant release rates over time (5). 
 
Figure 4.1. Loading and release mechanism for small drug molecules and spider silk particles taken from 
Lammel et al. [23] 
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The aim of the work described in this chapter was to investigate the applicability of 
eADF4(C16) particles as drug carrier for high molecular weight drugs like protein 
pharmaceuticals. In accordance to the study using small drug molecules, loading was carried 
out after particle preparation, the so-called ‘remote loading’ procedure. Two different 
proteins, namely lysozyme and nerve growth factor, were employed as they represent a 
model protein and a potential therapeutic drug candidate. Furthermore, the loading 
mechanism was investigated using fluorescein isothiocyanate (FITC) labeled 
macromolecules for loading on eADF4(C16) particles and subsequent analysis of the 
corresponding particle dispersions by confocal laser scanning microscopy (CLSM). The in 
vitro release of the proteins was investigated in dependence of ionic strength and pH of the 
release medium. 
Secondly, the different but common approach of drug encapsulation was performed. 
Rhodamine B and lysozyme were added to the aqueous protein solution and co-precipitated 
during phase separation. The resulting loading and release behavior was examined and is 
reported in section 4.3. Altogether, this chapter gives a detailed overview of the applicability 
of spider silk particles as a drug carrier system for protein delivery. 
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4.2 PROTEIN LOADED eADF4(C16) PARTICLES VIA REMOTE LOADING 
As it has already been shown in chapter 3, eADF4(C16) particles exhibit an isoelectric point 
of approx. 4.0. Attractive electrostatic interactions at neutral pH can therefore only occur 
between spider silk particles and positively charged drug molecules. It has been reported 
previously that the interactions between spider silk particles and low molecular weight 
substances, which belong to the class of weak organic bases, depend further on the partition 
coefficient log P and the molecular weight of the drug [23]. Strong bases like ethacridine 
lactate or molecules with a permanently positive charge like methyl violet showed the highest 
loading efficiency at comparable loading conditions. In order to transfer these findings to 
protein molecules, one has to consider the complex and completely different structure of 
proteins compared to small molecules. The charge of a protein molecule at a given pH is 
primarily determined by the amino acid residues being present in the primary sequence so 
that an overall net charge of the protein can be defined [24]. Nevertheless, the folding of the 
molecule plays a very important role in the interaction with other protein molecules as well as 
with solvent molecules or spider silk particles. The native conformation of a protein in an 
aqueous solution is usually characterized by presenting hydrophilic amino acid residues 
towards the solvent molecules, whereas hydrophobic residues are buried inside the globular 
protein molecule. As a consequence, the known contribution and relation of electrostatic and 
hydrophobic forces to the interaction of small molecules with spider silk particles has to be 
reassessed for the interaction of protein molecules with eADF4(C16) particles. 
4.2.1 LYSOZYME 
The overall net charge of a protein can be determined by dynamic light scattering as it is 
known for particles or polymers [24]. The resulting pH titration profile of zeta-potential and 
hydrodynamic diameter for lysozyme is shown in Figure 4.2. 
 
Figure 4.2. Zeta-potential, hydrodynamic diameter and calculated isoelectric point of lysozyme as 
determined by dynamic light scattering (conc. = 10 mg/mL, background: 10 mM sodium chloride) 
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The isoelectric point of lysozyme was determined at 10.9 so that a distinct positive overall net 
charge of the lysozyme molecule is present at neutral pH. Lysozyme with a molecular weight 
of 14.3 kDa was therefore chosen for the evaluation of protein loading on eADF4(C16) 
particles. 
In order to facilitate electrostatic interactions, ensure protein stability and avoid particle 
agglomeration, the standard buffer for remote loading was defined as follows: 
10 mM phosphate buffer, pH 7.0, addition of sodium chloride (0.573 g/L) to achieve a total 
ionic strength of 30 mM. Using this standard loading buffer enabled a loading of lysozyme on 
eADF4(C16) particles in large quantities, which is illustrated in Figure 4.3, A. At this ionic 
strength of 30 mM, it was possible to load more than 30% [w/w] lysozyme by incubation of 
eADF4(C16) particles in the lysozyme containing phosphate buffer. The associated loading 
efficiencies remained upon 95% for w/w-ratios during incubation ranging from 6 to 20%, 
representing a very effective loading of lysozyme and a strong interaction between 
eADF4(C16) particles and lysozyme. Figures 4.3, B and C, show the corresponding zeta-
potentials and particle sizes of lysozyme-loaded eADF4(C16) particles. 
 
  
Figure 4.3. Remote loading of eADF4(C16) particles with lysozyme. (A) Loading and loading efficiencies 
as a function of w/w-ratio of lysozyme-to-eADF4(C16) particles during incubation at pH 7.0/30 mM ionic 
strength. Zeta-potential (B) and particle size (C) of different lysozyme-loaded eADF4(C16) particles at 
pH 7.0 / 30 mM ionic strength. 
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If we assume that only surface loading takes place on eADF4(C16) particles, an increase in 
particle size combined with a decrease of the absolute value of the zeta-potential should be 
detectable due to the adsorption of lysozyme molecules to the particles’ surface. However, 
we observed that loading of eADF4(C16) particles with lysozyme does not lead to a 
significant change in the zeta-potential up to a loading of 30% (see Figure 4.3, B). 
Simultaneously, the particle size of the corresponding lysozyme-loaded eADF4(C16) 
particles did not significantly increase during loading up to a w/w-ratio of 20% during 
incubation (see Figure 4.3, C). 
The strong increase in the mean hydrodynamic diameter at higher w/w-ratios detected by 
dynamic light scattering was further analyzed by scanning electron microscopy. One 
example of the obtained particle dispersions is demonstrated in Figure 4.7, D, using nerve 
growth factor. The SEM micrographs of protein-loaded eADF4(C16) particles demonstrated 
that the high Z-average values were only the result of particle agglomeration but not of larger 
individual particles due to the protein payload. 
Altogether, it is assumed that a substantial fraction of the overall loaded lysozyme diffuses 
into the protein matrix of eADF4(C16) particles and is not only loaded on the particles’ 
surface. This aspect will further be discussed in detail in section 4.2.3. 
The influence of ionic strength on loading and loading efficiencies is shown in Figure 4.4, A 
and B. An increase in ionic strength from 30 to 100 mM led to a significant decrease in 
loading and loading efficiencies. For example, loading at 30% w/w-ratio was reduced from 
28% at 30 mM to 24% at 60 mM and 20% at 100 mM. The decreased loading caused by 
higher ionic strength clearly indicates that loading of negatively charged eADF4(C16) 
particles with positively charged lysozyme is driven by electrostatic interactions. 
  
Figure 4.4. (A) Loading of eADF4(C16) particles with lysozyme at different ionic strengths at pH 7.0. 
(B) Loading efficiences of lysozyme at different ionic strengths at pH 7.0 
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In order to describe the hydrophilic/hydrophobic character of a protein, the grand average of 
hydropathicity (GRAVY) value for a peptide or protein can be calculated as the sum of the 
individual hydropathy values of the protein’s amino acids divided by the number of residues 
in the sequence [25]. A negative value represents hydrophilic and a positive value more 
hydrophobic proteins. The GRAVY of the employed lysozyme is -0.472 calculated on its 
amino acid sequence (ExPASy, ProtParam tool, [26]). The corresponding hydropathicity plot 
is displayed in Figure 4.5, A. The GRAVY values and hydropathicity plot clearly indicate that 
lysozyme has more negative hydropathy values and therefore a more hydrophilic character 
compared to nerve growth factor (see Figure 4.5, B) or eADF4(C16) (see Figure 4.5, C). 
Consequently, loading of lysozyme is most likely driven by predominantly electrostatic 
interactions rather than hydrophobic van der Waal’s forces. 
  
 
Figure 4.5. Hydropathicity plot of lysozyme (A), nerve growth factor (B) and eADF4(C16) (C) according to 
Kyte and Doolittle [25]. More positive values indicate stronger hydrophobicity. The position at the x axis 
reflects the corresponding amino acid of the protein starting at the amino terminus and ending at the 
carboxy terminus. 
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was loaded onto eADF4(C16) particles at a w/w-ratio of 20% with a loading efficiency of 
97.5% [w/w] and even at a w/w-ratio of 30% with an efficiency of 94.9% [w/w]. It has to be 
further mentioned that methyl violet was dissolved in purified water without the addition of 
buffer components or salts so that the obtained values present the maximum achievable 
loading. Therefore, the total mass of loaded drug at comparable loading conditions is 
distinctly higher for lysozyme compared to methyl violet or other small molecules which 
exhibited an even lower loading efficiency [23]. 
4.2.2 NERVE GROWTH FACTOR 
Remote loading was further carried out using nerve growth factor which is regarded as a 
potential protein drug candidate for future applications of silk proteins [27, 28]. The 
biochemical properties of recombinant human nerve growth factor have already been 
described in chapter 2, section 2.1.1.3, but according to the knowledge from previous studies 
the charge of the protein plays a very important role. For this reason, the determination of net 
charge vs. pH was performed by dynamic light scattering and the resulting titration profile 
and IEP are displayed in Figure 4.6. Nerve growth factor exhibits a positive zeta-potential of 
+15 mV at pH 7, which is almost equal to the corresponding zeta-potential of lysozyme. In 
combination with an almost similar molecular weight of the monomer molecule (13.5 kDa vs. 
14.3 kDa), the loading potential of nerve growth factors was assessed to be as good as for 
lysozyme. However, it has to be considered that the native conformation of NGF in an 
aqueous solution consists of non-covalent dimers. It can be clearly depicted from the 
comparison of the volume mean diameter that dimer formation leads to a larger 
hydrodynamic diameter for native NGF molecules compared to lysozyme. 
 
Figure 4.6. Zeta-potential, hydrodynamic diameter and calculated isoelectric point of nerve growth factor 
as determined by dynamic light scattering (conc. = 4.4 mg/mL, background: 10 mM sodium chloride). An 
aggregated sample (*) means that the volume mean diameter was too high to be displayed in the 
diagram. 
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Loading with NGF was carried out at standard loading conditions according to the previous 
study with lysozyme (30 mM ionic strength, pH 7.0). The residual protein concentration in the 
supernatant was determined by Micro BCA Protein Assay as well as by size-exclusion 
chromatography. The resulting payloads and loading efficiencies are shown in Figure 4.7, A. 
High loading of eADF4(C16) particles with NGF was possible with almost 100% loading 
efficiency at an incubation at 20% w/w-ratio. However, a further increase of the NGF content 
in the loading solution resulted in a distinct decrease of the loading efficiency to approx. 82%. 
At this point, the loading efficiency for lysozyme was still above 90% so that it can be 
concluded that lysozyme is superior to NGF regarding the payload and loading efficiency at 
higher w/w-ratios during remote lading. 
Another important difference between loading with lysozyme and nerve growth factor was 
detected when the zeta-potential and particle size of NGF-loaded eADF4(C16) particles was 
determined (see Figure 4.7, B and C). The zeta-potential of NGF-loaded spider silk particles 
did not change up to a payload of 10% [w/w], but an increase in particle size, meaning 
agglomeration of NGF-loaded particles as shown by the SEM (see Figure 4.7, D), was 
already observed at this protein payload. In contrast, loading with lysozyme did not 
significantly alter the particles’ properties till a payload of more than 20%  w w .  
In order to further clarify the influence of electrostatic interactions, the ionic strength of the 
loading buffer was increased to 60 mM and 100 mM by adding sodium chloride. Figure 4.8 
illustrates that the impact of ionic strength was significant upon a w/w-ratio of 5% because 
remote loading was less efficient the higher the ionic strength had been. Again, the 
comparison to lysozyme (see Figure 4.4, A and B) shows that remote loading with nerve 
growth factor is less efficient. Besides surface charge and molecular weight, the hydrophilic 
or hydrophobic properties of the protein have to be taken into account to explain and 
compare the interactions between lysozyme, nerve growth factor and eADF4(C16) particles. 
The GRAVY value of NGF is -0.292 compared to -0.472 for lysozyme according to Kyte and 
Doolittle [25]. Additionally, the hydropathicity plot displayed in Figure 4.5 B shows more 
hydrophobic amino acid residues (positive index values) for the NGF molecule compared to 
lysozyme. Therefore, NGF is considered as more hydrophobic protein, but regarding the 
efficiency of remote loading this parameter had no significant influence as the more 
hydrophilic lysozyme was superior to nerve growth factor. This fact can be explained by 
stronger electrostatic interactions as lysozyme exhibits a charge distribution (‘dipole’) in the 
protein sequence of 9/17 (neg./pos.) charged amino acid residues vs. 12/17 for NGF, 
resulting in a higher isoelectric point of 10.9 vs. 9.86 for NGF. The larger hydrodynamic 
diameter of the NGF dimer is certainly further attenuating the protein-particle interactions 
leading to reduced loading efficiencies. 
Spider silk particles for drug delivery 
 
118 
  
 
 
Figure 4.7. Loading of eADF4(C16) particles with nerve growth factor. (A) Loading and loading efficiencies 
as a function of the w/w-ratio of NGF-to-eADF4(C16) particles in the incubation dispersion at pH 7.0/30 mM 
ionic strength. Zeta-potential (B) and particle size (C) of different NGF-loaded eADF4(C16) particles at 
pH 7.0/30 mM ionic strength. (D) SEM micrograph (magnification: 9,500x) of eADF4(C16) particles loaded at 
30% [w/w] NGF in the loading buffer. 
Summing up the results obtained for lysozyme and NGF, it has to be stated that electrostatic 
interactions are the dominating forces when protein molecules are loaded onto eADF4(C16) 
particles. The molecular weight or rather the hydrodynamic radius of the protein molecule 
also influences the interaction as the charge density of the protein molecule is higher for 
smaller molecules. In contrast to low molecular weight substances, at which the 
hydrophobicity significantly influenced the loading behavior, the hydrophobicity of protein 
molecules does not play a decisive role as shown by comparing between lysozyme and 
nerve growth factor. 
Remote loading with NGF performed in this work has to be compared with already published 
studies about the delivery of nerve growth factor using different biomaterials. 
10% [w/w] NGF combined with a loading efficiency of 100% was only achieved by Lam et 
al. [29]. This study included the preparation of PLGA microspheres using spray freeze drying 
and stabilization of nerve growth factor by forming an insoluble NGF-zinc complex prior to 
encapsulation. All other drug delivery systems aimed for NGF delivery in peripheral nerve 
repair, which requires in principle only a fraction of the payload described in this thesis [27, 
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30-32]. Therefore, the reported colloidal instability of eADF4(C16) particles with 10% [w/w] 
NGF payload will not be a concern for such applications so that in summary, the developed 
NGF-loaded spider silk particles present a promising platform for pharmaceutical applications 
of NGF. 
  
Figure 4.8. (A) Loading of eADF4(C16) particles with nerve growth facotr at different ionic strengths at 
pH 7.0. (B) Loading efficiences of nerve growth factor at different ionic strengths at pH 7.0 
4.2.3 INVESTIGATION OF LOADING MECHANISM 
The aim of this study was to prove and to visualize the hypothesis that macromolecules can 
permeate into the matrix of eADF4(C16) particles. Thus, loading was conducted with three 
fluorescently-labeled macromolecules having different charges and sizes at the investigated 
loading conditions of pH 2 and pH 7 (see Table 4.1). 
Table 4.1. List of employed macromolecules with regard to remote loading of eADF4(C16) particles 
 Mw [kDa] 
IEP 
(theoretical) 
Net charge 
at pH 2 
Net charge 
at pH 7 
eADF4(C16) 47.7 3.48 positive negative 
FITC - lysozyme 14.3 11.35 positive positive 
FITC - BSA 66 4.7 – 4.9 positive negative 
FITC - dextran 21.2 N.A. uncharged uncharged 
Dextran is an uncharged polysaccharide and was used as control as no electrostatic 
interactions with charged spider silk particles are possible. Bovine serum albumin (BSA) has 
a molecular weight of 66 kDa and an isoelectric point of ~4.7. Therefore, it exhibits a 
negative overall net charge at pH 7 and is positively charged at pH 2. The biochemical 
properties of lysozyme have already been discussed in section 4.2.1. 
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Figure 4.9. Confocal micrographs of dispersed and positively charged eADF4(C16) particles at pH 2 after 
loading with FITC-dextran (A), FITC-lysozyme (B) and FITC-BSA (C). Images (D), (E) and (F) show the 
confocal micrographs of dispersed and negatively charged eADF4(C16) particles at pH 7 after loading 
with FITC-dextran (D), FITC-lysozyme (E) and FITC-BSA (F) 
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In order to investigate eADF4(C16) particles by confocal laser scanning microscopy (CLSM), 
micrometer sized particles had to be prepared by dialysis. Herein, eADF4(C16) particles with 
a particle size of 2.1 ± 0.06 µm determined by laser diffraction (mean size) were obtained. 
eADF4(C16) particles prepared by the micromixing system exhibited particle sizes in the 
submicron range and would have been too small to be precisely investigated by CLSM. 
Confocal micrographs of the obtained spider silk suspensions are shown in Figure 4.9. It has 
to be noted that suspensions were investigated after mixing of eADF4(C16) particles with 
FITC-labeled macromolecules and incubation at room temperature for a minimum of 
30 minutes. Due to the uncharged nature of FITC-dextran molecules, empty eADF4(C16) 
particles were detected both at pH 2 (see Figure 4.9, A) and pH 7 (see Figure 4.9, D). As a 
result, unloaded spider silk particles appear at pH 7 as dark spots upon strong green 
fluorescence caused by the unbound FITC-dextran in solution, whereas at pH 2 the 
fluorescence signal of FITC-dextran only present in the solution and not bound to the 
particles was too low to be detected. This can be explained, because the fluorescence 
intensity is pH-dependent and has its maximum at pH 8 and above (as per manufacturer’s 
instructions). In contrast, FITC-labeled lysozyme was loaded onto eADF4(C16) particles as a 
result of its opposite charge at pH 7 (see Figure 4.9, E). The FITC-lysozyme loaded protein 
spheres appeared as filled bright green spots upon a dark background. Considering that no 
washing steps were applied after loading, almost the entire FITC-lysozyme was loaded onto 
eADF4(C16) particles. This finding confirms the previous results of the loading experiments 
(see section 4.2.1), where 15% [w/w] loading with lysozyme was achieved combined with 
almost 100% loading efficiency. Due to its negative charge at pH 7 (identical to eADF4(C16) 
particles), it was not possible to load FITC-BSA onto eADF4(C16) particles. Again, this 
conclusion could be derived from dark particle spots on the green fluorescent background 
(see Figure 4.9, F). 
At pH 2, loading behavior of FITC-labeled lysozyme and FITC-BSA changed significantly. 
Exhibiting the identical charge as eADF4(C16) particles, both FITC-lysozyme and FITC-BSA 
have to overcome repulsive electrostatic forces in order to be loaded on positively charged 
particles. Surprisingly, eADF4(C16) particles appeared as hollow spots with green 
fluorescence at the surface when FITC-BSA was present in the loading suspension (see 
Figure 4.9, C). In contrast, FITC-lysozyme loaded eADF4(C16) particles appeared as filled 
green spots (see Figure 4.9, B). 
To further confirm these findings, images of the suspension containing FITC-lysozyme at 
pH 7 were taken every 100 nm of the z-axis and are shown in Figure 4.10. It has to be 
highlighted that the FITC-lysozyme-loaded spider silk particles are visible as filled green 
spots in each section plane. Following a single particle throughout the image set, it is 
possible to observe that the fluorescence is covering the entire particle matrix even at the 
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edges of the particle (referring to the z-axis). This aspect is of major importance because the 
investigation of loaded eADF4(C16) particles by CLSM is on this account able to distinguish 
between only surface-loaded (see Figure 4.9, C) and matrix-loaded eADF4(C16) particles 
(see Figure 4.10). 
Consequently, it was visualized that FITC-BSA molecules were only adsorbed on the 
eADF4(C16) particles’ surface at pH 2 and that FITC-BSA was not able to permeate into the 
particles’ matrix. On the other hand, FITC-labeled lysozyme molecules diffused and 
permeated into the spider silk matrix and were not only adsorbed to the particles’ surface. 
It was shown previously for spider silk microcapsules that their shell made of eADF4(C16) 
protein had an average molecular weight cutoff of 27 kDa, meaning that molecules exhibiting 
a smaller radius of gyration than 27 kDa dextran are expected to pass through the 
membrane [33, 34]. Results obtained using FITC-labeled lysozyme and BSA provide an 
indication that a molecular weight cutoff in the same range may exist for diffusion into 
eADF4(C16) particles. Proteins with a molecular weight comparable or higher than that of 
bovine serum albumin (66 kDa) are not likely to permeate into the eADF4(C16) particles’ 
matrix and bind only to the surface. 
 
Figure 4.10. Confocal micrographs of FITC-lysozyme loaded eADF4(C16) particles at pH 7. The distance in 
the upper left corner represents the distance of the slice level on the z-axis (vertical) from the starting 
point of the z-scan. 
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Regarding the loading behavior of nerve growth factor, which is somehow special due to its 
non-covalent dimer formation, it is supposed that also matrix loading of the spider silk 
spheres takes place. The obtained loading efficiencies and payloads are almost comparable 
to lysozyme and a saturation of the surface only would not allow such high payloads. 
4.2.4 IN VITRO RELEASE FROM PROTEIN LOADED SPIDER SILK PARTICLES 
First studies on the in vitro release from eADF4(C16) particles were performed by Lammel et 
al. using low molecular weight drugs [23]. It was found that the release of methyl violet and 
ethacridine lactate is constant at physiological conditions over a period of 30 days with only 
low burst release (11%) during the first 24 hours. After this initial period, approx. 5% of the 
entrapped molecules were released per day. The release rate was further dependent on the 
pH of the release medium with higher release rates obtained at acidic release conditions. 
This was assigned to the importance of electrostatic interactions between small molecules 
and eADF4(C16) particles. 
Based on these findings, different release conditions were employed to investigate the in 
vitro release from protein-loaded eADF4(C16) particles more deeply and to elucidate the 
underlying mechanisms. 
4.2.4.1 INFLUENCE OF pH, IONIC STRENGTH AND PAYLOAD 
The in vitro release of lysozyme from eADF4(C16) particles was studied in several different 
release media (see chapter 2, Table 2.4) starting with the approach to completely replace the 
release medium every 24 hours during the first 5 days. 
The pH of the release medium was varied to evaluate its impact on the release profile of 
lysozyme. The total ionic strength of the release media in this study was set to 50 mM. The 
obtained results are illustrated in Figure 4.11. At pH 2 and pH 4, almost 90% of loaded 
lysozyme were released from eADF4(C16) particles within the first 48 hours. In contrast, no 
significant amounts of lysozyme were detected at pH 7.4, even after 28 days of release. 
Interestingly, the reduction from pH 7.4 to pH 6 showed no effect at all, indicating still very 
strong interactions between the spider silk protein particles and lysozyme at pH 6 and 50 mM 
ionic strength. 
Figure 4.12 displays the cumulative release of lysozyme from eADF4(C16) particles 
incubated in release media with different ionic strength. The pH was set to 7.4 during the 
study and the ionic strength of the release medium was increased from purified water to 50, 
100 and 160 mM. The release profiles show that the change of ionic strength had a very 
strong influence on the resulting release rate. The reduction of the ionic strength from 
160 mM to 50 mM or purified water (HPW) resulted in a dramatic decrease of the released 
Spider silk particles for drug delivery 
 
124 
lysozyme fraction from around 78% to no detectable amounts after 7 days of release. The 
initial burst release was small up to 100 mM ionic strength as not more than 11% lysozyme 
were released during the first 24 hours. No detectable amounts of lysozyme were released 
over the whole period of 21 days neither at 50 mM nor in highly purified water. 
 
Figure 4.11. In vitro release of lysozyme from eADF4(C16) particles at 50 mM ionic strength and different 
pH determined over 28 days. 
 
 
Figure 4.12. Influence of ionic strength on the in vitro release of lysozyme from eADF4(C16) particles at 
pH 7.4 determined over 21 days 
Therefore, it can be concluded that the release of lysozyme from eADF4(C16) particles is 
mainly controlled by the degree of electrostatic interactions and not by hydrophobic forces. A 
decrease in pH and an increase in ionic strength weakens the electrostatic interactions 
between positively charged lysozyme molecules and negatively charged eADF4(C16) 
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particles so that lysozyme is released more easily. On the contrary, lysozyme is strongly 
attached to the particles at neutral pH and low ionic strength (pH 7.4 / pH 6 and 50 mM ionic 
strength or lower). 
The lysozyme payload was varied and the in vitro release was investigated at physiological 
conditions in another experiment. As it can be seen in Figure 4.13, no significant differences 
between the release from spider silk particles loaded with 5, 10 and 15% [w/w] lysozyme 
were observed. However, these results demonstrate that the release at physiological 
conditions (pH 7.4 and isotonic ionic strength of 160 mM) is quite fast as over 70% lysozyme 
is released during the first 4 days (daily sampling). In comparison to the controlled in vitro 
release described previously for methyl violet or ethacridine lactate [23], it has to be stated 
that the release of lysozyme is much faster. Therefore, the interactions between eADF4(C16) 
particles and the protein molecule have to be weaker than between spider silk particles and 
small, positively charged molecules. 
 
Figure 4.13. In vitro release of lysozyme from differently loaded spider silk particles at pH 7.4 and 
160 mM ionic strength (10 mM phosphate buffer) 
4.2.4.2 ANALYSIS OF DRUG RELEASE FROM REMOTE LOADED eADF4(C16) PARTICLES 
During the first release studies, time points for replacing the supernatant with fresh release 
medium were varied in order to concentrate the released drug prior to analysis. However, an 
extension of the sampling interval to seven days resulted in the same release profile as 
obtained with a daily exchange of the release medium. This was so far not expected. The 
release was thought to be also driven by diffusion processes of the loaded drug inside the 
particle matrix (see Figure 4.1). On this account, the sampling interval was decreased to one 
hour to clarify whether the same release profile can be obtained again. The results of all 
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three different release setups are shown in Figure 4.14, in which the x-axis is displayed in 
logarithmic scale. 
It can be observed that the release rate of lysozyme is independent of the time interval 
between the individual sampling points. The amount of released lysozyme is almost equal in 
all three experiments at the first, second, third and fourth time point of analysis, which is 
accompanied with the replacement of the entire volume of the release medium. 
As this release behavior was quite contrary to those described in literature [23], release 
studies employing methyl violet were performed in order to evaluate if the discovered 
phenomena also occurs in case of low molecular weight substances. 
Daily sampling revealed only slightly different results compared to literature as 14% and 39% 
of the loaded compound were released over the first 24 hours and 4 days, respectively (see 
Figure 4.15, A). 
 
Figure 4.14. In vitro release of lysozyme from identically loaded eADF4(C16) particles using different time 
intervals for replacement of the release medium: 1 hour (light gray), 1 day (black) and 7days (gray) 
This data confirms the release profile of low molecular weight substances as described in 
literature providing that the release medium is replaced every 24 hours. Systematic errors 
leading to differences in the release profiles can be therefore excluded. 
Next, the release of methyl violet was determined by exchanging the release medium every 
hour and using release media with different ionic strength (Figure 4.15, A). The strong 
dependency of the release on the ionic strength was expected as it was already shown for 
lysozyme, but more interestingly, the same release behavior as observed for daily sampling 
was also obtained for hourly sampling. 
Taking both results together, it was proven that the release of small molecules is also 
dependent on the experimental setup, but not on the time interval between the individual 
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sampling points. As a consequence, the hypothesis proposed by Lammel et al. (see 
Figure 4.1) seems to be inaccurate regarding the suggested release process. The constant 
and comparatively slow release rates were explained by a transport of the drug molecule 
from the inside of the spider silk matrix to the particle’s surface. The driving force was the 
concentration gradient between the surface and the particle’s matrix. The additional results 
presented in this thesis do not support this explanation any longer. In fact, the release 
process of a remote-loaded drug substance seems to be a result of an equilibrium state 
rather than a transport or diffusion based release process. The main criterion supporting this 
hypothesis is the fact that release rates were independent of the time interval between the 
sampling points both in the case of methyl violet and lysozyme. An interval of 60 minutes or 
seven days resulted in exactly the same concentration of lysozyme present in the 
supernatant of the release medium (see Figure 4.14). 
 
 
Figure 4.15. (A) In vitro release of methyl violet from eADF4(C16) particles at pH 7.4 / 160 mM ionic 
strength. eADF4(C16) particles were loaded with 10% [w/w] methyl violet according to the remote loading 
procedure. (B) Release of methyl violet from eADF4(C16) particles at different ionic strength. The samples 
were drawn every hour. 
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Otherwise, parameters which are able to alter the equilibrium state are strongly influencing 
the resulting release profile. Reducing the ionic strength in the release medium led to a 
significant reduction of the release rate, meaning that fewer positively charged ions are able 
to displace less drug molecules from the spider silk particle. Furthermore, it has to be 
considered that matrix loading was assumed for small molecules [23] and proteins up to a 
certain molecular weight (see section 4.2.3). Remote loading of eADF4(C16) particles 
assumes that unhindered diffusion of drug molecules into the particles’ matrix is possible. 
In addition to lysozyme, the in vitro release of nerve growth factor was determined. 
Figure 4.16 shows the release profiles which were obtained by exchanging the release 
medium every hour. Once again, a fast release of the loaded protein was observed at 
physiological conditions with more than 80% of NGF being already released during the first 
two hours. The release rate was slowed down at decreased ionic strength of the release 
medium. The dispersion of NGF-loaded eADF4(C16) particles in purified water showed no 
drug release at all, which was similar to lysozyme-loaded spider silk particles. 
However, the release of NGF was significantly faster at 50 mM and 100 mM ionic strength 
(pH 7.4) compared to lysozyme. This confirms the statement made in section 4.2.2: 
interactions between spider silk particles and nerve growth factor are weaker than between 
the eADF4(C16) particles and lysozyme. The overall time scale of the release proved again 
that loaded NGF molecules were neither retarded by the interaction with the particle matrix 
nor that time dependent transport/diffusion processes occurred during the incubation in the 
release medium. 
 
Figure 4.16. In vitro release of NGF from 10% [w/w] loaded eADF4(C16) particles in release media with 
different ionic strength (pH 7.4). The samples were drawn every hour and eADF4(C16) particles were 
loaded according to the remote loading procedure. 
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4.2.4.3 IN VITRO RELEASE IN THE PRESENCE OF ALBUMIN 
In order to further simulate physiological conditions, albumin was added to the in vitro 
release medium. Human serum albumin (HSA) constitutes about 60% of the human plasma 
protein. The common range of human serum albumin in adults is 3.5 – 5 g/dL. For this 
reason, an albumin concentration of 40 mg/mL was chosen for the release experiments. 
Human serum albumin was only used in two release media due to the high albumin 
concentration and higher costs, and was compared to bovine serum albumin as shown in 
Figure 4.17, A. No difference between human and bovine serum albumin was detectable 
both at 100 mM and 160 mM ionic strength. Therefore, solely bovine serum albumin (BSA) 
was employed in the following release studies. 
The release profiles of lysozyme displayed in Figure 4.17 A have to be compared to 
Figure 4.12. In doing so, an acceleration of the release rate in the presence of albumin could 
be depicted. The difference became apparent especially at 50 mM ionic strength, at which in 
the absence of albumin no release of lysozyme was detectable (see Figure 4.12). It was 
further shown that a lower albumin concentration of 4 mg/mL resulted in an identical release 
profile as at 40 mg/mL (data not shown). Thus, an impact of the different osmotic gradient 
can be excluded. Taken together, it is suggested that binding of lysozyme to albumin takes 
place which alters the equilibrium distribution and results in a higher release of lysozyme. 
Nevertheless, albumin molecules alone were not able to sufficiently alter the equilibrium as 
no lysozyme release was detected in purified water (see Figure 4.17, A). 
This release behavior of methyl violet was considerably altered by the addition of albumin 
(see Figure 4.17, B compared to Figure 4.15). Very strong interactions between methyl violet 
and albumin shifted the equilibrium from originally electrostatic interactions between the 
spider silk particles and methyl violet towards the complex formed between methyl violet and 
albumin. Thus, very fast release of methyl violet was detected independent of the ionic 
strength of the release media (see Figure 4.17, B). Nevertheless, this result should not be 
too surprising as it is general knowledge that a wide range of low molecular weight drugs 
exhibit an excessively high affinity for albumin (> 95% bound), which is often driven by the 
lipophilicity of the drug and drug-specific molecular recognition [35]. The binding of crystal 
violet to albumin was investigated in detail and hydrophobic interaction forces played the 
major role in stabilizing the complex [36]. Crystal violet differs from methyl violet in only one 
methyl group attached to the amine functional group. Thus, this fact can be certainly 
transferred to methyl violet so that the strong affinity of methyl violet to albumin can be 
attributed to its high lipophilicity. As a result, the release is dramatically accelerated in the 
presence of albumin due to its strong influence on the equilibrium state. 
On this account, these results confirm that fast equilibrium distribution and not slow, diffusive 
transport processes are responsible for the drug release from spider silk particles. 
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Figure 4.17. In vitro release from eADF4(C16) particles loaded with 15% [w/w] lysozyme (A) and 10% [w/w] 
methyl violet (B). BSA or HSA were added to the release media at a concentration of 40 mg/mL. The 
concentration of lysozyme was determined by measuring the activity of lysozyme in the release medium. 
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4.3 ENCAPSULATION OF DRUGS INTO eADF4(C16) PARTICLES 
Besides the described procedure of loading drugs after particle preparation, drugs can be 
encapsulated into polymeric particles during the particle preparation process. This approach 
is commonly used for the development of particulate delivery systems aiming a sustained 
release of the incorporated drug. Several drug products comprising microparticles made of 
PLGA are on the market as depot formulations for Gonadotropin-releasing hormone agonists 
such as Leuprorelin or Triptorelin. However, encapsulation of susceptible drugs into polymer 
matrices constitutes different concerns which are specified in Table 4.2. It has to be 
considered as well that the preparation process for spider silk particles is pretty different to 
those processes applied for other polymers such as PLGA. Therefore, comparisons or 
predictions on the feasibility of drug encapsulation during eADF4(C16) particle preparation 
are hardly possible. 
Table 4.2. Comparison of encapsulation and remote loading of drugs onto spider silk particles 
Encapsulation / Co-precipitation Remote loading 
+ 
Drug is completely incorporated in the 
spider silk protein matrix 
theoretically: 
→ longer diffusion pathways 
→ slower release rates 
+ 
Particles can be prepared without 
being influenced by the presence of 
the drug 
→ control of particle size 
  + 
Drug is not exposed to the conditions 
required for particle preparation 
→ beneficial for susceptible drugs 
  + 
Loading conditions can be set to 
optimal conditions 
- 
Drug stability during the encapsulation 
process 
- 
Weak drug-matrix interactions result in 
fast release rates 
- 
Influence of the drug on the particle 
preparation process 
→ particle size 
  
- 
Presence of high salt concentration 
during encapsulation 
→ Encapsulation efficiency 
  
Two different studies on the encapsulation of small molecules into eADF4(C16) particles can 
be found in literature [37, 38]. On the one hand, encapsulation was evaluated as an 
opportunity to formulate and deliver poorly soluble drugs [37]. β-carotene as a very 
hydrophobic compound was dissolved in tetrahydrofuran, mixed with an aqueous 
eADF4(C16) solution (10 mg/mL) and spider silk particle formation was induced by dialysis 
against 1 M potassium phosphate. It was shown that nanoparticles of β-carotene, which were 
formed due to dilution into the aqueous protein solution, could be embedded into the matrix 
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of eADF4(C16) microbeads. The obtained β-carotene loaded microbeads exhibited a rather 
rough surface compared to empty microbeads. In order to study the release, proteinase K 
was added and a complete degradation of microbeads and release of β-carotene was 
achieved. However, this study focused more on proving that eADF4(C16) interacts with 
hydrophobic molecules and is able to stabilize those substances in aqueous solution rather 
than on investigating eADF4(C16) microbeads as a drug delivery system for therapeutic 
drugs. 
This approach was evaluated in a different study carried out by Blüm et al. [38]. Five different 
preparation routes including remote loading and encapsulation were investigated regarding 
loading capacity and release of the loaded substance. Rhodamine B was chosen as model 
drug for this study. It has to be considered that rhodamine B adopts a zwitterionic form at 
neutral pH in contrast to positively charged lysozyme, NGF or methyl violet. For this reason, 
electrostatic interactions between Rhodamine B and eADF4(C16) molecules or particles are 
not likely to occur. Co-precipitation was slightly superior to loading by diffusion processes 
(remote loading), but loading efficiencies were very low (< 1%) and the release was very fast, 
independent of the loading strategy (release medium: 10 mM Tris buffer). Furthermore, 
crosslinking of eADF4(C16) using ammonium persulfate and Rubpy (Tris(2,2’-
bipyridyl)dichlororuthenium(II)) was performed in order to modify the release behavior. 
However, the release rates were not significantly slowed down and the amount of not 
released drug at the end of the release study increased due to the spider silk crosslinking. 
In order to evaluate the different issues listed in Table 4.2, encapsulation was performed at 
first using rhodamine B in accordance to the presented study from Blüm et al. [38]. 
Afterwards, lysozyme was employed to compare the encapsulation data with results obtained 
by remote loading from section 4.2. 
4.3.1 RHODAMINE B 
As the influence of rhodamine B on eADF4(C16) particle characteristics during particle 
formation was not investigated by Blüm et al. [38], we performed identical experiments and 
focused on this part of the story. Figure 4.18 illustrates the results for loading and loading 
efficiency (A) as well as particle size and zeta-potential (B) of rhodamine B loaded particles 
prepared via co-precipitation. Interestingly, not more than 1% loading [w/w] could be 
achieved so that apparently uncharged molecules like rhodamine B can hardly be 
encapsulated into negatively charged eADF4(C16) particles. This data is consistent with the 
results reported by Blüm et al. [38] and is especially important, because it demonstrates 
clearly that electrostatic interactions are the basic prerequisite for sufficient loading of 
eADF4(C16) particles. Hydrophobic interactions, as they are the primary interactions in the 
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case of rhodamine B, are not at all potent enough to achieve reasonable loading capacities 
even for low molecular weight substances. 
The addition of rhodamine B to the protein solution before particle preparation led to changes 
in the resulting particle size, whereas the charge of the particles was not affected. The more 
rhodamine B was present during phase separation, the larger the resulting eADF4(C16) 
particles became. At the highest Rhodamine B to eADF4(C16) particles ratio of 30% [w/w], 
no spider silk particles were formed at all. This shows that drug molecules can have a 
significant influence on the phase separation process, but the impact of the respective drug 
has to be considered case-to-case as the drug-protein interaction will be different regarding 
electrostatic and hydrophobic interactions. 
Due to the unsatisfying low encapsulation capability for rhodamine B, follow-up release 
studies were not carried out. The data from the aforementioned study showed that even at 
low salt concentrations (10 mM Tris-buffer) a fast release occurred independent of the 
employed loading strategy [38]. 
  
Figure 4.18. (A) Loading and loading efficiencies of the encapsulation of rhodamine B into eADF4(C16) 
particles at pH 7 / 30mM ionic strength. (B) Particle size and zeta-potential of eADF4(C16) particles loaded 
with rhodamine B. and prepared by co-precipitation 
4.3.2 LYSOZYME 
Co-precipitation of lysozyme was investigated to obtain data about the encapsulation 
behavior of negatively charged macromolecules. Encapsulation can be carried out by two 
different strategies, meaning that the drug can be mixed with either the spider silk protein 
solution or the salt solution prior to the phase separation process. However, lysozyme could 
not be dissolved in 2 M potassium phosphate as those conditions are used to crystallize 
lysozyme. On this account, only the addition of lysozyme to the eADF4(C16) solution was 
carried out. 
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First, the protein-protein interaction between lysozyme and eADF4(C16) in aqueous solution 
(10 mM Tris, pH 8.0) was investigated. This interaction is the major issue prior to the phase 
separation process and was considered as critical due to the strong electrostatic attraction 
between both protein molecules. AF4 was chosen as analytical technique, because it allows 
the simultaneous determination of soluble and insoluble protein species. Different lysozyme 
to eADF4(C16) ratios were analyzed at a fixed eADF4(C16) concentration of 1.0 mg/mL. 
An overlay of the 1:1 mixture (red) and lysozyme (green) or eADF4(C16) (blue) injection is 
depicted in Figure 4.19. It can be derived that at this ratio both a loss of lysozyme and spider 
silk protein recovery occurred most likely due to insoluble protein aggregates. Soluble, 
heterogeneous protein aggregates were not detected. However, at lower ratios of lysozyme 
to eADF4(C16) such as 1:5, both protein recoveries were determined to be adequate for 
encapsulation (> 90%, data not shown). Therefore, the addition of lysozyme to eADF4(C16) 
solutions (c=1.0 mg/mL) at w/w-ratios below 1:1 and followed by immediate phase separation 
was considered as uncritical regarding protein loss due to protein-protein interactions. 
 
Figure 4.19. UV-chromatogram (280 nm) of lysozyme (green), eADF4(C16) (blue) and a mixture (red) of 
equivalent masses of lysozyme and eADF4(C16) analyzed by AF4 
4.3.2.1. LYSOZYME-LOADED NANOPARTICLES 
The eADF4(C16) concentration was set to 1.0 mg/mL in order to obtain spider silk 
nanoparticles. Different amounts of lysozyme dissolved in 10 mM Tris buffer (pH 8.0) were 
added and phase separation was immediately induced by flushing the buffer solution into 
equal volumes of 2 M potassium phosphate (pH 8) by a pipette. Nanoparticles around 
350 nm were obtained for lysozyme-free solutions (see Figure 4.20, B). Loading and loading 
efficiencies [w/w] were determined according to the procedure for remote-loaded particles 
and the corresponding values are shown in Figure 4.20, A. A maximum of approx. 4% 
Lysozyme 50µg 
eADF4(C16) 50µg 
Lysozyme 50µg + eADF4(C16) 50µg 
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loading was achieved at a lysozyme to eADF4(C16) ratio of 50% and 100% [w/w]. Therefore, 
the corresponding loading efficiencies were quite low (< 10%), representing an inefficient 
loading process. This situation was marginally improved at lower lysozyme to eADF4(C16) 
ratios, but efficiencies were still below 40% [w/w].  
Particle size slightly increased with increasing lysozyme amount during precipitation (see 
Figure 4.20, B), but investigation by SEM did not reveal altered particle characteristics as 
depicted in Figure 4.21. 
The low loading efficiencies can be explained by the presence of high salt concentration 
during particle formation. As it was shown for remote loading of lysozyme (see section 4.2), 
high ionic strength weakens the electrostatic interactions and releases the protein from 
eADF4(C16) particles. This happens now already during the loading procedure so that less 
lysozyme is finally incorporated into or bound to eADF4(C16) particles than using the remote 
loading approach at low ionic strength. 
 
 
Figure 4.20. (A) Loading and loading efficiencies of lysozyme-co-precipitated eADF4(C16) particles at an 
eADF4(C16) concentration of 1.0 mg/mL. (B) Particle sizes and polydispersity indices of the resulting 
spider silk particles as determined by dynamic light scattering. 
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Figure 4.21. SEM micrographs (magnification: 20,000x) of particles prepared at different lysozyme to 
eADF4(C16) ratios and an eADF4(C16) concentration of 1.0 mg/mL: 0% (A), 30% (B) and 100% (C). 
The major advantage of encapsulated lysozyme in comparison to the remote loaded delivery 
system is theoretically a sustained or at least slowed down release rate from the 
eADF4(C16) particles due to longer diffusion pathways (see Table 4.2). For this reason, 
release from co-precipitated particles was directly compared to release from particles loaded 
with a comparable amount of lysozyme via the remote loading procedure. The corresponding 
results are displayed in Figure 4.22.  
However, co-precipitated lysozyme was released as fast as remote loaded lysozyme. Hence, 
encapsulation by co-precipitation was not successful in the retardation of the release from 
eADF4(C16) nanoparticles at physiological conditions. This result will be further discussed in 
section 4.4. 
 
Figure 4.22. In vitro release of lysozyme from remote loaded and co-precipitated eADF4(C16) particles. 
The release study was conducted at 37°C and physiological ionic strength. The release medium was 
refreshed every hour. The amount of released lysozyme was determined by measuring the activity of 
released lysozyme. 
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4.3.2.2. LYSOZYME-LOADED MICROPARTICLES 
In order to improve the unsatisfying results obtained for the loading and release of co-
precipitated lysozyme from eADF4(C16) nanoparticles, lysozyme was added to solutions 
with an eADF4(C16) concentration of 10 mg/mL (10 mM Tris-buffer, pH 8.0) with the 
intention to prepare spider silk microparticles. However, protein-protein interactions between 
eADF4(C16) and lysozyme were dramatically increased at this high protein concentration. 
 
  
  
Figure 4.23. (A) Loading and loading efficiencies of lysozyme-co-precipitated eADF4(C16) particles at an 
eADF4(C16) concentration of 10 mg/mL. (B-E) SEM micrographs of particles prepared at different 
Lysozyme:eADF4(C16)-ratios and an eADF4(C16) concentration of 10 mg/ml: 0% (B), 10% (C), 30% (D) 
and 50% (E). 
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Precipitation was observed right after the addition of lysozyme to the spider silk solution as if 
spider silk particles would have been formed immediately. Nevertheless, atomization of the 
2 M potassium phosphate solution via the ultrasonic nozzle was subsequently started and 
co-precipitation took place. 
The resulting loading and loading efficiencies (see Figure 4.23, A) were higher compared to 
the co-precipitation at an eADF4(C16) concentration of 1.0 mg/mL, but still considerably 
below the corresponding values achieved by the remote loading procedure. The 
aforementioned explanation of weakened electrostatic interactions due to the presence of 2 
M potassium phosphate holds also certainly true at this eADF4(C16) concentration. 
The particle formation process seemed to be affected by the presence of lysozyme in a way 
that larger and more noncircular particles were obtained (see Figure 4.23, B-E). 
Nevertheless, particle yield was still satisfying with more than 99% precipitated spider silk 
protein also in the presence of lysozyme. The absence of eADF4(C16) in the supernatant 
was proven by SDS-PAGE (data not shown). 
After co-precipitation and determination of the loaded amount of lysozyme, the in vitro 
release was studied from the obtained eADF4(C16) microparticles. The determined release 
profiles are displayed in Figure 4.24 and show a cumulative release of lysozyme of 
approx. 50% after 4 hours. Such low release rates were not obtained so far, but it has to be 
mentioned that the loading values were determined indirectly, meaning that they were 
calculated by measuring the concentration of lysozyme in the supernatant after the particle 
preparation process. Therefore, a loss of lysozyme due to protein-protein interactions prior to 
particle preparation could not be assessed and would result in an overestimated loading 
percentage of lysozyme. The course of the release indicates that release is almost finished 
after the investigated time period. This fact is in agreement with other release profiles 
obtained for remote loaded and co-precipitated nanoparticles where the release was almost 
completed after 4 hours. The run of the release curve is further identical to previous release 
experiments except the absolute value of the endpoint. 
Altogether, these comments considerably argue for an inaccurate determination of the 
loaded amount of lysozyme so that the residual amount of the protein in eADF4(C16) 
particles after 4 hours of release is significantly overrated. 
Albeit, a sustained release of lysozyme from eADF4(C16) microparticles was not detected, 
because at least 50% released lysozyme after 4 hours still represent a too fast release and 
can on no account be explained by a diffusion-based release mechanism. 
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Figure 4.24. In vitro release of lysozyme from co-precipitated eADF4(C16) microparticles. The release 
study was conducted at 37°C and the release medium was refreshed every hour. The amount of released 
lysozyme was determined by measuring the activity of released lysozyme. 
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4.4 SUMMARY AND CONCLUSIONS 
Two different strategies for loading eADF4(C16) particles are described in this chapter. 
On the one hand, spider silk particles were loaded after particle preparation via incubation in 
a drug containing buffer solution. This procedure was called ‘remote loading’. On the other 
hand, drugs were mixed with the spider silk protein solution prior to particle preparation. 
Subsequently, co-precipitation was induced and the drug was incorporated into the spider 
silk matrix. This approach is typically known as drug encapsulation. 
Remote loading is most efficient when the ionic strength of the loading buffer is as low as 
possible. In this case, lysozyme as well as nerve growth factor were loaded into eADF4(C16) 
particles up to payloads of more than 20% [w/w], whereas the corresponding loading 
efficiencies were still sufficiently high (> 80%). The same holds true for small and essentially 
positively charged molecules like methyl violet which could also be loaded on eADF4(C16) 
particles in large amounts without losing too much drug substance during loading. The 
predominant driving force during loading was shown to be electrostatic attraction, whereas 
hydrophobic forces may only play a subsidiary role. The higher the electrostatic attraction, 
the higher the resulting loading efficiencies and payloads will be. It was furthermore proven 
by CLSM experiments that in fact matrix loaded spider silk particles were obtained by remote 
loading even with macromolecules like proteins.  
In comparison to these results from remote loading, encapsulation did only lead to a low 
payload for any of the investigated drug substances. Remote loading offers the possibility to 
optimize the loading conditions, whereas co-precipitation has to deal with the conditions 
required for particle preparation. This is of special importance in the case of spider silk 
particles as a very high ionic strength is necessary for the induction of the phase separation 
process and finally particle formation. The presence of 2 M potassium phosphate inhibits the 
electrostatic interactions between eADF4(C16) particles and the drug molecules. Therefore, 
only low amounts can be co-precipitated into the spider silk protein matrix. It has also to be 
mentioned that uncharged molecules like rhodamine B could not be loaded on spider silk 
particles even during co-precipitation. Therefore, electrostatic attraction is also a prerequisite 
for successful encapsulation. 
The in vitro release was investigated using several different setups and drug molecules. In 
summary, release from spider silk particles was very fast at physiological conditions 
independent of the performed loading procedure. So far data does not prove that an 
incorporation of drug molecules into the spider silk protein matrix lead to a sustained release 
rate due to diffusion through a dense polymer matrix. On the contrary, the spider silk matrix 
seems to be visually dense, but not in a way that diffusion out of the particle is hindered 
neither for small nor large drug molecules like proteins. The determined release can be 
better understood as the creation of an equilibrium distribution between the particle with its 
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loaded drug molecules and the buffer environment including ions or other molecules like 
albumin. Any change of this equilibrium modifies the release of the drug molecules from the 
spider silk particles. Therefore, pH, ionic strength and the addition of albumin strongly 
influence the determined amount of free drug substance. 
Altogether, the usage of spider silk particles for a sustained delivery of drug substances has 
to be assessed as very challenging on the basis of the data presented in this chapter. 
However, eADF4(C16) particles may act as appropriate drug carriers for applications where 
the local environment may allow a slowed down release of the loaded drug substance or 
where a sustained release is not absolutely necessary. Physiological conditions are 
furthermore more complex than the employed in vitro conditions so that a simple transfer of 
the release data to the in vivo situation is in general difficult. Therefore, in vivo studies have 
to prove if spider silk particles fulfill the requirements for the desired application. 
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CHAPTER 5 
SPIDER SILK PARTICLES AS NOVEL EXCIPIENT FOR THE 
STABILIZATION OF NERVE GROWTH FACTOR 
5.1 INTRODUCTION 
The stabilization of therapeutic proteins during manufacturing processes and ensuring the 
shelf-life of the drug product are the major tasks in formulation development of 
biopharmaceuticals [1]. Due to the need of freezing, buffer-exchange, filtration or stirring 
during manufacturing, protein formulations are exposed to multiple and very different types of 
stress factors (see Table 5.1.) which may lead to physical and chemical instability of 
proteins [2]. Protein aggregation is arguably the most important and relevant pathway of 
protein instability in biopharmaceuticals and should be considered as a critical quality 
attribute of the drug product [3]. The reason is that protein aggregates are associated with 
product quality, toxicity and potentially enhanced immunogenicity [3-5]. In order to prevent 
aggregation therapeutic proteins are usually stabilized by the addition of excipients which act 
by different mechanisms [6, 7]. The most important types of excipients are certainly buffer 
components, tonicity agents, stabilizers like sugars or polyols, antioxidants and surfactants 
like polysorbates for the stabilization against surface-induced protein aggregation and the 
prevention of protein adsorption [8]. 
Table 5.1. Stress factors a protein is encountered during real-life conditions, adapted from Hawe et al. [9] 
Stress factor Encountered 
Elevated temperature Production processes, improper shipment, storage or handling 
Freezing, freeze-thawing 
Accidental freezing during storage or shipment, storage of (frozen) bulk 
material, lyophilization 
Mechanical stress Production (pumping, filtration, stirring, etc.), shipment, handling 
Light 
Exposure to daylight or artificial light during production, shipment, 
storage or handling; UV-detection during downstream processing 
Oxidative stress 
Contact with oxygen; excipients; metal ion traces from production 
equipment; light; cavitation 
pH changes Processing (downstream); freezing; formulation 
Interfaces 
Air-water interface; filters; primary packaging material; silicone oil; 
extraneous particles 
Spider silk particles as novel excipient for the stabilization of nerve growth factor 
 
146 
Nevertheless, commonly used excipients like polysorbate or primary packaging materials 
exhibit important limitations and can themselves induce protein aggregation under certain 
conditions [10]. Thus, developing strategies to overcome these challenges and to stabilize 
therapeutic proteins is still in the focus of academic research [11-13]. Unfortunately, research 
and investment in excipient development for pharmaceutical drug products has been very 
complicated and expensive from an industrial perspective as excessive safety studies almost 
similar to those for a new drug substance were required for successful approvals [14]. 
For this reason, one objective of this thesis was the investigation whether protein drugs could 
be stabilized by adsorption to spider silk particles. The interaction of several proteins with 
foreign micro- or nanoparticles has already been described in literature. Bee et al. 
investigated the interaction of an IgG1 with glass, cellulose, stainless steel and 
F2O3 microparticles [15]. Interestingly, each particle type revealed a different result regarding 
the adsorption behavior of the antibody so that a transfer or comparison of the results to 
spider silk particles is pretty difficult. In theory, loading of a therapeutic protein onto or into 
the particulate spider silk matrix may be beneficial as the protein itself is less exposed to 
stress factors compared to the particle-free formulation. Furthermore, binding to the particles, 
which is mainly driven by electrostatic interactions, may stabilize the native, folded state of 
the protein. 
The drug delivery system used in this study was a suspension of NGF-loaded spider silk 
particles in a phosphate buffer at pH 7.0 and 30 mM ionic strength adjusted with sodium 
chloride (see chapter 2, section 2.3.1.1). In literature, silk fibroin matrices have been 
employed for the stabilization of proteins as well but so far only silk films were 
investigated [16, 17]. Furthermore, these studies primarily focused on the stabilization of an 
API in a silk matrix which was dried after incorporation of the drug, i.e. by lyophilization. 
These approaches were shown to be successful for the stabilization of a vaccine (measles, 
mumps, rubella) and an antibiotic (tetracycline). However, this stabilization is not very 
surprising since the mechanism is based on the reduction of the water content which is well-
known from the stabilization of liquid protein formulations by spray- or freeze-drying [16]. 
Another interesting study from Uebersax et al. incorporated nerve growth factor into a silk 
fibroin matrix [17]. The silk fibroin films and tubes were air-dried or freeze-dried, respectively, 
and a successful release of the biologically active protein over a period of three weeks was 
shown by HP-SEC, PC 12 cell bioactivity and ELISA-reactivity. However, the very low NGF 
payload of this study is especially noteworthy (payload: 0.02% [w/w]). In contrast, the 
payloads described in this thesis using eADF4(C16) particles are 2.5%, 5% and 10% [w/w]. 
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In order to evaluate the potential of eADF4(C16) particles to stabilize bound protein 
molecules forced degradation studies comparing the suspension and the original protein 
formulation were performed. Freeze-thawing, stirring, light exposure and incubation at 
elevated temperatures of both types of formulations were conducted to obtain an insight into 
the different processes and mechanisms occurring with or without spider silk particles. 
Besides, this study should be considered as a first proof-of-concept study given that NGF is 
a protein where little information is available on the performance during degradation studies. 
On the other hand, nerve growth factor is an ideal candidate to be loaded onto eADF4(C16) 
particles due to its biochemical properties (see chapter 4, section 4.2.2). 
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5.2 DEVELOPMENT OF A STANDARD DESORPTION PROCEDURE 
The loading and in vitro release of NGF from eADF4(C16) particles was studied and reported 
earlier and aimed at sustained release of the drug (see chapter 4, section 4.2.2 and 4.2.4). 
The goal of this study was on protein stabilization of the loaded compound during forced 
degradation studies. Therefore, in contrast to the setup of the release experiments, a 
standard desorption procedure had to be developed resulting in a sufficiently efficient release 
of the protein without affecting the protein’s stability and conformation. A sufficiently efficient 
release was achieved when more than 80% of the loaded NGF amount was found in the 
supernatant by employing a maximal dilution factor of two. A higher dilution during desorption 
should be avoided due to the comparatively low protein concentration of 0.5 mg/mL of the 
original formulation. 
The conclusions from the release studies present two different strategies to obtain a fast and 
complete release. The first approach is the increase of ionic strength of the medium, and the 
second approach is the decrease of the pH from 7.4 towards an acidic pH approximating the 
isoelectric point of eADF4(C16) particles (see chapter 3, section 3.4). Nevertheless, as a 
main criterion the desorption procedure has to maintain the protein’s chemical and physical 
state present in the formulation before and after the degradation study. For this reason, 
different desorption procedures were compared to a freshly thawed, non-stressed sample of 
NGF in bulk solution. 
In preliminary experiments the influence of acidic pH values was investigated. However, the 
detected NGF concentrations in the supernatant were not sufficient regarding the 
aforementioned definition (data not shown). Therefore, the addition of sodium hydroxide was 
tested and it was found that an increase of the pH towards or above the isoelectric point of 
NGF is more effective than acidic solutions. This result was somewhat unexpected, but 
lowering the charge of nerve growth factor molecules clearly improved the desorption 
procedure. Otherwise, it has also been reported in literature that deamidation of recombinant 
human nerve growth factor occurs after 16 to 18 hours incubation at pH 8.1 so that alkaline 
solutions above pH 10 were generally excluded from further experiments [18]. The protein 
content has so far been determined by UV-spectroscopy and size-exclusion 
chromatography, but this had to be changed to reversed phase chromatography for the study 
described here. This change was necessary to detect deamidation or other chemically 
modified protein species [18]. 
In order to optimize the desorption procedure samples were placed in a Thermomixer to heat 
and shake the suspensions under controlled and reproducible conditions. Solutions were 
adjusted to three different pH-values (pH 6, 8 and 10) and different amounts of sodium 
chloride were added to the buffer component (200 mM sodium phosphate) to modify the ionic 
strength (400 mM, 800 mM and 1200 mM sodium chloride). 
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Figure 5.1. Efficacy of different solutions regarding the amount of displaced NGF from eADF4(C16) 
particles determined by RP-HPLC. All solutions consisted of 200 mM sodium phosphate and the 
declared amount of sodium chloride. 
After mixing the same volume of the solution with the suspension containing 5 mg/mL 
NGF-loaded spider silk particles in 10 mM phosphate buffer pH 7.0 (30 mM ionic strength), 
the sample was agitated at 600 rpm for 30 minutes at the corresponding temperature. The 
pH of the resulting suspensions was 6.38 ± 0.05, 7.90 ± 0.04 and 10.19 ± 0.09, respectively. 
Desorption at 25°C revealed an impact of the pH on solutions with different amounts of 
sodium chloride. At 400 mM sodium chloride, the amount of released NGF is significantly 
increased at higher pH-values. Formulations with higher sodium chloride concentration 
showed an opposite behavior as the amount of released NGF was not further enhanced at 
800 mM and even decreased at 1200 mM sodium chloride. Taking these results together, it 
seems that at comparatively low ionic strength an increase of the pH towards or above the 
IEP of NGF further decreased the electrostatic interactions between the spider silk particles 
and NGF. At higher ionic strength the change in pH was not able to affect the charge-charge 
interactions further. This can be explained by the fact that due to the very high ionic strength 
the electric charge density has already been reduced to a minimum. Therefore, using even a 
pH above the IEP of NGF is not able to further decrease the electrostatic interactions. 
As the interaction between the eADF4(C16) particles and the loaded compound is dominated 
by electrostatic and hydrophobic interactions and an equilibrium is created after the addition 
of the required solution, elevated temperature should also enhance the dissociation of bound 
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NGF from eADF4(C16) particles. This assumption was confirmed when the temperature 
during the agitation step was increased from 25°C to 37°C and 50°C, respectively. The 
highest amount of released NGF of all investigated solutions and procedures was achieved 
using a formulation consisting of 200 mM sodium phosphate and 800 mM sodium chloride at 
pH 8, and a process temperature of 50°C. The released amount of NGF was 92% of the 
protein originally loaded onto the particles, and the protein showed no change in its chemical 
or physical state as determined by RP-HPLC and HP-SEC. Thus, this desorption procedure 
was applied for all further forced degradation studies. Samples which were treated according 
to this standard desorption/washing procedure are further referred as ‘ iquid NGF WP’. 
Samples which were treated with the formulation buffer instead are further referred as ‘ iquid 
NGF FB’. 
  
Chapter 5 
 
151 
5.3 FORCED DEGRADATION STUDIES 
5.3.1 FREEZE-THAW STUDY 
Freezing and thawing processes can occur at many different stages in a lifecycle of a drug 
product. Bulk substance is routinely stored in the frozen state due to superior storage stability 
to the storage of liquid formulations. In addition, accidental freezing and thawing may happen 
during storage at different development processes. As a consequence, the prevention of 
protein aggregation generated by freeze-thaw cycles plays a major role in formulation 
development and the development of robust manufacturing processes even for drug 
products where lyophilization is not necessary [19]. 
Protein aggregation is the result of different factors appearing during freezing and thawing: 
low temperature, high local solute concentration, formation of ice-water interfaces, potential 
pH changes and phase separation [19, 20]. As a result, soluble as well as insoluble protein 
aggregates can be generated, and surfactants like the non-ionic polysorbate 20 or 80 are 
usually added to successfully minimize protein-ice interactions. Furthermore, formulations 
having a low protein concentration are more prone to freeze-thaw induced aggregation 
because the protein to surface-ratio is larger than for higher concentrated solutions [20]. 
In the following study it was investigated if there is a potential stabilizing or even destabilizing 
effect of eADF4(C16) particles on nerve growth factor. So far it is the first study which 
evaluates the effect of binding a protein to nanoparticles and subsequent freezing and 
thawing of the nanoparticle suspension without further additives. In literature, plenty of 
studies have been performed on the freeze-thawing or freeze-drying of nanoparticle 
suspensions, but their focus was the conservation of the colloidal stability of the 
nanoparticles and the characterization of the freeze-drying process [21-23]. In this study the 
stabilization of bound protein towards freeze-thaw induced stress was investigated in order to 
find a possible application of spider silk particles as a novel excipient for protein stabilization 
during drug development and manufacturing.  
Unfortunately, no information about the stability of nerve growth factor during freezing and 
thawing in a liquid formulation is available in the literature. The already described loading 
buffer (10 mM phosphate, adjusted to 30 mM ionic strength with sodium chloride, pH 7.0) 
was therefore chosen as formulation buffer for the complete forced degradation study as it 
had already been shown that NGF at the employed protein to nanoparticle ratios will 
completely adhere to the particles over a sufficiently long period of time (see chapter 4, 
section 4.2.2). The amount of spider silk particles was set to 0.5%, 1% and 2% [w/V], which 
corresponds to a nanoparticle concentration of 5, 10 and 20 mg/mL, respectively. As 
described in chapter 2, section 2.3.1.1, the NGF concentration of 0.5 mg/mL was kept 
constant in all formulations. 
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The amount of total NGF recovered after 5, 10 and 15 freeze-thaw cycles is depicted in 
Figure 5.2 and was determined by RP-HPLC with UV-detection at 215 nm. This diagram 
shows one important fact of the entire forced degradation study. If one considers the 
formulation ‘ iquid NGF FB’ as reference formulation (  100% at t0), it can be observed that 
desorption was less efficient for formulations containing more than 0.5% [w/V] eADF4(C16) 
particles. This can be well explained by the equilibrium between loaded and displaced NGF 
molecules which is created during the desorption process similar to the release process (see 
chapter 4, section 4.2.4). The higher the particle concentration is the less NGF molecules are 
displaced at the same ionic strength and pH in the solution. 
 
Figure 5.2. Total protein content after freeze-thawing of NGF formulations as analyzed by RP-HPLC (UV-
detection at 215 nm). The displayed protein recovery is calculated regarding the total protein content of 
the reference formulation ‘Liquid NGF FB’ at t0. The bars represent the mean of three samples ± SD. 
To improve the visualization of the stabilizing effect, the NGF content of each formulation at 
t0 was set to 100%. The same calculation was carried out for the remaining dimer content 
which was determined by HP-SEC and referred to the total AUC of each formulation at t0. 
Both diagrams are depicted in Figure 5.3. 
Taking together, the result from the freeze-thaw study is clear: Neither the particle-free 
formulation nor the suspensions comprising bound NGF showed any significant degradation 
or aggregation of NGF throughout 15 freeze-thaw cycles. The total protein recoveries as well 
as the dimer contents of all investigated formulations remained at almost 100%. SDS-PAGE 
under non-reducing conditions showed no additional protein species or decreased protein 
content as all formulations exhibited a single band which represents the monomeric form of 
NGF with a molecular weight of 13 kDa (see Figure 5.4). 
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Subvisible particle analysis is more sensitive towards early and quite low fractions of protein 
aggregation compared to chromatographic methods [5, 24, 25]. Therefore, spider silk 
particle-free formulations were analyzed by light obscuration as depicted in Figure 5.5. The 
increasing number of subvisible particles indicates that protein aggregation took place 
throughout freeze-thawing. The difference in the particle counts between both formulations 
illustrated that already formed particles were partly dissolved again due to the high ionic 
strength of the solution used for desorption. 
 
 
Figure 5.3. (A) Freeze-thawing of NGF formulations analyzed by RP-HPLC and UV-detection at 215 nm. 
(B) Freeze-thawing of NGF formulations analyzed by HP-SEC and UV-detection at 215 nm. The remaining 
protein/dimer content is calculated regarding the total protein/dimer content of each formulation at t0. 
The symbols represent the mean of three samples ± SD. 
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Figure 5.4. SDS-PAGE of unstressed (t0) and freeze-thawed NGF formulations after 5 (A), 10 and 15 FT-
cycles (B) 
This difference was also slightly visible regarding the determined turbidity as the values of 
the formulation ‘ iquid NGF FB’, which was diluted 1:1 with formulation buffer, were always a 
little higher than those for the formulation ‘ iquid NGF WP’, which was diluted 1:1 with the 
buffer required for desorption. This trend was observed throughout all different applied stress 
methods, but an interpretation of the light obscuration results is certainly still possible. 
Regrettably, formulations containing spider silk nanoparticles had to be centrifuged in order 
to obtain a spider silk particle-free, NGF containing supernatant. Thus, these formulations 
were not analyzed by light obscuration. 
So far it can be concluded from the freeze-thaw study that only marginal protein aggregation 
took place under the investigated conditions, which was not enough to study any stabilizing 
effect of protein binding to spider silk particles. Apparently, NGF is not prone to significant 
aggregation during freezing and thawing even at this low concentration. At least, the 
presence of spider silk particles and the binding of NGF did not lead to a diminished stability 
of these formulations. 
A B 
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Liquid NGF WP 
# of FT-
cycles 
Turbidity 
[FNU] 
0 0.63 ± 0.04 
5 0.69 ± 0.09 
10 0.71 ± 0.07 
15 0.80 ± 0.05 
Liquid NGF FB 
# of FT-
cycles 
Turbidity 
[FNU] 
0 0.73 ± 0.06 
5 0.81 ± 0.07 
10 0.80 ± 0.03 
15 0.86 ± 0.02 
 
Figure 5.5. The diagram shows the subvisible particle count occurred during freeze-thawing of NGF 
formulations determined by light obscuration. The bars represent the mean of three samples ± SD. The 
corresponding turbidity values are tabulated alongside the diagram. 
5.3.2 STIRRING 
In order to evaluate whether spider silk nanoparticles are capable to stabilize nerve growth 
factor against further stress conditions that occur during pharmaceutical processing, a stirring 
study was carried out. It is known from literature that stirring is more harmful to the stability of 
an IgG1 antibody than agitation or shaking [26, 27]. For example, it has been described in 
literature that non-ionic surfactants such as polysorbate 20 or 80 are able to prevent agitation 
and therefore air-water-interface induced protein aggregation, but fail to sufficiently stabilize 
antibodies during stirring studies [11, 26, 27]. Additional stress factors like cavitation, 
accelerated mass transport, local heating and particularly shear are held responsible for this 
more detrimental effect compared to agitation, where protein molecules are solely exposed 
to the air-water interface. Furthermore, the types of aggregates created by stirring and 
shaking of antibodies are quite different and depend strongly on the employed conditions of 
the stirring or shaking study. 
As a conclusion of these findings, stirring was chosen as method of choice for studying 
mechanical stress on NGF formulations. For that purpose all formulations were filled into 
small glass vials typically used for HPLC samples and stirred over a period of 92 hours using 
Teflon-coated stirring bars and a stirring speed of 400 rpm. For each sampling point separate 
vials were used and non-stirred samples were analyzed as a control. 
The amount of remaining total protein (A) and remaining dimer (B) over the investigated 
stirring time is depicted in Figure 5.6. The stirring stress led to a steady loss in dimer and 
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total protein recovery in formulations containing spider silk particles whereas NGF 
formulations without spider silk particles showed no significant protein loss. Interestingly, the 
protein loss in formulations comprising eADF4(C16) particles increased with increasing 
particle concentration so that the formulation comprising 20 mg/mL eADF4(C16) particles 
exhibited the lowest amount of residual dimer content with a recovery lower than 60%. 
Therefore, it can be stated that the more particles are present in the formulation, the higher 
the degree of protein loss during stirring will be. This result is so far contrary to the 
expectation which was defined in the forefront of the study. The binding of NGF onto or into 
eADF4(C16) particles was intended to prevent the protein from shear, surface or cavitation 
induced stress, but it seems that the opposite occurred. 
 
 
Figure 5.6. Total protein recovery (A) and remaining dimer content (B) during stirring of NGF 
formulations over 92 hours determined by HP-SEC (UV-detection at 215 nm). The displayed protein 
recoveries are calculated referring to the total AUC of each formulation at t0. The symbols represent the 
mean of three samples ± SD. Separate samples of each formulation were prepared for different sampling 
points. 
0 24 48 72 96
0
20
40
60
80
100
to
ta
l 
p
ro
te
in
 r
e
c
o
v
e
ry
 -
 S
E
C
 [
%
]
 stirring time [h]
 Liquid NGF FB
 Liquid NGF WP 
 0.5% eADF4(C16)
 1% eADF4(C16)
 2% eADF4(C16)
0 24 48 72 96
0
20
40
60
80
100
 stirring time [h]
d
im
e
r 
re
c
o
v
e
ry
 -
 S
E
C
 [
%
]
 Liquid NGF FB
 Liquid NGF WP 
 0.5% eADF4(C16)
 1% eADF4(C16)
 2% eADF4(C16)
A 
B 
Chapter 5 
 
157 
Further analysis of the formulations was obtained by SDS-PAGE under non-reducing 
conditions and is illustrated in Figure 5.7. This method confirmed the loss of NGF content 
especially for the formulation with 2% [w/V] spider silk particles. An important additional 
information is that traces of soluble aggregates were neither detected by SDS-PAGE nor by 
HP-SEC so that the loss of protein has to be referred to the formation of insoluble protein 
aggregates or the enhanced adsorption of stressed, partially unfolded NGF to spider silk 
particles. 
Light obscuration results for particle-free formulations are displayed in Figure 5.8 and reveal 
slightly increased particle counts for stirred formulations compared to control samples. As 
already described in the freeze-thaw study (see section 5.3.1), this indicates the early start of 
protein aggregation, but the degree was much too low to be detected by HP-SEC or RP-
HPLC. Nevertheless, the issue of protein loss in the particle containing formulations remains 
open as the detection of protein aggregates in presence of spider silk protein nanoparticles 
poses a huge challenge for the analytics currently available. The differentiation just by size 
using light obscuration or static light scattering will be nearly impossible because of the 
presence of agglomerates of nanoparticles which will interfere with protein aggregates in the 
micrometer range. The high concentration of nanoparticles will also require the need of 
excessive sample dilution that will affect the particulate protein aggregates as well. A 
different and meaningful approach compared to light obscuration would be the use of newly 
developed imaging techniques such as Micro-flow Imaging™ [28, 29]. This analytical 
technique allows an image-based particle analysis which is e.g. able to distinguish between 
silicon oil droplets and protein particles. The differentiation is based on the different intensity 
or shape of the material after analysis of the obtained image set. For that reason, there may 
be an opportunity to achieve a separation between eADF4(C16) particles and NGF 
aggregates, but due to presumably similar refractive indices this analysis will be very difficult 
and was therefore not considered due to time restraints. 
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Figure 5.7. SDS-PAGE (non-reducing conditions) of unstressed (t0) and stirred NGF formulations after 
24 (A), 48 and 92 hours (B) of stirring time 
In summary, all formulations comprising NGF bound to spider silk particles exhibited a 
detrimental effect on the protein stability during stirring. The formulation without spider silk 
particles did not show a significant protein degradation under the investigated conditions and 
was therefore unambiguously superior to eADF4(C16) particle containing formulations. The 
mechanisms responsible for the protein loss could not be clarified due to analytical 
limitations. It can be only speculated whether insoluble aggregates are formed or an 
unfolding of protein molecules takes place that leads to very strong interactions with spider 
silk particles. As a result, these protein molecules would not be washed from the particles 
matrix and reduced protein content would be determined in the supernatant. 
B 
A 
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Liquid NGF WP 
stirring 
time [h] 
Turbidity 
[FNU] 
0 0.63 ± 0.03 
24 0.71 ± 0.03 
48 0.78 ± 0.05 
92 0.84 ± 0.13 
Liquid NGF FB 
stirring 
time [h] 
Turbidity 
[FNU] 
0 0.73 ± 0.03 
24 0.82 ± 0.11 
48 0.96 ± 0.04 
92 0.90 ± 0.17 
 
Figure 5.8. Cumulative counts for particles greater than 1 µm obtained during stirring of NGF formulations 
as determined by light obscuration. The bars represent the mean of three samples ± SD. The 
corresponding turbidity values are tabulated alongside the diagram. 
5.3.3 LIGHT EXPOSURE 
Protein formulations are exposed to light several times in real-life conditions. This includes 
the potential exposure to UV-light during different production steps using UV-detection 
systems and to artificial or daylight during production, shipment, storage and administration 
of the drug to the patient [30, 31]. The primary target of photodegradation in proteins is their 
peptide backbone consisting of tryptophan, tyrosine, phenylalanine and cysteine, but 
absorption of light can also induce protein oxidation by the formation of reactive oxygen 
species. Mostly, photodegradation leads to chemical changes of the primary sequence and 
generates cross-linking reactions via disulfide or dityrosine formation [31]. As a 
consequence, protein formulations after light exposure exhibit a complex mixture of multiple 
protein species from soluble to insoluble and covalent to non-covalent protein aggregates. 
Performing studies on the photodegradation of protein formulations ICH guideline Q1B 
defines the type of light source needed and the procedure for confirmatory studies that 
should provide an overall illumination of not less than 1.2 million lux hours and an integrated 
near ultraviolet energy of not less than 200 watt hours/square meter [32]. Usually, 
confirmatory testing of protein formulations results in strong and severe protein degradation 
so that for forced degradation studies different settings can be used [9]. 
The following study was performed using a Suntest® CPS device equipped with a xenon arc 
lamp and an ultraviolet energy of 60 watt hours/square meter. Throughout preliminary 
experiments the appropriate time of light exposure was evaluated and samples were drawn 
after 8, 16 and 24 hours, respectively. It was expected from this study that NGF molecules 
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are protected from light by a shielding effect of the surrounding spider silk protein matrix and 
scattering or absorption of the incoming light by protein particles. Thus, the degree of 
photodegradation of NGF may be significantly reduced. 
 
 
Figure 5.9. Total protein recovery (A) and remaining dimer content (B) of NGF formulations after light 
exposure as analyzed by HP-SEC (UV-detection at 215 nm). The displayed protein recoveries were 
calculated referring to the total AUC at t0 of each formulation. The symbols represent the mean of three 
samples ± SD. Separate samples of each formulation were prepared for different sampling points. 
Light exposure of NGF containing formulations resulted in fast and excessive protein 
degradation as depicted in Figure 5.9. Less than 25% dimer content was remaining after 
24 hours in the case of particle-free NGF formulations (red and black dots, see 
Figure 5.9, B). This severe protein degradation came along with the formation of large 
amounts of soluble protein aggregates as the total protein recovery for these formulations 
decreased to only 45% of the starting value. 
Figure 5.10 A shows the amount and type of soluble protein species determined by HP-SEC. 
An increasing fraction of tetramers and oligomers (HMW-aggregates) was detected and after 
24 hours, 48% of the remaining soluble NGF was assigned to protein aggregates. This 
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finding was confirmed by results obtained from SDS-PAGE using the more sensitive silver 
staining in order to visualize also very low quantities of aggregates. As shown in Figure 5.11, 
significant amounts of protein aggregates with molecular weights above 26 kDa were formed. 
This correlated well to the results from HP-SEC. In addition, SDS-PAGE under non-reducing 
conditions revealed interesting information about the nature of the protein dimers present in 
the formulations. In HP-SEC analysis NGF elutes in its native form which is a non-covalent 
homodimer with a molecular weight of 26 kDa (see chapter 2, section 2.1.1.3). Therefore, 
this technique is not able to distinguish between non-covalent dimers consisting of two 
monomers stabilized via cysteine-knot motif (=native) or covalently linked dimers (=non-
native aggregates). This lack of information can be filled with the result from SDS-PAGE 
under non-reducing conditions. Here, it is clearly visible that the amount of covalently linked 
NGF dimer was drastically increased following the absorption of light. This dimer formation 
can be easily explained by the aforementioned cross-linking reactions of cysteine groups 
which are a characteristic component of growth factor proteins [33]. 
Similar to particle-free formulations spider silk particle suspensions failed to stabilize nerve 
growth factor against light induced degradation as derived from the decrease in dimer and 
total protein recovery (see Figure 5.9). None of the employed eADF4(C16) particle 
concentrations showed a significant improvement. Spider silk particles seemed to be even 
detrimental for NGF stability at low concentrations such as 0.5% [w/V] (cyan diamonds). 
However, the formulation having the highest particle concentration of 2% [w/V] (green 
triangles) showed the best result with 38% dimer recovery vs. 25% for the particle-free 
formulation. This value is of course too low to declare a stabilizing effect, but at least the 
correlation between higher dimer recovery and higher eADF4(C16) particle concentration 
can be concluded at this point. 
  
Figure 5.10. Soluble protein species of ‘Liquid NGF WP’ (A) and the formulation containing 
2% [w/V] eADF4(C16) particles (B) determined by HP-SEC (UV-detection at 215 nm). The bars represent 
the mean of three samples ± SD. Separate samples of each formulation were prepared for the different 
sampling points. 
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Figure 5.11. Comparison of particle-free vs. 0.5% [w/V] spider silk particle comprising NGF formulations 
by SDS-PAGE under non-reducing conditions (silver staining) 
The Coomassie blue staining of the entire sample set is illustrated in Figure 5.12. It 
confirmed the already described results regarding the distinct decrease of total protein 
content over time. Nevertheless, the amount of NGF aggregates was quite different in spider 
silk particle comprising samples in contrast to particle-free samples, which was also 
observed in the silver staining of the formulation including 0.5% [w/V] spider silk particles 
(see Figure 5.11). All stressed samples showed an additional dimer bond, but especially after 
24 hours of light exposure the dimer bond of particle-free samples was much more 
pronounced than for particle containing formulations. Consequently, the NGF monomer bond 
at 13 kDa showed the opposite behavior. This difference in aggregation behavior was also 
detected by HP-SEC as only small amounts of aggregated protein were determined (see 
Figure 5.10, B). 
The dramatic loss in protein content suggests that also significant amounts of insoluble 
protein particles had been formed during degradation. As depicted in Figure 5.13 and 
keeping the dilution factor of 1:20 in mind, the assessed particle counts for particle-free 
formulations with values around 30,000 particles ≥ 1 µm per m  supported this assumption. 
Interestingly, the nephelometric analysis of these samples showed only a marginal increase 
which was not higher than for stirring or freeze-thaw stress. This finding may be considered 
as a hint for the formation of larger protein aggregates and will be discussed in comparison 
to heat-induced aggregates in the next section 5.3.4. 
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Figure 5.12. SDS-PAGE (non-reducing conditions) of unstressed NGF formulation (t0) and after 8 (A), 16 
and 24 hours (B) of light exposure 
 
 
 
 
 
Liquid NGF WP 
time of light 
exp. [h] 
Turbidity 
[FNU] 
0 0.57 ± 0.04 
8 0.72 ± 0.08 
16 0.82 ± 0.03 
24 0.76 ± 0.07 
Liquid NGF FB 
time of light 
exp. [h] 
Turbidity 
[FNU] 
0 0.70 ± 0.03 
8 0.78 ± 0.02 
16 0.91 ± 0.03 
24 0.92 ± 0.11 
 
Figure 5.13. The diagram shows the subvisible particle count occurring after light exposure of NGF 
formulations determined by light obscuration. The bars represent the mean of three samples ± SD. The 
corresponding turbidity values are tabulated alongside the diagram. 
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To sum up the results from light exposure experiments, it has to be stated that a sufficient 
stabilization of NGF has not been achieved by adding spider silk particles to the formulation. 
Severe protein degradation took place in all samples investigated in this study and led to the 
formation of soluble and insoluble protein aggregates. Interestingly, the formulation 
containing 2% [w/V] spider silk particles showed the same amount of residual protein 
compared to the reference formulation, but the residual protein consisted of 99% dimer vs. 
52% dimer content in the particle-free formulation. The dimer content determined by HP-SEC 
has to be furthermore analyzed by SDS-PAGE under non-reducing conditions to clarify the 
nature of the protein dimer. Particle-free formulations contained large amounts of covalently-
linked molecules whereas the suspensions showed only a weak dimer and a strong 
monomer bond. Therefore, at least a week stabilizing effect can be attributed to the 
2% [w/V] eADF4(C16) particle containing formulation, which provides an opportunity to 
achieve a substantial stabilizing effect by further increasing the spider silk particles’ 
concentration. Moreover, a successful analytical differentiation between spider silk particles 
and particulate NGF aggregates as already discussed in section 5.3.2 may help to clarify the 
mechanism of protein degradation in the suspensions and thereby offer a starting point for 
further optimization of the formulation. 
5.3.4 INCUBATION AT ELEVATED TEMPERATURE 
The pathway of protein aggregation has been described as a very complex process which 
can broadly differ between stress factors applied during development and production and 
also strongly depends on the protein itself [34, 35]. Herein, thermal stress is the most 
common method to investigate protein degradation of biopharmaceuticals [9]. Regarding 
heat stress, the starting point of protein aggregation appears to be a conformational 
modification or partial unfolding into a non-native protein conformation which exhibits a high 
propensity to form irreversible protein aggregates [35]. Therefore, excipients stabilizing the 
native conformation provide the potential to inhibit heat-induced protein aggregation.  
In order to shorten the time period required for a long-term stability study according to ICH 
guideline Q1A, accelerated stability testing at higher temperatures is commonly used and the 
experimental design has to be defined case-by-case [9]. These studies are performed to 
investigate and characterize protein aggregates in detail, to clarify the effect of different 
formulation excipients and to define lead candidates during formulation development. 
Therefore, incubation temperatures are required at which severe protein aggregation takes 
place over a limited period of time. As a rule of thumb, the incubation temperature should be 
10-20°C below Tm of the protein in the corresponding formulation. The Tm is defined as the 
temperature where 50% of the protein molecules are unfolded during a thermal scan and can 
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be determined by microcalorimetry or other analytical techniques like Fourier transformed 
infrared spectroscopy [36]. 
The melting temperature of the employed particle-free NGF formulation was determined by 
microcalorimetry and the corresponding thermogram is shown in Figure 5.14. The calculated 
Tm value of 74.7°C reflects a comparatively stable protein formulation regarding heat-induced 
aggregation. eADF4(C16) particle containing NGF formulations were also examined by 
microcalorimetry, but the corresponding thermograms did not show any exo- or endothermic 
events. It is likely that the presence of highly concentrated eADF4(C16) particles inhibited the 
detection of any signals arising from folding processes of NGF. As a conclusion, an 
incubation temperature of 60°C and sampling points after 1, 3 and 7 days of incubation were 
chosen for the first study. 
 
Figure 5.14. Thermogram of nerve growth factor formulated in the loading buffer (= formulation buffer) at 
a concentration of 0.5 mg/mL measured by µDSC 
The results from HP-SEC after 1 and 3 days of incubation are summarized in Figure 5.15. All 
formulations showed a fast and severe degradation of NGF already after 1 day of incubation 
at 60°C. For this reason, data from the last sampling point at 7 days is not displayed. 
Comparing the total protein recovery of all formulations with the remaining dimer fraction, it is 
visible that less than 1% of soluble aggregates were present. This finding is contrary to the 
NGF degradation detected during light stress where up to 50% soluble aggregate species 
were formed. This implicates that heat-induced aggregation of NGF is rather different in its 
mechanism compared to light-induced aggregation.   
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Figure 5.15. Total protein recovery (A) and dimer recovery (B) of NGF formulations after incubation at 
60°C analyzed by HP-SEC (UV-detection at 215 nm). The displayed protein recoveries are calculated 
referring to the total AUC of each formulation at t0. The symbols represent the mean of three samples ± 
SD. Separate samples of each formulation were prepared for different sampling points. 
This difference was also observed by SDS-PAGE under non-reducing conditions (see 
Figure 5.16). All samples showed an intense bond representing the dissociated NGF 
monomer with a molar mass of 13 kDa, but no significant amounts of NGF dimer or 
oligomers. Only a slight smearing was observed in particle-free formulations which can be 
explained by the fact that during denaturation of the samples parts of insoluble aggregates 
are dissolved again. Hence, cross-linking of cytosine or tyrosine residues did not occur 
during incubation at 60°C.  
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Figure 5.16. Comparison of particle-free vs. 0.5% [w/V] spider silk particle comprising NGF formulations 
after incubation at 60°C by SDS-PAGE (non-reducing conditions, silver staining). 
The eADF4(C16) particle containing formulations showed unfortunately no significant 
stabilizing effect during incubation at 60°C. Interestingly, the ranking of the formulations, 
which was set according to results from light-exposure (2% > 1% > 0.5%), is turned upside 
down regarding the dimer recovery after 1 day. The formulation comprising 
2% [w/V] particles was even worse, but at least the addition of 0.5% [w/V] spider silk particles 
resulted in significantly higher remaining dimer content than the particle-free formulation. 
Certainly, the stabilizing effect was not satisfying, but the formulation with the lowest 
employed amount of spider silk particles showed that stabilization may be possible by a 
further reduction of the particle concentration and the identification of the right balance 
between particle concentration and protein payload. 
To complete the overall picture on heat-induced aggregation of NGF, samples were analyzed 
by light obscuration, and turbidity measurements were carried out (see Figure 5.17). The 
severe decrease in protein recovery detected by HP-SEC had to result in return in large 
amounts of insoluble aggregates as already explained. This was confirmed by more than 
50,000 particles ≥ 1 µm per m  (1:20 dilution) after 3 days of incubation. For the first time 
also the determined FNUs showed a clear increase to values around 3 compared to values 
below 1 after light exposure. Taking both numbers into account, more subvisible particles as 
well as smaller particles were formed at 60°C than during light exposure. This outcome 
further confirmed the different kind of aggregation mechanism of nerve growth factor induced 
by different stress methods.  
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Liquid NGF WP 
Incubation 
time [d] 
Turbidity 
[FNU] 
0 0.57 ± 0.04 
1 2.92 ± 0.17 
3 3.24 ± 0.07 
Liquid NGF FB 
Incubation 
time [d] 
Turbidity 
[FNU] 
0 0.70 ± 0.04 
1 3.08 ± 0.12 
3 3.79 ± 0.14 
 
Figure 5.17. The diagram shows the subvisible particle count after incubation at 60°C determined by 
light obscuration. The bars represent the mean of three samples ± SD. The corresponding turbidity 
values are tabulated alongside the diagram. 
A second study was performed at 40°C to slow down the heat-induced aggregation. As 
depicted in Figure 5.18, the particle-free formulation showed no loss in NGF dimer content, 
whereas the spider silk particle containing formulations already indicated a detrimental effect 
on protein stability with 85% (2% [w/V] nanoparticles), 93% (1% [w/V] nanoparticles) and 
95% (0.5% [w/V] nanoparticles) dimer recovery after only 3 days of incubation. Again, more 
eADF4(C16) particles led to a larger loss in dimer content and at 40°C the formulation 
comprising 0.5% [w/V] spider silk particles also exhibited a decreased protein recovery 
compared to the particle-free formulation. 
Taking all results from incubation at 60°C and 40°C together, it can be concluded that in the 
presence of spider silk particles NGF is presumably more prone to heat-induced aggregation 
than in nanoparticle-free formulations. In contrast to light exposure, heat-induced 
aggregation did not lead to an increase in soluble protein aggregates. Otherwise, an 
immense appearance of comparatively small subvisible particles was found and visually 
turbid formulations were obtained. The particle formation may be a result of conformational 
changes of native NGF molecules at elevated temperatures without the occurrence of 
covalently-linked protein species as they were detected after light exposure.  
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Figure 5.18. Remaining dimer content of NGF formulations after incubation at 40°C as analyzed by 
HP-SEC (UV-detection at 215 nm). The displayed protein recovery was calculated referring to the total 
AUC of each formulation at t0. The symbols represent the mean of three samples ± SD. Separate 
samples of each formulation were prepared for the different sampling points. 
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5.4 SUMMARY AND CONCLUSIONS 
The stability of nerve growth factor in a particle-free formulation vs. spider silk nanoparticle 
formulations was investigated. The impact of binding NGF onto foreign particles during 
accelerated stability studies has been performed for the first time to our knowledge. Freeze-
thawing, stirring, light exposure and incubation at elevated temperature were carried out after 
an appropriate procedure for the desorption of NGF from eADF4(C16) particles had been 
developed. This procedure included the mixing of the corresponding formulation at a ratio 
of 1:1 with a solution containing 200 mM sodium phosphate and 800 mM sodium chloride at 
pH 8.0. The mixture was incubated for 30 min at 50°C and an agitation speed of 600 rpm. 
As it is known from multiple studies reported in literature, different stress methods lead to 
different results regarding the type and degree of protein aggregation [26, 34, 35]. The 
underlying mechanisms strongly depend on the type of protein as well. Additionally, little 
knowledge is available about the behavior of proteins being bound to foreign particles and 
subjected to forced degradation studies so that the outcome of this study could hardly be 
estimated. 
The results from the freeze-thaw study showed that freezing and thawing of NGF bound to 
eADF4(C16) particles was not detrimental regarding protein stability. All formulations 
including the one without spider silk particles exhibited no loss in protein or dimer content 
after 15 freeze-thaw cycles in liquid nitrogen. According to this data, the formation of ice-
water interfaces and local freeze-concentration did not lead to significant conformational 
changes of the native protein. Only slightly increased subvisible particle counts were 
obtained giving a first hint of protein aggregation. 
Stirring studies were performed in order to obtain information on the impact of shear and 
other stress factors associated with mechanical stress on NGF stability. The applied stirring 
stress of 92 hours at 400 rpm did not affect the NGF in solution, but the presence of spider 
silk particles deteriorated the stability of NGF significantly. The higher the particle 
concentration in the formulation, the larger the loss in protein and dimer recovery had been. 
An explanation for this effect is difficult to find, but maybe more particles enhance the 
probability that partially unfolded NGF molecules come close to other protein molecules and 
cause a higher degree of protein aggregation. More particles also create a larger surface 
area where NGF molecules are able to adsorb and desorb due to electrostatic and 
hydrophobic forces. Thereby, unfolding processes are maybe enhanced. 
Exposing NGF formulations to xenon light interestingly led to a completely different behavior 
of the formulations. In this case, none of the formulations was able to sufficiently stabilize 
NGF against degradation, but more spider silk particles in the formulation were favorable 
compared to lower concentrations. Nevertheless, an interesting result was that in 
formulations with spider silk particles the dimer content of the residual protein remained 
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above 95% whereas NGF in the solution alone showed an almost 50% proportion of soluble 
NGF aggregates consisting of covalently-linked dimers and oligomers. Again, a well-defined 
explanation is difficult, but it can be speculated that the residual NGF content is protected 
through the binding to the spider silk matrix. A lower particle concentration implies a lower 
mass and volume of available eADF4(C16) matrix and results in a higher degree of surface 
adsorption where NGF molecules are not protected against light-induced degradation 
processes. 
The formulations were additionally subjected to an accelerated stability testing at elevated 
temperatures of 60°C and 40°C, respectively. A fast and severe loss in NGF content was 
detected at 60°C. Already after 1 day of incubation all formulations showed significant protein 
degradation independent of the presence of nanoparticles. Therefore, incubation at 40°C 
was carried out. All eADF4(C16) particle comprising formulations revealed a reduced NGF 
content after 3 days, whereas the particle-free formulation did not show that severe protein 
aggregation. For this reason, enhanced desorption processes from the spider silk particles 
accompanied by protein unfolding are also considered as potential sources of increased 
protein aggregation. 
In summary, nerve growth factor could not be stabilized by the addition of spider silk 
nanoparticles. Although different stress methods showed different results regarding the 
underlying mechanisms of aggregation, a significant stabilizing effect was not observed 
throughout the entire degradation study. In order to clarify the protein degradation in 
presence of spider silk particles, further studies have to be performed and an analytical 
technique enabling the differentiation between spider silk particles and particulate protein 
aggregates should be developed. 
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CHAPTER 6 
FINAL SUMMARY AND CONCLUSION 
The general aim of this thesis was to investigate the recombinant spider silk protein 
eADF4(C16) in depths with regard to applications as new biomaterial for colloidal drug 
delivery of proteins. The objective originated in the work of Andreas Lammel and Martin 
Schwab who showed that spider silk particles can be easily prepared by a salting out 
process, and that particles size and size distribution can be adjusted by appropriate process 
parameters [1]. Small hydrophobic guest molecules were employed in their work to 
investigate the applicability of eADF4(C16) particles for drug delivery. However, this simple 
and gentle preparation technique makes such a delivery system a promising platform even 
for controlled drug delivery of sensitive drugs like therapeutic proteins. 
In Chapter 1 a general introduction into the area of drug delivery of proteins and the 
biomaterial silk is given. There is still a clear need for biodegradable materials which exhibit 
the potential and prerequisites to be approved as delivery systems / excipients for human 
use by the health authorities. For this reason, it is essential to understand the biochemical 
and material properties of spider silk proteins and the technical processing into different 
morphologies including spider silk protein particles. Reviewing literature, the potential of 
Bombyx mori (silkworm) silk and the spider silk protein eADF4(C16) becomes apparent. 
The materials and methods applied throughout this thesis are described in Chapter 2. 
Particle preparation techniques, deep-dive physical characterization and freeze-drying of 
spider silk particles are presented in Chapter 3. The phase separation process was 
exploited by two different techniques. eADF4(C16) particles were prepared in the nanometer 
as well as in the micrometer range. In terms of nano-sized spider silk particles, a micromixing 
system consisting of two syringe pumps and a T-shaped mixing element was established as 
standard preparation technique due to its upscalability and excellent reproducibility. 
eADF4(C16) particles slightly below 300 nm with a narrow particle size distribution were 
obtained applying elevated process temperatures. Spider silk microparticles were produced 
using an ultrasonic spray nozzle to atomize potassium phosphate into aqueous eADF4(C16) 
solutions. Further process optimization enabled the preparation of microparticles between 
5 and 7 µm and offers the potential to further increase the resulting particle size for future 
work. However, the intention of simultaneous atomization of potassium phosphate and the 
protein solution resulted only in non-spherical protein aggregates like threads and fibrils due 
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to an inadequate phosphate to eADF4(C16)-ratio present at the atomizing surface and in the 
atomized droplet mixture. 
As the aqueous eADF4(C16) solution is one important factor influencing the phase 
separation process, detailed analysis of this protein formulation was performed. eADF4(C16) 
stability during incubation at 80°C was investigated since pre-heating of the protein solution 
is applied for the preparation of eADF4(C16) nanoparticles. It was shown that the spider silk 
formulation (1.0 mg/mL, 10 mM Tris-buffer, pH 8.0) exhibits only limited protein stability over 
a period of four hours at 80°C as thin spider silk fibers were formed. However, a short 
preheating step before particle preparation will not significantly affect the phase separation 
process according to the determined protein aggregation behavior. 
Spider silk particle suspensions comprising sucrose, trehalose or mannitol were successfully 
freeze-dried above a threshold of an excipient-to-particles ratio of 10:1 [w/w] using a 
conventional freeze-drying cycle. It was possible to maintain all particle characteristics 
throughout the drying process. Lysozyme-loaded eADF4(C16) particles produced via remote 
loading were successfully freeze-dried as well. Freeze-dried nanosuspensions provide better 
storage stability compared to an aqueous eADF4(C16) suspension which was shown to be 
sensitive towards changes in pH and ionic strength. Nevertheless, the particle stock solution 
prepared in purified water and in the absence of additional ions could be stored over a period 
of six months. 
In Chapter 4 two different strategies for drug loading of eADF4(C16) particles are described. 
First, the so-called remote loading was performed which means that drug loading was 
achieved in a second step after particle preparation by addition of the drug substance to the 
particle suspension. Lysozyme and nerve growth factor (NGF) were loaded onto 
eADF4(C16) particles up to payloads of more than 20% [w/w] with corresponding loading 
efficiencies above 80% [w/w]. It was concluded from the loading studies that the predominant 
driving force is electrostatic attraction and that hydrophobic forces may only play a subsidiary 
role. Interestingly, confocal laser scanning microscopy revealed matrix loaded spider silk 
particles as a result of the remote loading procedure. Matrix loading was considered to be 
beneficial for a sustained protein release compared to simple surface adsorption. 
Secondly, a typical encapsulation process was conducted by addition of the drug substance 
to the aqueous eADF4(C16) solution prior to particle preparation. However, encapsulation 
did not lead to comparable payloads due to the required conditions for particle formation 
during the encapsulation process. The high ionic strength (1 M potassium phosphate) 
strongly diminished electrostatic interactions so that less protein molecules were co-
precipitated into the eADF(C16) matrix. Additionally, neutral substances such as Rhodamine 
B could not be efficiently encapsulated. Hence, electrostatic attraction was also regarded as 
prerequisite for a successful encapsulation of drug molecules into eADF4(C16) particles. 
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Several in vitro release studies were carried out to examine the underlying release rates and 
mechanisms. Release from spider silk particles was very fast at physiological conditions 
independent of the performed loading procedure. All results indicated that an incorporation of 
the drug molecule into the protein matrix does not lead to a sustained release rate caused by 
potential slow diffusion through a dense polymer matrix. In contrast, the determined release 
has to be understood as the creation of equilibrium between the particle with its loaded drug 
molecules and the aqueous environment including ions, other substances like albumin and 
the potentially already released drug molecules. Any change of this equilibrium modifies the 
release, for which reason changes of pH, ionic strength or the addition of albumin 
significantly alter the release profile. Therefore, the eADF4(C16) matrix was not able to 
prevent fast dissolution neither of small molecules nor macromolecules like protein drugs 
except during storage of loaded particles in purified water. Herein, the loaded compound is 
not released at all which allows for a long-term storage of loaded spider silk particles in 
purified water. Nevertheless, a sustained delivery of drug substances from eADF4(C16) 
particles has to be assessed as very challenging on the basis of the current data. This kind of 
triggered release behavior may be especially of interest for applications in diagnostics where 
the loaded particles are stored in aqueous solution and the release of the loaded compound 
starts immediately upon dilution with e.g. salts, buffer or albumin. 
A different approach for using eADF4(C16) particles was examined in Chapter 5. Recently, 
silk fibroin films were successfully employed for the stabilization of a vaccine in order to 
eliminate the necessary cold chain [2]. On this account, spider silk particles were employed 
in forced degradation studies in order to evaluate their potential to stabilize the loaded 
protein molecules. Different stress conditions were applied to a suspension comprising 
eADF4(C16) particles loaded with nerve growth factor via remote loading and the particle-
free NGF formulation. A standard procedure was developed that allowed for reproducible 
and gentle desorption of nerve growth factor from eADF4(C16) particles at pH 8.0 and high 
ionic strength. 
Freeze-thawing, stirring and accelerated stability testing of the formulations revealed that a 
potential stabilizing impact of binding NGF onto spider silk nanoparticles cannot be verified. 
Protein aggregation was actually provoked by the presence of eADF4(C16) particles as the 
occurring desorption and adsorption processes are considered to force unfolding and 
subsequent protein aggregation. Only light exposure of NGF formulations showed that 
eADF4(C16) particles were able to mitigate the degree of protein aggregation. Higher particle 
concentrations were superior, but the best performing formulation was still not able to 
prevent protein degradation even though a significantly reduced formation of soluble protein 
aggregates (covalently-linked dimers and oligomers) was detected. It was assumed that the 
amount of NGF being incorporated into the spider silk matrix is protected from light exposure. 
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Taking together conclusions from all chapters, different proof of concept studies were 
performed in order to show the potential benefit of using eADF4(C16) particles as an 
alternative to other polymeric drug delivery systems as well as the present limitations. 
Although the release from eADF4(C16) particles is not retarded by the spider silk matrix, the 
characteristics of this drug delivery system offer certain possible applications. It may be used 
e.g. for diagnostics where the long-term storage in purified water and the immediate and fast 
release only upon a distinct trigger is of great advantage. 
Furthermore, the material properties are very interesting in the area of wound healing. 
Negatively charged polystyrene microspheres (PolyHeal™) with a size of 5-microns were 
introduced as a safe and clinically effective treatment option for hard-to-heal wounds [3] and 
functionalized silk biomaterials (films) were recently evaluated by Kaplan et al. [4]. In this 
context, the development of endotoxin-free and sterile spider silk material (e.g. particles or 
films) has to obtain priority. 
Another possible application is the area of vaccination where particulate vaccine-delivery 
systems with comparable dimensions to the pathogens are desired [5]. Spider silk particles 
may act as adjuvants per se for which reason a broad screening of different particulate 
formulations should be performed to proof this hypothesis. Furthermore, chemical or 
genetical modification as exemplarily shown by Scheibel et al. [6] using eADF4(C16) in 
conjunction with a specific antigen will be an innovative approach to combine the properties 
of both single molecules. As a result, spider silk particles with antigen sequences on the 
surface may be formed and act as a smart vaccine-delivery system. Future work should 
therefore focus on in vitro and in vivo vaccination studies to verify the potential benefits of 
this new biomaterial. 
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